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ABSTRACT 
 
 
MECHANISTIC AND CLINICAL STUDIES OF PLATELET RICH PLASMA: 
 
A SIMPLE CLINICAL METHOD FOR ENHANCING BONE 
 
AND SOFT TISSUE HEALING 
 
 
 
 
 
By 
 
James L. Rutkowski  
 
December 2008 
 
 
 
Dissertation Supervised by David A. Johnson Ph.D. 
 
     Platelet rich plasma (PRP) is a methodology of using a patient’s own platelets to 
enhance bone and soft tissue healing following oral surgical procedures.  Whole blood is 
drawn from the patient by conventional phlebotomy techniques and then centrifuged with 
the formation of a distinct middle layer that contains platelets and white blood cells 
(WBCs).  This layer of platelets and WBCs is then placed into the surgical site to enable 
faster and more predictable healing.  This technique has also found use in general 
medical surgeries and is gaining in popularity.   
      Platelets contain growth factors and other cytokines that are beneficial for healing 
following surgical trauma.  This project uses both in vitro and in vivo studies to provide 
the mechanistic basis for the continued and possible expanded clinical use of PRP. 
 v
     A simple and inexpensive technique for acquiring PRP is examined and provides 
evidence that during the platelet harvesting steps the platelets are properly concentrated, 
not altered, and that growth factors (GFs) critical to bone formation are present.   
     A retrospective clinical trial provides data that illustrate a significant decrease (p < 
.0001) in the frequent complication of “dry socket” (alveolar osteitis, AO) formation 
following mandibular tooth extractions.  The study reveals that not using PRP is a risk 
factor for AO formation.   
     The project also utilizes a molecular study utilizing human mesenchymal stem cells 
(hMSCs) to provide a mechanistic basis for bone formation following PRP use.  
Enhanced proliferation and inducement of differentiation of hMSCs were found to the 
possible explanations for the clinical successes reported with PRP use. 
      A prospective clinical study provides radiographic evidence for increased 
radiographic opacity (indicating bone formation) during the initial two weeks following 
placement of PRP at the time of mandibular third molar removal. 
     This translational research offers scientific support for the use of PRP in osseous 
surgeries.  The use of this simple and inexpensive PRP technique could help patients 
recover faster, with fewer complications and greater bone formation predictability 
following surgeries involving bone manipulation.            
 vi
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Introduction 
Literature Review of Platelet Rich Plasma 
 
      Improved rate and predictability of healing is a goal for various medical and dental surgical 
procedures.  It has become increasingly common in the clinical practice of dentistry to use 
autologous platelet-rich plasma (PRP) to facilitate soft and hard tissue healing following surgical 
procedures (1-8).  PRP has been found to accelerate bone formation and induce healing in non-
healing wounds (8-14).  These referenced techniques involve expensive techniques that require 
60 to 480 mL of whole blood to be drawn from the patient, however the method examined in this 
dissertation uses an inexpensive technique that requires only 5 to 10 mL of whole blood.  
 
PRP is 
a generic term that has some specific variations.  These variations include: platelet concentrates 
(PC), concentrated platelet rich plasma (cPRP), gelled platelet rich plasma (PG), and the “buffy 
coat” (BC).  The terms are often erroneously interchanged and many clinicians are unaware of the 
differences.   Although one common aspect of all variations is a higher than normal baseline 
concentration of platelets (10, 15), there are subtle, but often clinically significant, differences 
between each of these blood products.   The reason PRP (and its variants) is of interest is because 
platelets contain growth factors (GF), which are released upon activation.  The literature 
pertaining to the role of growth factors in soft and hard tissue regeneration is abundant (8).  PRP 
was approved for clinical use in 1998 (16).  Since that time several PRP variants have been used.  
Review of the medical and dental literature supports (with some discrepancies) the use of 
2 
 
autologous PRP in clinical practice (16).   Clinical uses of PRP are as a healing adjuvant for soft 
tissue injuries, chronic diabetic foot ulcers, injuries to muscles, tendons or ligaments, distraction 
osteogenesis of extremities in patients with achondroplasia/hypchondroplasia, and for increased 
predictability following urologic, dental, ophthalmic, and plastic surgery procedures (17-31).   
     The studies of this dissertation examine a simple, cost-effective method of obtaining PRP.  
The studies provide evidence of suitable platelet concentration, platelet viability, growth factor 
content, positive effects on human mesenchymal stem cell (hMSC) proliferation, and positive 
effects on bone development in third molar tooth extraction sites, in addition to decreased 
alveolar osteitis (AO) following mandibular molar tooth removal in patients.  In vitro molecular 
studies also suggest that this technique may have a positive effect on hMSC differentiation down 
the osteoblastic lineage.  This project provides the necessary scientific basis to prove the efficacy 
of a simple BC method and therefore its suitability for use in a clinical setting.  
A.  Platelets  
 
Histology 
      Platelets are anuclear, void of genomic DNA and discoid in shape (32).  They are 
produced during hematopoiesis by budding off from megakaryocytes (33).  Each 
megakaryoctye undergoes controlled cellular fragmentation that produces 5,000 to 
10,000 platelets (34).  Platelets are rapidly depleted and must be replaced every 7 to 10 
days (15). Unless activated, platelets circulate normally in a resting state for 
approximately 7 to 9 days and are destroyed by the spleen and Kupffer cells in the liver.  
Platelets contain high concentrations of cytoskeleton, signaling, membrane-bound, 
protein-processing, and cytoskeletal regulatory proteins.  These presynthesized proteins 
are made in the megakaryocytes and packaged into granules through vesicle-trafficking 
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processes.  There are other proteins synthesized from platelet mRNA during platelet 
activation (35).  Platelets contain RNA, mitochondria, a canalicular system (similar to an 
endoplasmic reticulum), and several different types of granules.  There are three main 
storage compartments in platelets: lysosomes, dense granules, and α-granules.  The 
lysosomes contain acid hydrolases; the dense granules contain ADP, ATP, serotonin, 
histamine and calcium; and the α-granules contain fibrinogen, factor V, vitronectin, 
thrombospondin, von Willebrand factor (vWF) and several growth factors.  Platelets 
release the contents of intracellular granules in response to activation (15).  
Morphology 
     Platelets appear in stained blood film as small, blue or colorless bodies with several 
purple-red granules (34).  They average about 0.5 to 3 µm in diameter, although there is a 
wide variation in shape, from round to elongated, cigar-shaped forms (15, 36).  
 
Platelet Count  
     Platelets are counted by enumerating particles in the unlysed whole blood sample 
within a specific volume window (e.g., 2-20 fL), where volume may be measured by 
electrical impedance or light scattering.  Accurate platelet quantification is difficult and 
presents with variation because of their small size, predisposition to aggregation and 
potential overlap of platelets with more numerous red blood cells.  Contemporary platelet 
quantifying instruments typically create a platelet volume histogram based upon the 
measured platelet size within the platelet volume window, and mathematically 
extrapolate the histogram to account for platelets whose size overlaps with debris of 
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small red cells.  Platelet counts show substantial ethnic variation (37).
  
The normal 
platelet count is lower in individuals of African ethnic origin (38).
  
See Table 1 for ethnic 
difference in normal leukocyte and platelet count values  
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Gender
 
Men Women 
Nationality
 
European 
Descent 
n=100 
Afro-
Caribbean 
n=51 
African 
n=65 
European 
Descent 
n=100 
Afro-
Caribbean 
n=51 
African 
n=50 
Leukocyte 
count* 
5.7(3.6-9.2) 5.2(2.8-9.5) 4.5(2.8-7.2) 6.2(3.5-
10.8) 
5.7(3.3-9.9) 5.0(3.2-7.8) 
Neutrophil 
count 
3.2(1.7-6.1) 2.5(1.0-5.8) 2.0(0.9-4.2) 3.6(1.7-5.5) 3.0(1.4-6.5) 2.4(1.3-4.2) 
Lymphocyte 
count  
1.7(1.0-2.9) 1.9(1.0-3.6) 1.8(1.0-3.2) 1.8(1.0-3.5) 2.0(1.2-3.4) 2.0(1.1-3.6) 
Monocyte 
count 
0.34(0.18-
0.62) 
0.33(0.18-
0.52) 
0.29(0.15-
0.58) 
0.30(0.14-
0.61) 
0.31(0.16-
0.59) 
0.28(0.15-
0.39) 
Eosinophil 
count 
0.12(0.03-
0.48) 
0.13(0.03-
0.58) 
0.12(0.02-
0.79) 
0.13(0.04-
0.44) 
0.10(0.03-
0.33) 
0.10(0.02-
0.41) 
Platelet count 218(143-
332) 
196(122-
313) 
183(115-
290) 
246(169-
358) 
236(149-
374) 
207(125-
342) 
 
 
Table 1. Ethnic Differences in Normal Leukocyte and Platelet 
Count Values 
All counts expressed in thousands per μL.  Geometric mean and 95% reference range are 
in parentheses (15). 
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Function 
      Platelets have two distinct physical states.   
 
 Figure 1. Two States of Platelets 
 
 Platelets in their resting form (A) and at the beginning of activation (B) (39). 
 
 
 
At rest, the platelets circulate through the vasculature as small discs of 
reproducible structure having an elegant, actin-based cytoskeleton.  In response to 
vascular damage or when blood flow ceases (becomes stagnant), the platelets enter a 
second stage where they rapidly convert  into their active form with filopodia and 
lamellipodia that derive from a remodeled actin skeleton and a sophisticated assembly of 
new actin filaments (36).  This change in physical state allows platelets to interact with 
each other and adhere to, the injured vessel, specifically with the subendothelium.  This 
process is mediated by von Willebrand factor (vWF), collagen, fibrinogen, 
thrombospondin, and different platelet membrane glycoproteins (Figure 2) (15, 40). 
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 Figure 2. Platelet Shapes   
                  
 Top-resting platelets shown as small discs.  Middle - platelets increasing in size due to  
vascular damage.  Bottom-active platelets showing filopodia (36). 
 
Aggregation  
      As platelets change their shape, they begin to aggregate which results in a hemostatic 
plug (clot).  Platelet aggregation is stimulated by thromboxane and α2 adrenergic 
receptor-activation.  Platelets adhere to each other via adhesion receptors or integrins and, 
in conjunction with fibrin, to endothelial cells in the wall of the blood vessel forming the 
hemostatic plug.  Myosin and actin filaments within the platelets are stimulated to 
contract during aggregation, further reinforcing the plug.  The most abundant platelet 
adhesion receptor is glycoprotein (GP)IIb/IIIa. This is a calcium-dependent receptor for 
fibrinogen, fibronectin, vitronectin, thrombospondin and vWF.  Activation of the 
GPIIb/IIIa receptor facilitates the aggregation process, which helps generate thrombin.  
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Thrombin leads to the activation of other platelets.  The GPIIb/IIIA receptor action is 
further augmented by other elements secreted by platelets, such as ADP, 5-HT, collagen, 
and thromboxane A2.   Two other receptors involved are GPIb-V-IX complex (VWF) and 
GHPVI (collagen) (40).  Epinephrine is a weak platelet agonist (α2 adrenergic receptor), 
but probably plays a significant role by enhancing the platelet’s response to other 
agonists (15, 40).    
     Several inhibitory factors prevent excessive platelet aggregation.  The endothelial cells 
synthesize three anti-aggregation products: PGI2 (prostacyclin), PGD2, and nitric oxide.  
Other important inhibitory factors include platelet-leukocyte interactions and the speed of 
blood flow (15, 40). 
Platelet Activation     
     Activation follows the aggregation process and occurs when platelets experience 
several biochemical changes before secreting their active components.   Platelets are 
activated when brought into contact with collagen, thrombin, fibronectin, laminin, 
thromboxane A2, epinephrine, ADP, a negatively charged surface (e.g. glass), and 
platelet-activating factors.  If whole blood is collected in a glass tube, it must contain an 
anticoagulant (heparin or tri-sodium citrate) to prevent coagulation.  Activation involves 
specific extracellular membrane receptors that transduce the signal via G-proteins or 
other mechanisms that induce intracellular signaling.  Figure 3 illustrates the steps 
involved in platelet activation.  
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Figure 3. Schematic Representation of Platelet Activation by 
Extracellular Factors (40)  
Several platelet membrane receptors bind with extracellular factors in response to platelet 
adhesion and aggregation, resulting in platelet activation. GPIb in the platelet membrane 
binds von Willebrand factor (vWF) and mediates adhesion. Not illustrated is a second site 
on vWF that binds to GPIIb/IIIa. GPIIB-IIIa in the membrane binds fibrinogen and 
mediates platelet-platelet interactions. ADP and thrombin receptors are illustrated to 
show the relationship between ADP stimulation and arachidonic acid pathway (AA), with 
release of thromboxane A2 (TXA2), which further stimulates aggregation. (40) 
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     Upon activation, granules contained within the platelets release coagulation factors, 
platelet activating factors, adhesion molecules, cell-activating molecules, cytokines, 
integrins, inflammatory molecules, and GFs.  The release process is mediated by 
molecular mechanisms homologous to other secretory cells, uniquely coupled to cell 
activation by intracellular signaling events (41).  Platelets in the resting state do not 
expose negatively charged phospholipids on the surface.  However binding to collagen 
initiates a sequence of biochemical reactions that results in the activation of the 
membrane protein scramblase.  Scramblase transports negatively charged phospholipids 
from the inner leaflet of the membrane to the outer leaflet.  The presence of negatively 
charged phospholipids allows the binding and the formation of a prothrombinase 
complex.  These phospholipids provide a catalytic surface (with the charge provided by 
phosphatidylserine and phosphatidylethanolamine) for tenase and prothrombinase 
complexes. The tenase complex is formed by the activated forms of the blood coagulation 
factors, factor VIII and factor IX.  It forms on a phospholipid surface in the presence of 
calcium and is responsible for the activation of factor X.  Prothrombinase is the protein 
complex which consists of negatively charged phospholipid (phosphatidylserine), 
prothrombin, Factors Va and Xa.  The prothrombinase complex converts the inactive 
protease prothrombin into thrombin, which has proteolytic activity to convert fibrinogen 
into fibrin.  
     Some of the substances released by platelets – in particular adenosine diphosphate, 
serotonin, and thromboxane, can act in an autocrine and paracrine manner to further 
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enhance platelet activation and aggregation (39).  In addition, thrombin also stimulates 
platelet activation producing a positive feedback loop (41).  
Role of Platelets in Inflammation  
      Platelets, the chief cellular effectors of hemostasis, are also deployed to sites of injury 
or infection to modulate inflammatory processes by interactions with leukocytes through 
the secretion of cytokines, chemokines and other inflammatory mediators (42-45).  
     Cytokines particularly involved with healing include: transforming growth factor- 1 
(TGF 1), platelet derived growth factors (PDGFs), and insulin-like growth factor 
(ILGF).  These cytokines and others of significance will be discussed in detail in the 
discussion of α-granules.   
Plasma Membrane  
     The platelet plasma membrane consists of a phospholipid bilayer in which cholesterol, 
glycolipids, and glycoproteins are embedded (46, 47).  Platelets have more intramembranous 
particles embedded in the outer platelet membrane leaflet than in the inner leaflet.  The greater 
number of particles in the outer membrane most likely reflects the many external receptors that 
mediate platelet interactions. The plasma membrane contains sodium- and calcium-adenosine 
triphosphatase (ATPase) pumps that control the platelet’s intracellular ionic environment.  It is 
estimated that slightly over half of platelet phospholipids are contained in the plasma membrane.   
When platelets are in the resting state, negatively charged phospholipids are almost exclusively 
present in the inner leaflet, whereas other phospholipids are more uniformly dispersed (48). 
When platelets are in the resting state the negatively charged phospholipids, including 
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phosphatidylserine, are capable of initiating several steps of the coagulation sequence. Therefore, 
the presence of phosphatidylserine in the inner leaflet of resting platelets sequesters them from 
circulating plasma coagulation factors thereby preventing inappropriate coagulation (49, 50). 
When agonists induce platelet activation, the aminophospholipids become exposed on the 
platelet surface or on the surface of microparticles associated with the activation cascade (49-
52).
 
 The location of phospholipids in quiescent platelets is maintained by an ATP-dependent 
aminophospholipid translocase that actively moves phosphatidylserine and 
phosphatidylethanolamine (PE) from the outer leaflet to the inner leaflet (49, 53).  
      The asymmetry of the negatively charged phospholipids may also be maintained by 
interactions that occur with cytoskeletal or other cytoplasmic elements (49, 50, 54, 55).   
Platelet Membrane Receptors 
     Platelet receptors, some of which are expressed only on activated platelets (41), are 
comprised of glycoproteins that receive signals from outside the platelet and transduce 
them to the interior.   Receptors are also activated by signals orginating inside the platelet 
that affect surface domains.  Membrane receptors determine the reactivity of the platelets 
with a wide range of agonists and adhesive proteins.     
     Platelet receptors are derived from several different receptor families including 
integrins, leucine-rich glycoproteins, immunoglobulin (Ig) cell adhesion molecules, 
selectins, quadraspanins, and seven transmembrane (7TM) domain receptors (15).  A 
single member of the integrin family, αIIβ3, is thought to be exclusive to platelets, as is 
GPVI.  The leucine-rich glycoproteins GPIb-IX and GPV appear to have a limited 
expression that includes platelets and cytokine-activated endothelial cells (56-58).  The 
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αIIbβ3 integrin receptor mediates interactions between platelets and between proteins and 
platelets (15, 59).  
 αIIbβ3 (GPIIb/IIIa; Fibrinogen Receptor; CD41/CD61) Receptor 
      The integrin αIIbβ3 (Figure 4) is among the most densely expressed 
adhesion/aggregation receptors present on any cell type, (15) and is necessary for platelet 
aggregation (59).  It is a heterodimeric receptor composed of an alpha chain and a beta 
chain that binds fibrinogen, vWF, fibronectin, and vitronectin.  Expression of the receptor 
is thought to be limited to cells of the megakaryoctye lineage (59-61).  The genes for the 
αIIb (α chain) subunit are encoded by the gene designated ITGA2B.  The β3 portion (β 
chain) is encoded from the ITGB3 gene (15, 34).  The αIIb chain undergoes post-
translational cleavage to yield disulfide-linked light and heavy chains that join with beta 
3 to form the receptor.  
     The αIIbβ3 receptor not only plays a crucial role in coagulation, but is also significant 
in cell-surface mediated signaling, resulting in activation.  Upon activation, these 
receptors are able to join the plasma membrane and undergo the release of the GFs 
contained within the α-granules (62-64).  On quiescent platelets, αIIbβ3 has low affinity 
for fibrinogen. However when platelets are activated by ADP, epinephrine, thrombin, or 
other agonists, αIIbβ3 binds fibrinogen with higher affinity (65-67).  Platelet activation 
induces changes in the αIIbβ3 integrin receptor that are responsible for the change in 
fibrinogen-binding affinity (68-70), although changes in the environment surrounding 
αIIbβ3 may also be involved.  αIIbβ3 receptors in α-granules appear to cycle to and from 
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the plasma membrane (70).  This recycling explains the capacity of αIIbβ3 to take up 
fibrinogen from plasma and transport it to α-granules, where it is concentrated (71, 72).   
α2β1(GPIa-IIa; Collagen Receptor; CD49b/CD29) Receptor 
     Unlike the integrin αIIbβ3, α2β1 (Figure 4) is widely expressed in many cell types and 
can mediate adhesion to collagen (73-79).  The GPVI receptor activates α2β1, as well as 
other integrins.  α2β1 promotes firm adhesion of the platelet to collagen, stabilizes 
thrombus growth on collagen, and promotes procoagulant activity (15, 80, 81).  It is 
linked to the membrane skeleton and is competent to mediate adhesion of resting platelets 
(15, 82).  Interestingly, activation of α2β1 can initiate protein synthesis in platelets (15, 
83).  
Cytoskeletal Elements 
     A planar network of thin, elongated spectrin tetramers interconnected by the ends of 
actin filaments is present immediately below the plasma membrane of the platelet and the 
membranes of the open canalicular system (15).  Filamin-A (actin-bonding protein) can 
interact with both the transmembrane glycoprotein (GPIbα) and the actin immediately 
below the plasma membrane.  This interaction connects these components to the 
cytoskeleton protein spectrin (on the intracellular side of the plasma membrane) forming 
a scaffolding cytoskeleton that possibly stabilizes the membrane’s discoid shape.  In 
addition, the association of GPIbα with the membrane skeleton restricts the expansion of 
the spectrin network and probably helps to organize receptors into linear arrays on the 
platelet surface, thus enhancing receptor cooperation (84).  
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       Figure 4: Platelet Membrane Transmembrane Glycoproteins 
 
      Depiction of selected platelet transmembrane glycoprotein connections to the 
      cytoplasmic skeleton (15, 85). 
 
     Talin is another protein found in the membrane skeleton and is implicated in the 
control of αIIbβ3 activation by virtue of binding to the cytoplasm domains of αIIbβ3 (61, 
84, 86-89).  When platelets are activated, receptors αIIbβ3 and α2β1 may bind to the 
cytoskeleton as well. Therefore, the cytoskeleton may affect whether receptors are free to 
move in the plane of the membrane have a role in moving certain receptors from the 
surface to the interior of platelets and vice versa, via the canalicular system (84, 90).   
  
 
GP1b-α 
αIIbβ3
3 
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Microtubules 
     The circumferential band of microtubules present underneath the plasma membrane in 
all probability plays a significant role in platelet formation from megakaryocytes and 
contributes to the platelet's discoid shape (15, 34, 91-93). Microtubules are hollow 
polarized polymers (25 nm diameter) that contain 13 protofilaments consisting of α, β, β-
tubulin dimers (15, 34, 61, 84). Four tubulin isoforms (β1, β2, β4, β5) are found in 
platelets.  β1 is dominant and is megakaryoctye- and platelet-specific.  Approximately 50 
to 60 percent of platelet tubulin is utilized in microtubules, with an equilibrium 
maintained between polymerized and free tubulin subunits (34, 94).  Motor proteins 
associated with the microtubules contribute to the development and function of platelets 
(15).  
Organelles 
     Peroxisomes, mitochondria, lysosomes, dense bodies, exosomes, α-granules, and 
ribosomes (with mRNA) are all found in platelets.  Alpha-granules and ribosomes are of 
particular importance to this project and are discussed below.  
α-Granules 
     The majority of secretory substances found in platelets are localized in α-granules, 
numbering approximately 50 to 80 per platelet (15, 34, 95).  The α-granules are 
approximately 200 nm in diameter and demonstrate internal variation in electron density, 
often with an eccentric area of accentuated electron density, termed a nucleoid, in which 
β-thromboglobulin, platelet factor 4 (PF4), and proteoglycans are concentrated (46).  The 
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less dense electron areas include tubular elements in which vWF, multimerin, and factor 
V are preferentially contained (96).  Table 2 lists some of the most important proteins 
relevant to this research that are present in α-granules. 
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Category  Term Biological activities 
Adhesive proteins  vWf + propeptide, Fg, Fn, Vn, 
TSP-1, laminin-8 
Cell contact interactions, 
clotting, extracellular matrix 
composition  
Clotting factors and 
associated proteins 
Factor V/Va, factor XI, 
multimerin, gas6, protein S, 
high-molecular weight 
fibrinogen, antithrombin, tissue 
factor pathway inhibitor (TFPI) 
Thrombin production and its 
regulation, angiogenesis  
Fibrinolytic factors and 
associated proteins  
Plasminogen, PAI-I, u-PA, 
osteonectin, α2-antiplasmin, 
histidine-rich glycoprotein, 
TAFI, α2-macroglobulin 
Plasmin production and 
vascular remodeling 
Proteases and anti-proteases Tissue inhibitor of 
metalloprotease-4 (TIMP-4), 
metalloprotease-4, platelet 
inhibitor of FIX, protease 
nexin-2, C1 inhibitor, α1-
antitripsin 
Angiogenesis, vascular 
modeling, regulation of 
coagulation, regulation of 
cellular behavior 
Growth factors, cytokines, and 
chemokines 
PDGF, TGFβ1,and 2, EGF, 
IGF-1, VEGF (A and C), bFGF, 
and FGF-2, hepatocyte GF, 
RANTS, IL-8, MIP-1α, growth 
regulated oncogene-α, ENA-
78, MCP-3, angiopoietin-1, Il-
1β,IGF BP-3, neutrophil 
chemotactive protein 
Chemotaxis, cell proliferation 
and differentiation, 
angiogenesis 
Basic proteins and others  PF4, β-thromboglobulin, 
platelet basic protein, 
connective tissue activating 
peptide III, neutrophil 
activating peptide-2, 
endostatins 
Regulation of angiogenesis, 
vascular modeling, cellular 
interactions 
Anti-microbial proteins Thrombocidins Bactericidal and fungicidal 
properties 
Others Chondroitin 4-sulfate, albumin, 
immunoglobulins 
Diverse 
Membrane glycoproteins αIIbβ3, αβ3, GPIb, PECAM-1, 
most plasma membrane 
constituents, receptors for 
primary agonists, CD40L, 
Platelet aggregation and 
adhesion, endocytosis of 
proteins, inflammation, 
thrombin generation, platelet-
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Category  Term Biological activities 
tissue factor, P-selectin leukocyte interactions 
Table 2. Contents of the Platelet α-granules 
Platelet α-granule contents by category (39, 97).  
     Small quantities of nearly all plasma proteins are nonspecifically taken up into -
granules.  Platelet levels of these proteins are determined by their plasma concentrations 
(98, 99).  This is especially significant for the -granule pool of immunoglobulins (Ig), 
because the majority of total platelet Ig is affected by plasma Ig levels, rather than by 
changes in platelet surface Ig (15, 98, 99).  
     The concentrations of the platelet-specific proteins, PF4 and the β-thromboglobulin 
family members, in -granules are on the order of 20,000 times higher than their plasma 
concentrations. These proteins also share amino acid sequence homology with each other 
and with other members of the "intercrine-cytokine" family of molecules.  Once PF4 is 
released from platelets, it inhibits angiogenesis, perhaps through inhibition of endothelial 
cell proliferation (100).  
     The α-granules also contain platelet-derived growth factor (PDGF).  PDGF is a 
disulfide-linked dimeric molecule of the tyrosine kinase receptor family (101).  PDGF is 
mitogenic for smooth muscle cells (102).  After PDGF was discovered in platelets and 
was given its name, other tissues were found to produce the same factor; thus, the name 
platelet-derived growth factor is misleading because its presence is not limited to 
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platelets.  The PDGF in platelet -granules contains a mixture of a homodimer PDGF-
BB (30%) and a heterodimer PDGF-AB (70%).  These two isoforms appear to have 
different functional activities (103).  Platelet-derived growth factors PDGFs (PDGF-AA, 
PDGF-BB) are essential regulators for migration, proliferation and survival of 
mesenchymal cell lineages. (104-106)  PDGF’s function in regulating mesenchymal cell 
lineages is of great importance for bone development, remodeling  (104, 107)  and 
cicatrization (fibrous scar formation) (104, 108).  PDGF may also be instrumental in 
normal cell proliferation and in the development of atherosclerosis, tumor growth, wound 
repair, and fibroproliferative responses (pulmonary and renal fibrosis) (109-111).  
      Vascular endothelial growth factor (VEGF), an important stimulator of angiogenesis, 
is also found in high concentrations in α-granules.  VEGF is released after platelet 
stimulation during the hemostatic response to a bleeding wound (112-114).  Platelets and 
megakaryocytes express the gene transcript for a VEGF receptor termed KDR (115).  
VEGF is the most prominent and ubiquitous of the known vascular growth promoters 
(116, 117).  It is instrumental in the control of endothelial cell proliferation, migration, 
specialization, and survival (116, 118, 119).  The singular presence of VEGF is enough to 
initiate angiogenesis and the availability of different isoforms VEGF makes it possible to 
direct and refine the development plan for tissue growth (46, 116, 120). 
      Insulin-like growth factors (ILGFs) I and II are positive regulators of proliferation 
and differentiation for most cell types, including tumor cells.  ILGF also is important in 
the regulation of apoptosis regulation by inducing survival signals and inhibiting pro-
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apoptotic stimuli (104, 121).  ILGF is released during platelet degranulation and is also 
ubiquitous in circulating blood (104).  
      Platelet α-granules contain high concentrations of the growth factor TGF-β1.  TGF-  
is a large superfamily with more than 30 members.  TGF-β is of great importance for 
bone formation and is the isoform of greatest abundance not only in platelet α-granules, 
but is also, important for intercellular signaling (104, 122).  In vitro, the effects of TGF-β 
are varied depending upon the concentration, the matrix environment and cell type.  
TGF-β1 has been shown to stimulate the proliferation of osteoblasts as well as causing 
their inhibition (104, 123).  Despite TGF- 1’s variable effects on proliferation, for the 
great majority of cell types, it represents the most powerful fibrosis inducing agent 
among all cytokines (104, 124).  Therefore, TGF- 1 can be considered an inflammation 
regulator because of its ability to induce fibrous wound healing leading to scar formation.  
      Depending on the cell type being affected, TGF-β1 can promote or inhibit the growth 
of cells (125).  TGF-β1 can increase thrombopoietin production by bone marrow stromal 
cells. Thrombopoietin, in turn, induces megakaryoctye expression of TGF-β1 receptors.  
This enables TGF-β1 to arrest the maturation of megakaryoctye colony forming units 
(126).  TGF-β1 also promotes synthesis of extracellular matrix proteins, plasminogen 
activator inhibitor-1 (PAI-1), and metalloproteinases. TGF-β1 has been implicated in 
wound healing, malignancy, and tissue fibrosis (125).  TGF-β1 acts as a chemoattractant 
for monocytes and fibroblasts, but inhibits the migration of endothelial cells. There are 
three isoforms-TGF-β1, TGF-β2, and TGF-β3- with a wide tissue distribution, but platelets 
contain only TGF-β1.  TGF-β1 released from platelets can stimulate smooth muscle cells 
to express and release VEGF, thus supporting re-endothelialization after vascular injury 
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(127).  TGF-β1 is released from platelets in an inactive (latent) form that is complexed 
with a portion of the precursor protein (latency-associated peptide, LAP).  A fraction of 
LAP is covalently coupled to another protein latent TGF-β–binding protein (LTBP), 
which localizes the complex to the extracellular matrix (128).  Activation of latent TGF-
β1 is a multifaceted process that is thought to involve a conformational change in LAP 
that unmasks the active site of TGF-β1 (128).  Activation of latent TGF-β1 can be 
achieved by several different mechanisms, including acidification, proteolysis by 
plasmin, interaction with the integrin αVβ6, or interaction with thrombospondin-1 (TSP-
1) or a small peptide derived from TSP-1.  However, the physiologic activator(s) remains 
unclear (15, 128-130).  The ability of TSP-1 to activate TGF-β1 is of special interest 
because both TGF-β1 and TSP-1 are present in -granules. Only a small percentage of 
the TGF-β1 released from platelets with thrombin stimulation becomes activated, but the 
amount is sufficient to activate synthesis of plasminogen activator inhibitor-1(PAI-1) 
(130-132).  Active TGF-β1 can bind to three different cell surface proteins- a 
proteoglycan (β-glycan), and two serine/threonine kinases (125, 133).   
      Epidermal growth factor (EGF) has also been observed in platelet α-granules, but the 
kinetics of its release differs from that of other granule proteins (134). 
      Platelets also contain endothelial cell growth factor which stimulates endothelial cell 
proliferation and angiogenesis (135).  It is thought to be present in the cytoplasm of 
platelets but not the α-granules.  Therefore, it is released only at the time of platelet 
disintegration--not stimulation. 
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Ribosomes and Messenger RNA  
     Platelets contain a relatively small number of ribosomes and remnants of a Golgi 
apparatus. Platelets also have a small amount of mRNA on platelet polysomes carried 
over from megakaryocytes but cannot synthesize mRNA due to the lack of a nucleus 
(136-138).    Although mRNA is present in platelets where it corresponds with 
constitutively expressed factors, mRNA undergoes progressive decay due to the absence 
of any new gene transcription (138, 139).  Platelets contain a plethora of mitochondria, 
with each containing multiple copies of its own genome that can be actively transcribed 
(138, 139).  Regulated synthesis of new proteins by platelets has been reported upon 
thrombin activation as a result of redistribution of the eukaryotic initiation factor 4E.  
Signaling produced by ligand engagement of αIIbβ3 appears to be necessary to initiate 
the process of protein synthesis (83, 140, 141).  One of the translated proteins is pro–IL-
Iβ, which provides a link between thrombosis and inflammation (142).  Signaling through 
α2β1 (GPIa-IIa) also can initiate platelet protein synthesis (83). 
Membrane Systems 
     The open canalicular system is an intricate series of conduits that originate as 
indentations of the plasma membrane and course throughout the interior of the platelet 
(91, 143).   Electron microscopy of sectioned platelets demonstrates that the open 
canalicular system is contiguous with the exterior of the platelet, even though elements of 
the open canalicular system may appear as closed vesicles or vacuoles (91, 143, 144). 
The open canalicular system serves several functions. It provides a point for entry of 
external elements into the interior of the platelet and a potential means for the release of 
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granule contents to the outside, eliminating the need for granule fusion with the plasma 
membrane itself (144, 145).
  
This latter purpose is particularly significant because, under 
most circumstances, platelet granules move to the center of the platelet upon platelet 
activation, rather than to the periphery (91, 146).  However, the  degree to which α 
granule secretion occurs via the open canalicular system, versus direct fusion with the 
plasma membrane remains unclear (91, 147).  The open canalicular system is contiguous 
with the platelet plasma membrane. Platelet spreading after adhesion requires a 
significant increase in the surface area of the plasma membrane.  New membrane cannot 
be synthesized quickly enough to accommodate this phenomenon, therefore, the 
membrane of the open canalicular system contributes to the suface plasma membrane 
following platelet activation.  The membrane of α-granules also may contribute, but only 
if the stimulus is sufficient to induce the fusion of these organelles with the plasma 
membrane (also known as release reaction). Lastly, the membrane of the open canalicular 
system may serve as a storage site for plasma membrane glycoproteins.  For example, 
platelet activation by thrombin can lead to a predictable, selective loss of GPIb-IX from 
the membrane surface.  Electron microscopy analysis indicates the GPIb-IX becomes 
sequestered into the open canalicular system (90, 148, 149).  Plasmin may stimulate a 
similar event (90, 150).  Platelet activation leads to an increase in surface αIIbβ3, and 
although much of this αIIbβ3 is thought to derive from α-granule, some may come from 
αIIbβ3 in the membranes of the open canalicular system (15, 90, 151).  
Platelet Secretion 
     Granule secretion is thought to be mediated by a contractile mechanism involving 
actin and myosin, but the details remain obscure (152, 153).  After an initial platelet 
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shape change, actin becomes centrally organized into thick filamentous masses, where it 
most likely associates with myosin filaments (96).  The contractile reaction is initiated by 
an increase in cytosolic calcium, which results in the formation of a calcium–calmodulin 
complex that activates myosin light-chain kinase.  Phosphatases and cyclic adenosine 
monophosphate (cAMP) kinase modulate the reaction. The centralization of organelles in 
a contractile ring correlates with secretion (15, 91).  However, as stated earlier, it is 
unclear if platelets secrete the contents of their granules by fusion with the open 
canalicular system in the center of the platelet or by direct fusion with the plasma 
membrane (91, 147).   A complex multistep model for granule secretion has been 
suggested in which granules tether and dock to the inner leaflet of the plasma membrane 
and then additional molecular interactions lead to fusion of the lipid bilayers (15, 34, 152, 
154-163).  
Platelet Growth Factors in Treating Wounds and Soft-Tissue Injuries 
    Platelets are not only critical for hemostasis, but also in promoting tissue repair, 
angiogenesis, and inflammation by releasing growth factors.  Tissue repair begins with 
the formation of a clot and subsequent platelet activation and degranulation that releases 
inflammatory and mitogenic substances that are involved in all aspects of wound-healing  
(164).  The released substances include growth factors (GFs) that are necessary for 
wound repair.  These GFs are proteins that enhance tissue repair mechanisms including 
chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition, and 
remodeling (39, 165).  
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    More than 60 biologically active substance groups are found in platelets that are 
involved in tissue-repair mechanisms such as chemotaxis, cell proliferation and 
differentiation, angiogenesis, intracellular matrix deposition, immune modulation, 
antimicrobial activity, and remodeling (39).  Of all these substances, GFs are the most 
important (Table 3). 
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Growth Factor Function 
EGF (epidermal growth factor), β-Urogastron  Stimulates the proliferation of 
epidermal and epithelial cells, 
fibroblasts, and embryonic cells  
 Chemoattractant for fibroblasts and 
epithelial cells 
 Stimulates re-epithelialization, 
augments angiogenesis  
 Influences the synthesis and turn-over 
of extracellular matrix 
PDGF (platelet-derived growth factor)  A and B isoforms are potent mitogens 
for fibroblasts, arterial smooth muscle 
cells, chondrocytes, and epithelial and 
endothelial cells 
 Potent chemoattractant for 
hematopoietic and mesenchymal cells, 
fibroblasts, and muscle cells, stimulates 
chemotaxis toward a gradient of PDGF 
 Activates TGF-β, stimulates neutrophils 
and macrophages, mitogenesis of 
fibroblasts and smooth muscle cells, 
collagen synthesis, collagenase 
activity, and angiogenesis 
TGF-α (transforming growth factor alpha) 
 
 
 
 
 
 
 
 
 Resembles EGF, binds to the same 
receptor 
 Stimulates mesenchymal, epithelia, 
and endothelial cell growth, endothelial 
chemotaxis, controls the epidermal 
development  
 Stimulate the proliferation of endothelial 
cells, more potent than EGF 
 Promotes the generation of 
osteoblasts, influencing them to lay 
down bone matrix during osteogenesis  
 Affects bone formation and remodeling 
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Growth Factor Function 
TGF-α (transforming growth factor alpha) 
(cont’d) 
by inhibition of the synthesis of 
collagen and release of calcium  
 
TGF-β1 (transforming growth factor beta)  Stimulates fibroblast chemotaxis and 
proliferation and stimulates collagen 
synthesis  
 Decreases dermal scarring  
 Growth inhibitor for epithelial and 
endothelial cells, fibroblasts, neuronal 
cells, hematopoietic cell types, and 
keratinocytes  
 Antagonizes the biological activities of 
EGF, PDGF, aFGF and bFGF 
KGF or FGF-7 (keratinocytes growth factor)  Most potent GF for skin keratinocytes, 
playing a role in tissue repair following 
skin injuries  
 Promotes wound healing via 
proliferation, differentiation, 
angiogenesis, and cell migration  
 Mitogens for many epithelial cells but 
not for fibroblasts and endothelial cells 
aFGF or FGF-1 (fibroblast growth factor; 
acidic) 
 Participates in proliferation, 
differentiation, angiogenesis, and cell 
migration  
 A mitogens for skin-derived 
keratinocytes, dermal fibroblasts, and 
vascular endothelial cells 
bFGF or FGF-2 (fibroblast growth factor; basic)  Stimulate the growth of fibroblasts, 
myoblasts, osteoblasts, neuronal cells, 
endothelial cells, keratinocytes, and 
chondrocytes  
 Stimulates angiogenesis, endothelial 
cell proliferation, collagen synthesis, 
wound contraction, matrix synthesis, 
epithelialization, and KGF production  
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Growth Factor Function 
VEGF/VEP (vascular endothelial growth factor)  Stimulates the proliferation of 
macrovascular endothelial cells 
 A strong angiogenic protein, induces 
neovascularization  
 Induces the synthesis of 
metalloproteinase, which degrades 
interstitial collagen type 1,2,and 3 
CTGF (connective tissue growth factor)  Induces the proliferation, migration, and 
tube formation of vascular endothelial 
cells and angiogenesis  
 A potent stimulator for the proliferation 
ad differentiation of osteoblasts, 
stimulates the matrix mineralization 
GN-CSF or CSF-α (granulocyte/macrophage 
colony-stimulating factor) 
 Stimulates proliferation and 
differentiation of osteoblasts 
 Synergizes with Epo in the proliferation 
of BM progenitor cells  
 Strong chemoattractant for neutrophils  
IGF (insulin-like growth factor)  Growth factor for normal fibroblasts, 
mitogenic in vitro for a number of 
mesodermal cell types  
 Promotes the synthesis of collagenase 
and prostaglandin E2 in fibroblasts 
 Stimulates collagen and matrix 
synthesis by bone cells, regulating the 
metabolism of joint cartilage  
TNFα (tumor necrosis factor alpha)  Growth factor for fibroblasts  
 Promotes angiogenesis 
IL-1βI (interleukin-1β)  Inhibits the growth of endothelial cells 
and hepatocytes  
 Activates osteoclasts, therefore 
suppresses the formation of new bone, 
but in low concentrations it promotes 
new bone growth 
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Growth Factor Function 
 Enhances inflammatory reactions and 
collagenase activity 
IL-8 (interleukin 8)  Supports angiogenesis mitogenic for 
epidermal cells 
NGF (nerve growth factor)  Responsible for the survival and 
differentiation and the functional 
activities of sensory and sympathetic 
neurons in the peripheral nervous 
system.   
 Play an important role in the 
development and functional activities of 
cholinergic neurons in the central 
nervous system.  
 Induces the synthesis of specific 
transmitter like peptides in sensory 
neurons, including substance P 
Table #3:  Growth Factors Contained Within Platelets. 
The growth factors of interest found in platelets and their function (166). 
Leukocyte Cytokines of Interest 
   The various PRP techniques, with the exception of the leukocyte poor method, contain 
concentrated white blood cells (WBCs).  The WBCs contain many cytokines that are 
instrumental in the inflammatory and healing processes.  The BC method examined in 
this project includes WBCs and therefore has an effect on the various cells types involved 
in tissue injury and healing.  The cytokines of relevance to bone formation are described 
below.    
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Interleukin-1 
    IL-1 is produced by activated macrophages and neutrophils.  It is also produced by 
endothelial cells, fibroblasts, keratinocytes, and Langerhans cells.  IL-1 is a significant 
mediator of inflammation (116, 167-169).    It exists as 2 isoforms, α and  with IL-1  
being the prevalent form.  IL-1 synthesis is mediated by TNF-α, Interferons (IFN) α, , 
and , and bacterial endotoxins (116).  The principle action of IL-1 is to stimulate T-
helper lymphocytes.  TNF-α and IL-1  are also present in the platelets and their 
combination is known to activate osteoclasts and inhibit bone formation (116, 170).  
Interleukin-6 (IL-6)  
     IL-6 is an inflammatory cytokine associated with the IL-1 /TNF-α pathway (116, 
171).  It is found in activated monocytes, macrophages, T and B lymphocytes, 
granulocytes, fibroblasts, endothelial cells, mastocytes, chondrocytes, and osteoblasts 
(116).  IL-6 secretion is stimulated by IL-1, bacterial endotoxins, TNF-α, and PDGFs.  It 
is also self-regulating in that it can stimulate or inhibit its own synthesis (116, 172).  IL-6 
increases the rate of antibody secretion by 120 to 400 times and in vitro is known to 
promote hematopoietic stem cell proliferation (116).  IL-6 constitutes an important 
amplification pathway for signaling immune cells and therefore supports the reaction 
chains leading to inflammation, destruction, and remodeling of tissues (116, 173, 174).  
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Tumor Necrosis Factor-α (TNF-α)  
     TNF-α is released during the inflammatory response induced by bacterial endotoxins.  
Once stimulated by bacterial antigens, TNF-α is secreted by monocytes/macrophages, 
neutrophils, polymorphonuclear leukocytes, and T lymphocytes.  The production of TNF-
α is down-regulated by IL-6 and TGF-  (116, 175).  TNF-α activates monocytes, 
stimulates the remodeling ability of fibroblasts, increases phagocytosis, neutrophil 
cytotoxicity and modulates the expression of key mediators such as IL-1 and IL-6 (116, 
176, 177).  
Interleukin-4 (IL-4)  
      IL-4 is produced principally by the subpopulation of activated T cells (TH2, CD4+), 
which also secrete IL-6 (116, 178).   It supports proliferation and differentiation of the 
activated B cell, but its effects are completely dependent upon the cytokine environment 
(116, 179, 180).   IL-4 supports the healing response by modulating inflammation.  IL-4 
increases fibrillary collagen synthesis by fibroblasts and inhibits stimulation of MMP-1 
and MMP-3 by IL-1  (116, 181).  It opposes transduction pathways mediated by IL-1 , 
such as stimulation of PGE2 synthesis (116, 182). When macrophages are treated with 
IL-4 there is diminished production of IL-1 , TNF-α, and prostaglandins in response to 
bacterial endotoxins or IFN-  (116, 183, 184).  
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B.  History of PRP Use 
        Autologous PRP was first developed in the early 1970s as a byproduct of multi-
component apheresis.  Various GFs from platelets had been discovered by that time, but 
the clinical use of PRP was rarely reported in the 1980s.  Historically it was principally 
used in an activated gel state.  PRP gel is made by the addition of thrombin and excess 
calcium, which promotes both platelet activation and the coagulation cascade, resulting in 
the formation of a thrombus-like gelatinous substance (platelet gel, PGEL).  Activated 
platelets are trapped within the fibrin network, where they secrete bioactive substances 
that slowly diffuse into the surroundings tissues (39, 185-192).  The use of thrombin has 
recently been questioned because of the possible auto-immune responses to bovine 
thrombin (193).  PRP was introduced to the dental community by Whitman et al. who 
hypothesized that the activation of platelets and the subsequent release of GFs would 
enhance surgical wound healing (39, 194).  Autologous PRP GFs had been proposed as a 
treatment option for enhancing wound healing of chronic cutaneous ulcers by promoting 
the formation of granulation tissue.  This hypothesis was confirmed by a randomized 
prospective double-blind study which demonstrated improved wound healing compared 
to standard treatments (39, 195).  Since the publication of the initial studies, the use of 
PRP by the medical and dental communities has increased, but has often been cost-
prohibitive for individual practitioners.  Anecdotally, it is now generally accepted that the 
best procedure for promoting wound healing by PRP is to prepare an autologous PRP or 
PRP platelet gel (PRP/PGEL) that contains relevant GFs and to administer it directly to 
the site of the surgical intervention or wounds (39, 196).  The various methods for 
collection of PRP are discussed elsewhere in this manuscript.   
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Clinical Use of Platelet-Gel or PRP Growth Factors   
      PRP (and PRP/PG) use is widespread in dentistry and oral-maxillofacial surgery.  It is 
routinely used in conjunction with dental implant placement and bone regeneration 
techniques (197, 198).  It is also used in cardiovascular, renal, opthalmological, 
orthopedic, and plastic surgeries.  Moreover, several wound clinics use PRP or 
recombinant GFs to promote healing for patients with chronic diabetic ulcerations and 
other slow healing wounds.  Treatment of diabetic wounds with PRP was more effective 
in patients with deeper wounds than superficial lesions (39, 199).  In a study of 54 
diabetic patients with 86 wounds, treatment with PGEL significantly improved healing 
efficacy and reduced the incidence of amputations (39, 200).  Surprisingly Crovetti et al. 
(201) found that patients experienced less pain when PGEL was applied to diabetic 
ulcers.  
      It has also been reported that the use of PRP in 14 patients with skin and soft-tissue 
losses caused by acute trauma or chronic pathology led to fewer infections and a 
shortened length of hospital stays (202).  This finding highlights the significance of the 
WBCs contained in PRP and their possible role in decreasing or preventing infection.  
Man et al. (27) demonstrated decreased capillary bleeding in the surgical flaps of 20 
patients undergoing various cosmetic surgical procedures (face lifts, breast size changes, 
or neck lifts.) PGEL or PRP is currently being used in the treatment of tendonitis, and 
tendon/muscle repairs (203). A study of 100 patients who received calcified autologous 
PRP matrix in the surgical treatment to reconstruct the anterior cruciate ligament had 
enhanced attachment of the new articular cartilage graft (204).  PGEL used in the 
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treatment of chronic elbow tendonitis improved function and decreased pain when 
compared to conservative standardized physical therapy  protocols  (205).    
      Each of the above studies used variants of PRP that were prepared with expensive and 
time consuming techniques that limited the use and benefits of PRP use to larger 
sophisticated medical centers.  This dissertation examines a less expensive and time 
efficient method of obtaining a variant of PRP so the benefits will be readily available for 
multiple procedures in smaller out-patient clinics.  
Soft Tissue Wound Healing 
      Soft tissue-healing is a complex process that includes coagulation, inflammation, 
ground substance/matrix synthesis, angiogenesis, fibroplasias, epithelialization, wound 
contraction, and subsequent remodeling.  The physiological process begins immediately 
upon tissue injury and includes four distinct, yet overlapping, phases: a) hemostasis, b) 
inflammation, c) proliferation, and d) remodeling (164).  
Hemostasis Phase  
      Immediately following tissue injury that includes a vascular injury, intracellular 
calcium is released activating coagulation factor VII and inducing the extrinsic 
coagulation cascade.  Concurrently with the coagulation cascade, the arachidonic acid 
pathways, and the release of GFs and cytokines work jointly to initiate and sustain the 
inflammatory phase including the sequencing of cells involved in the process.  Locally, a 
reflex vasoconstriction occurs to facilitate hemostasis.  Hemostasis is ultimately achieved 
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by the formation of a fibrin plug composed of a provisional wound matrix that functions 
as a lattice network upon which platelets aggregate (39, 164).  
Inflammation Phase   
      During the early post-injury period platelets provide an abundance of GFs.  These 
GFs act on inflammatory cells, fibroblasts, and endothelial cells to orchestrate wound 
healing including chemotaxis of neutrophils, monocytes, and fibroblasts into the wound 
(39, 164, 206, 207).  In the first two days of healing, the inflammatory process is initiated 
by the migration of neutrophils.  Neutrophils are responsible for debris scavenging, 
complement-mediated opsonization of bacteria, and bacteria destruction via 
myeloperoxidase (MPO)-driven oxidative burst mechanisms (i.e. superoxide and 
hydrogen peroxide formation) (39).  Neutrophils destroy bacteria and decontaminate the 
wound by removing lymphocytes and macrophages (monocytes).  The macrophages 
secrete multiple enzymes including collagenases, which lead to wound debridement.  The 
macrophages also secrete additional GFs, which in turn stimulate fibroblasts to produce 
collagen and promote angiogenesis.  This step marks the transition from the 
inflammatory phase to the proliferation phase of tissue reconstruction (39).  
Proliferation Phase 
       The proliferative phase begins approximately 2 to 3 days after wounding.  This phase 
begins with the arrival of fibroblasts into the wound site.  Fibroblasts migrate from the 
wound margins by means of the fibrin-based interim matrix established during the 
inflammatory phase.  During the first week of healing, fibroblasts are driven by a 
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macrophage-derived fraction, TGF-β, and PDGF to proliferate and synthesize 
glycosaminoglycans and proteoglycans.  The glycosaminoglycans and proteoglycans 
become the foundation for a new extracellular matrix of granulation tissue and collagen. 
(39, 164, 206)  Angiogenesis and fibroplasias begin after day three, followed by the 
initiation of collagen synthesis on days three to five (39, 208).  
Remodeling Phase 
        During the remodeling phase, macrophage numbers diminish in the wound, 
therefore fibroblasts become the primary source for TGF-β, PDGF, keratinocytes growth 
factor (KGF) and IGF-1.  Fibroblasts are the dominant cell type, reaching peak numbers 
at 7 to 14 days.  Once fibroblasts have secreted collagen molecules, fibroblasts then 
gather them extracellularly to form collagen fibers.  These collagen fibers then become 
cross-linked and assembled into a bundle form.  Collagen is the most important 
component of acute wound connective tissue, and production continues for the next 6 
weeks.  Increasing amounts of wound collagen correlates with greater tissue tensile 
strength (39, 206, 207).   The increased tensile strength is the most significant step in 
wound-healing, followed by epithelialization and finally wound remodeling (39).  
      During the wound-healing process, platelet GFs regulate the time-critical and 
multifaceted mechanisms involved in cell-cell and cell-matrix interactions (39, 189, 206, 
209).  Therefore, the local application of PRP or PGEL to enhance repair of surgically 
induced wounds has the benefit of providing numerous synergistically working 
autologous GFs to induce proliferation of mesenchymal and other stem cells at the wound 
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site (39, 210, 211).  Bone formation is covered in the section titled: Osteogenesis – 
Developmental Pathways for Bone Formation. 
 Platelet Concentrate Storage 
      Occasionally it is necessary to collect whole blood and process the PRP for use at a 
later time point.  This may be due to the complexity and extensive nature of the pending 
surgery or that the patient may have difficult veins to access and the end-user facility may 
not have the adequate personal to obtain the whole blood.  In these situations, it becomes 
necessary to store PRP for this future use.  The storage of PRP for clinical use with 
surgical procedures has only recently been studied.  Liu et al. (212) in 2008 found that 
levels of GFs in PRP that had been activated with calcium and thrombin and stored for 2 
to 10 days resulted in TGF-β1 and PDGF-AB concentrations that decreased rapidly when 
stored at various temperatures.  When stored at -20°C and -70°C the levels declined but 
were significantly higher than when stored at 4°C.  Therefore if PRP is to be stored it 
appears that lower temperatures (<-20°C) are preferred.  The optimal storage conditions 
for platelets differ from that of other blood cell types.  The isolation of platelets from 
other blood cells allows for the storage of the PC under optimal conditions.  This 
dissertation examines the effect of short-term storage (6 hours or less) at room 
temperature.  PRP is often collected prior to commencing the surgical procedure.  The 
time to final use of the PRP is dependent upon the time requirements for the intended 
procedure.  This may vary from as little as 15 minutes to more than 4 to 6 hours.  
Therefore, it is important that clinicians have a guideline as to how long PRP (processed 
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by the investigated technique) and its constituents are stable for at room temperature after 
processing. 
Platelet Collection for Surgical Site Application 
      Two major techniques are used to concentrate autologous platelets from whole blood 
in the medical or dental office setting.  Each method has several variations, but they can 
be summarized as concentrated platelet-rich plasma (cPRP) and the buffy coat (BC) 
methods (34, 213).  This dissertation investigates the BC method of acquiring PRP 
because it can be achieved in a time-efficient manner and with a standard clinical table 
top centrifuge that creates a force of 1150 x g. 
Concentrated Platelet Rich Plasma (cPRP) Collection Technique 
     The cPRP technique has widespread popularity in the United States (15).   The cPRP 
collection technique involves collecting whole blood that is anti-coagulated and is 
separated by centrifugation.  The separation is based on the physical properties of cells 
(specific gravity, size, and deformability) in addition to the viscosity of the plasma (34).  
Steps for this technique are as follows: 
1. Initially 20 - 450 mL of whole blood is subject to a low g force “soft” spin that 
allows for separation of the blood into 3 layers.  The bottom of the tube contains 
red blood cells (RBCs-55% by volume), the middle contains platelet rich plasma 
(PRP-5% by volume) and the top contains platelet poor plasma (PPP-40% by 
volume).  This low-speed centrifugation results in a PRP layer that contains the 
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majority of suspended platelets, 30 to 50% of the original total white blood cells, 
and some red blood cells.  
The PPP and PRP layers are transferred to a satellite container and centrifuged at 
a higher g force referred to as a “hard” spin for a longer time period.  This allows 
for platelets to be concentrated at the bottom of the tube and to subsequently 
obtain, once again, 3 distinct layers (some residual RBCs will be trapped at the 
bottom of this 2
nd
 tube).  
 
Figure 5: Schematic Showing Concentrated PRP Collection (214). 
2. It is recommended that the platelet pellet should be left undisturbed for 1 hour 
prior to the next step to minimize platelet aggregation and damage (215).  
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3. At this stage, it becomes easy to collect the PRP.  The major portion (50 to 80%) 
of the supernatant serum is now removed.  Enough serum is left behind to allow 
for suspension of the PRP and any remaining RBCs by gentle shaking.  This now 
provides concentrated PRP (cPRP), which has a rosy aspect due to the presence of 
some RBCs.  
4. Most techniques call for making a platelet gel (PGEL) from this suspension by the 
addition of calcium and bovine thrombin.  This can be achieved with the use of a 
mixing syringe.  Gelling of platelet concentrate will then occur quickly.  
Fibrinogen is also concentrated during the cPRP preparation, and its 
polymerization will constitute a fibrin matrix with hemostatic and adhesive 
properties.  
     This cPRP technique followed by gelling is a technology that is deemed new, but in 
reality is similar to conventional fibrin adhesives (214, 216-232).  The potential for 
platelet cytokines and growth factors being released en masse during platelet activation 
with bovine thrombin appear to be dependent on the time of activation and the 
mechanical and biological properties of the final fibrin matrix (214, 233).   Unfortunately, 
many studies indicate that the clinical effects of PGEL are very near those observed with 
conventional fibrin adhesives (204, 214, 216-232).  Concentrated PRP gelling with 
bovine thrombin and calcium chloride begins during the final stages of coagulation and 
results in sudden fibrin polymerization. This mode of polymerization will considerably 
influence the mechanical and biological properties of the final fibrin matrix (214, 233).  
The fibrin network is a condensed tetra-molecular or bilateral junction with high 
thrombin concentrations that forms a rigid network not favorable to cytokine 
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enmeshment and cellular migration (Figure 6).  Although PGEL should support cytokine 
action, cytokines may be released too quickly to be incorporated into the fibrin.  
Therefore, the released cytokines will be extrinsic, that is, trapped in the colloidal 
suspension during the gelling process.  Therefore, cytokine/fibrin synergies may be lost 
because of rapid elimination (104).  This could explain the modest clinical effects 
observed with PGELs (214).       
 
Figure 6.  Rigid Fibrin Junctions 
 
Theorectical computer model of rigid condensed tetramolecular or bilateral fibrin branch 
junctions (214). 
Buffy Coat Technique   
      The buffy coat technique is more common in Europe and is similar to the technique 
studied in this project.  Steps involved in the BC technique are as follows: 
1. The desired quantity of whole blood is drawn and is centrifuged for 7 to 10 
minutes at 3000 x g.  This creates a “buffy coat” (BC) of platelets and 
leukocytes.  During high speed centrifugation WBCs initially sediment with 
RBCs while platelets remain in the plasma supernatant.  Next the RBCs become 
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packed closely together and rapidly fall to the bottom of the collection vessel.  
This process forces WBCs upwards to the plasma interface.  The platelets in the 
supernatant plasma then settle and accumulate on this interface.  Interestingly, 
this settling of platelets on the red cell interface may explain the lesser degree of 
platelet activation when platelets are prepared in this manner as compared to the 
cPRP method (234).   The BC consisting of platelets and WBCs is removed 
along with a small portion of the lower plasma layer and the upper red cell layer.  
2. The BC is then centrifuged at low speed to separate the platelets from leukocytes 
and any remaining RBCs.  Collection vessel systems that have a top/bottom 
separation partition facilitate separation by allowing the platelets in the BC to 
remain undisturbed in the initial separation bag (with plasma and RBCs removed 
from the top and bottom ports, respectively) (235).   
3. The collection of platelets, now referred to as platelet rich plasma (PRP), is 
transferred to a delivery device for immediate use.  
      Platelet rich plasma acquired by other methods are referred to generically as PRP.  In 
this dissertation, the technique under investigation is referred to as the “buffy coat” or BC 
method and steps 2 and 3 is not followed during platelet processing.  Our technique also 
uses a g force of 1150 rather than 3000.  Therefore, the “platelet rich plasma” of this 
investigated technique is actually a combination of platelet concentrates and WBCs.    
     The two PRP methods (cPRP and BC) used in dental/medical offices are summarized 
in the figures 7 and 8.  PRP techniques that include the addition of exogenous bovine 
thrombin and excessive calcium are added at the completion of the “hard” centrifugation 
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seen in figure 7.  One-third to one-half of the platelet poor plasma (PPP) is also added 
back into the cPRP.  The BC technique examined here is similar to that shown in figure 
8, but does not include the “soft” centrifugation (2nd centrifugation).   
 
   
 
 
 
 
 
 
Figure 7: Preparation of cPRP 
 
Concentrated Platelet-rich plasma (cPRP) preparation from anticoagulated whole blood 
(34).  To make gelled PRP at the completion of the above steps, one-third to one-half of 
the platelet poor plasma (PPP) is added back into the cPRP, followed by the addition of 
bovine thrombin and excess calcium.  
Anticoagulated 
whole blood 
 
“Soft” 
centrifugation 
Red blood cells Platelet-rich plasma 
“Hard” centrifugation 
Platelet-concentrate 
cPRP 
 
cPRPR 
Platelet Poor 
Plasma (PPP) 
45 
 
 
     
                                              
 
 
 
 
 
 
Figure 8: Preparation of Buffy Coat From Anticoagulated Whole 
Blood  
Buffy coat (BC) preparation from anticoagulated whole blood (34).  The technique 
investigated in this dissertation utilizes the “hard”centrifugation at 1150 x g and does not 
include the “soft” centrifugation (2nd centrifugation). 
 
Concerns of Residual WBCs in Platelet Concentrates: 
      When platelets are obtained from one individual for transfusion into another 
individual the presence of WBCs is of concern.  WBCs from the donor can theoretically 
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induce the rare, incurable, and often-fatal degenerative neurological disorder Creutzfeld-
Jacob disease.  Another benefit of using leukocyte poor PRP is a decrease in the risk of 
common febrile non-hemolytic transfusion reactions such as cytomegalovirus (CMV) 
transmission, and HLA alloimmunization (34, 236, 237).  These complications are only 
of concern if the recipient of the PRP differed from the donor.  When the PRP donor and 
recipient is the same individual, the presence of WBCs in the PRP is of no concern.   
      Zimermann et al. (238) examined whether the presence of leukocytes had an 
effect on PDGF-AB, PDGF-BB, and TGF-β1 levels. The mean absolute levels of PDGF-
AB and PDGF-BB showed differences between leukocyte rich and leukocyte poor 
preparations.  Leukocyte rich PRP had significantly higher levels of PDGF-AB, PDGF-
BB, and TGF- β1 than leukocyte poor PRP did (P < .05).  Stepwise regression analysis 
revealed that platelet concentration was the most significant variable and the presence of 
monocytes was a significant co-variable for predicting the variance in PDGF-BB and 
TGF-β1 measurements (238).  
Platelet Rich Fibrin (PRF): A Second –Generation Platelet Concentrate 
     A new family of platelet concentrates has recently been developed that is a cross 
between an autologous fibrin glue and classical platelet concentrates.  This new 
biomaterial, referred to as platelet-rich fibrin (PRF), is similar to an autologous cicatricial 
matrix (214).  Study 2 of this dissertation examined the effect of the BC method on dry 
socket formation following mandibular tooth extraction using a gelled BC technique that 
is similar to PDF.  The BC had been prepared as described previously and followed by 
the addition ½ of the obtained PPP layer and 0.5 mL calcium chloride 10% and allowed 
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to set for 10 minutes.  This resulted in a fibrin gelled clot similar to this PRF platelet 
concentrate described in this section.  The gelled BC method collected the blood in a 
glass tube containing the anti-coagulant tri-sodium  citrate and the PRF method uses a 
glass tube that does not contain an anti-coagulant.  
      Fibrin adhesives have been used for the past 30 years as adjuncts for regulating 
inflammation and increasing healing following surgical procedures (214, 239).  Use of 
PRF has been limited due to the complexity of the production protocols for autologous 
adhesives and the risk of cross-infection from commercial adhesives.   
     Fibrinogen is present in platelet α-granules and is instrumental in platelet aggregation 
during hemostasis (214).  Fibrinogen is the final substrate for all coagulation reactions 
and is cleaved by thrombin to yield insoluble fibrin.  The result is a polymerized gel that 
constitutes the scar-like matrix for the injured site (214, 240-242).  Just as in PGELs, 
combining the advantages of a fibrin adhesive with the advantages of concentrated 
platelets may have greater benefits to the healing process.  However, since 1978 many of 
the commercial fibrin adhesives have been removed from the commercial market due to 
the risk of hepatitis.  To avoid this complication Tayapongsak et al. (243) developed an 
autologous fibrin adhesive technique in 1994 (214, 243). Due to the time and expense 
commitment, this methodology never gained widespread acceptance for simple 
procedures but did find a place in cardiothoracic, vascular, and plastic surgeries (214, 
243, 244).  The possibility of obtaining autologous growth factors from PRP or BCs 
sparked interest in combining a fibrin adhesive with PRP treatment.  The PRF protocol is 
similar to the BC technique examined in this dissertation. 
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PRF Protocol 
     Blood is drawn into 10 mL tubes without anticoagulant and then immediately 
centrifuged in a table top centrifuge at 3000 x rpm (approximately 400 x g) for 10 
minutes.  Since there is no anticoagulant present, platelet activation will begin once the 
blood comes in contact with the tube walls and subsequently initiate the coagulation 
cascade.  Fibrinogen is initially concentrated in the top and middle portions of the tube, 
before circulating thrombin transforms it into fibrin.  This leads to the development of a 
fibrin clot in the middle of the tube, just between the red blood cells at the bottom and the 
acellular plasma at the top of the tube. Platelets will theoretically be trapped in the fibrin 
clot (Figures 9 and 10) (214).  
 
Figure 9. Centrifuged Whole Blood                  
 
 
Result of centrifugation of whole blood by PRF protocol.  The fibrin clot is shown in the 
middle with the red blood cells below and the acellular plasma layer above (214). 
 
49 
 
 
 
 
 
 
Figure #9 Reference:(214)  
 
 
 
 
 
 
 
Figure 10.  Protocol for Platelet Rich Fibrin Processing 
 
A. Clinical centrifuge used for PRF protocol.  B. Results of centrifugation showing fibrin 
clot as PRF.  C. Removal of the clot from the tube.  D. Resistant autologous fibrin 
membranes obtained by driving out the serum from the clot (214). 
     The success of the technique depends entirely upon promptly centrifuging the whole 
blood after collection.  Without anticoagulant the collected whole blood begins to 
coagulate immediately upon coming in contact with the glass wall of the collection tube.  
It takes a minimum of a few minutes of centrifugation to concentrate fibrinogen in the 
middle and upper part of the tube.  Efficient handling is essential to obtaining a clinically 
usable PRF clot.  If the time required to collect blood and to begin centrifugation is 
prolonged, the fibrin will polymerize in a dispersed manner in the tube and only a small 
blood clot without consistency will be obtained (214).  
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     PRF is different from PGELs in that it polymerizes naturally and slowly during 
centrifugation.  Thrombin acts on fibrinogen to produce a fibrin mesh that has tri-
molecular or equilateral fibrin junctions.  These connected junctions allow the 
establishment of a fine and flexible fibrin network capable of supporting cytokine 
enmeshment and cellular migration.  The trimolecular fibrin organization (Figure 11) 
gives greater elasticity to the fibrin matrix in comparison to PGELs tetra-molecular or 
bilateral fibrin architecture (Figure 6). This results in a flexible, elastic, and strong PRF 
membrane (214).      
  
Figure 11.  Flexible Fibrin Junctions 
Theorectical computer model of flexible trimolecular or equilateral fibrin branch 
junctions (214). 
        
     It should also be noted that the PRF matrix enmeshes glycosaminoglycans (heparin 
and hyaluronic acid) from the blood and platelets.  The fibrillary architecture of fibrin is 
followed, meaning that the glycanic links are incorporated within fibrin polymers.  
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Glycosaminoglycans have high affinity for small circulating peptides including platelet 
cytokines and therefore support cell migrations and the healing processes (104, 240).   
     This PRF technique has relevance to this dissertation, because Study 2 uses a gelled-
BC methodology that is very similar to this technique.  The findings of a flexible fibrin 
junction and the trapping of GFs in this matrix may explain why the results of Study 1 
show stable or increasing levels of growth factors over bench set time after BC 
preparation. 
 
Bovine Thrombin 
  Many clinicians believe that PRP must have the platelets activated for the growth 
factors to be released and made available for healing benefits to be achieved (7).  The 
most common method to achieve this platelet activation is with the addition of bovine 
thrombin to the PRP.  The BC PRP technique examined in this dissertation does not 
utilize bovine thrombin for platelet activation because it may not be necessary to 
exogenously activate the platelets.  Activation will occur spontaneously due to the high 
calcium molar concentration that is available endogenously in plasma (approximately 2 
mM)  plus the many other activating agonists found at the site of injury such as collagen, 
thrombin, thromboxane A2, ADP, serotonin, vasopressin, thrombospondin, von 
Willebrand factor, fibrinogen, PAF, immune complexes, and plasmin. (15).  
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     Bovine thrombin is utilized in surgical procedures because of its biological ability to 
convert fibrinogen into fibrin.  Thrombin is a naturally occurring enzyme that has been 
widely characterized for its roles in hemostasis, inflammation, and cell signaling (193).  It 
has been purified from multiple sources and used as a clinical adjunct for topical 
hemostasis for more than 60 years in nearly all types of surgical procedures.  Thrombin is 
used routinely in cardiovascular, orthopedic, neurologic, general, gynecologic, oral 
surgical and dental procedures.  Thrombin is also used to aid in the thrombosis of 
vascular pseudo-aneurysms and for topical application at bleeding cannulation sites of 
dialysis access grafts (193, 245-247).  A conservative estimate is that at least 1 million 
patients in the United States are treated with topical thrombin each year. Currently, the 
only FDA approved stand-alone hemostatic product is a derivative from bovine sources.  
Bovine-derived thrombin has potent biological activity that converts fibrinogen to fibrin, 
activates platelets, and induces vascular contraction.  Thrombin can also induce a robust 
immune response in humans (193). There are several reports in the medical literature that 
document multiple clinical events following exposure to bovine thrombin in surgical 
settings (193, 248-261).   These events included the development of antibodies against 
thrombin, prothrombin, factor V, and cardiolipin (193).  In some cases, these antibodies 
cross-react with the analogous human coagulation proteins, specifically factor V, 
resulting in hypocoagulopathies (256, 262, 263).  Bovine thrombin is extremely 
immunogenic in cardiac surgical patients, and greater than 90% of the patients who are 
exposed to bovine thrombin develop a significant immunologic response.  It is of even 
greater concern that a significant number of these patients also develop cross-reacting 
antibodies to their own endogenous coagulation proteins with associated hematologic 
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abnormalities in more than 30% of these patients (193, 256).  The process of breaching 
self-tolerance through molecular mimicry can lead to autoimmunity (264-268).  It has 
been hypothesized by Lawson et al. (193) that the consequences of applying 
immunologically disparate, yet biologically active, thrombin at physiologically extreme 
concentrations (1000U/mL) into surgical sites may lead to direct immune recognition and 
other biologic cascades, resulting in deleterious complications.  
     Zimmermann et al. (238) compared the effect of the adding bovine thrombin and 
calcium gluconate 10% in a 1:1 mixture with PRP to untreated PRP.  They found the 
addition of the thrombin/calcium did not have an effect on PDGF-AB or PDGF-BB 
levels when compared with untreated PRP samples.  However, the addition of bovine 
thrombin and calcium gluconate did cause a significant decrease in TGF-β1 levels when 
compared with the untreated group (238).  This finding might explain reports that PRP 
mixed with bovine thrombin and calcium do not improve bone healing, but do improve 
soft tissue healing (269).  These reports may be explained by the following: PDGF-AB 
and PDGF-BB are significant to soft tissue healing and only contribute to bone formation 
when in the correct ratio with TGF-β1 levels.   PDGF-AB and PDGF-BB concentrations 
are unaltered by the addition of bovine thrombin, therefore  the soft tissue healing 
benefits would be present.  However, the addition of bovine thrombin does decrease 
concentrations of TGF-β1.  Therefore, one could expect that bone healing maybe 
diminished with the bovine thrombin formulation.   
     Most dental PRP procedures use a 1:10 (bovine thrombin/PRP) ratio (upwards of 
1000+ units) for converting cPRP to PGEL.  Because the use of bovine thrombin is 
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associated with a significant risk of immunologic side effects and a potential decreased 
TGF-β1 levels, its use for the production of PGELs should be questioned.  The BC PRP 
technique examined in this dissertation does not utilize bovine thrombin and may offer an 
alternative for clinicians.  If this technique is able to provide the necessary growth factors 
to facilitate healing, then the continual use of bovine thrombin with its potential 
autoimmune responses and decreased TGF- β1levels can be avoided.   
C.  Cellular Aspects of Bone Formation 
Genetic Markers of Osteoblast Differentiation 
       Osteoblasts synthesize the macromolecules responsible for forming and 
mineralizing bone matrix including type I collagen, osteocalcin, osteonectin, osteopontin, 
proteoglycans I and II, bone sialoprotein, matrix gla-protein, bone glycoprotein 75, and 
other proteins including growth factors (270).  Additionally, osteoblasts have high levels 
of the membrane-bound enzyme alkaline phosphatase, which is important in matrix 
mineralization, and receptors for tissue-specific hormones, such as parathyroid hormone, 
cytokines and growth factors.  These molecules act in concert to regulate bone growth, 
cell differentiation and metabolism.  Although these proteins are not exclusive to 
osteoblasts, together they characterize bone phenotype (270).  
The differentiation process of osteoblasts, originating from mesenchymal 
precursors, involves a complex process of timely activation of specific transcription 
factors that regulate the expression of certain genes.  The genes Runx2/Cbfa1 and Osterix 
(Osx) are master controllers of the osteoblastic lineage, and the absence of any of these 
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genes results in a complete lack of a mineralized bone (271-274).  The expression of 
these genes during osteoblast differentiation occurs in a stepwise fashion involving 
multiple regulatory factors.  Type I collagen and alkaline phosphatase are expressed early 
during differentiation while osteopontin and osteocalcin appear later during 
differentiation (270).   The gene for bone sialoprotein (IBSP) is expressed in newly 
formed osteoblasts (275).   Osteocalcin gene expression follows the expression of IBSP 
(276).  Osteoblasts pass through many phases in the differentiation process and the gene-
expression profile varies widely depending upon the stage of differentiation.  Therefore, 
changes in gene expression must be interpreted in a way that accounts for hMSC culture 
diversity with respect to the mixture of cells that may be in various stages of 
differentiation.  
There are several osteoblastic cell culture models available to study the 
expression of osteoblast-related genes in vitro.  These models include primary cultures 
from calvaria or trabecular, osteosarcoma-derived cell lines, and experimentally 
immortalized cells (270).  The current investigation uses a line of commercially available 
human mesenchymal stem cells.    
Osteocalcin Gene [BGLAP bone gamma-carboxyglutamate (gla) protein] 
[Homo sapiens] 
  This dissertation used the osteocalcin gene as a marker of hMSC differentiation 
into a mature osteoblast because it is known to be a late marker of this differentiation 
(276).  Osteocalcin is bone γ-carboxyglutamic acid-containing protein thought to be 
produced exclusively by relatively mature osteoblasts (276, 277).  Serum levels of 
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osteocalcin correlate well with histomorphometric parameters of bone formation.  
Osteocalcin controls hydroxyapatite crystal growth and signals osteoclast induced bone 
resorption.  In vitro experiments demonstrate that osteocalcin is a chemoattractant for 
monocytes, which are osteoclast precursors (276-278).  Osteocalcin gene expression has 
been used to study cell type-specific gene expression for osteoblasts (276, 279).    This 
study uses the osteocalcin gene (BGLAP-Homo sapiens) as a marker of late osteoblast 
differentiation. 
Bone Sialoprotein Gene (IBSP: integrin-binding sialoprotein (bone 
sialoprotein, bone sialoprotein II) [Homo sapiens] 
       This dissertation used the bone sialoprotein gene as a marker of hMSC 
differentiation down the osteoblast lineage because it is known to be a middle to late 
marker of this differentiation (280).  Bone sialoprotein (IBSP) is a bone extracellular 
matrix glycoprotein that represents 8 to 12% of the total noncollagenous proteins 
associated with mineralized tissues (281-285).  IBSP expression correlates with terminal 
osteoblastic differentiation and the onset of bone matrix mineralization. Expression of 
high levels of IBSP coincides with de novo bone formation.  Bone formation results from 
IBSP’s biophysical and chemical properties that include high binding affinity for calcium 
and for the ability to initiate hydroxyapatite formation (275, 281, 286-291).  It is well 
accepted that IBSP plays a major role in bone formation and remodeling and is 
considered one of the primary markers of terminally differentiated osteoblasts (288).  
IBSP has  cell attachment and cell signaling properties that are utilized in bone 
remodeling and may also play a role in various pathologies (288).   
57 
 
  Bone sialoprotein mRNA is highly expressed in newly formed cuboidal 
osteoblastic cells that form bone matrix (287)  and is readily detectable in osteoblasts of 
embryonic bone, indicating that IBSP is induced when osteoblasts are generated (275, 
282).  IBSP gene expression is up-regulated by hormones and cytokines that promote 
bone formation and down-regulated by factors that suppress bone formation (275).   
       There are few cell lines that constitutively synthesize IBSP.  Rat osteosarcoma 
cell lines ROS17/2.8 and UMR 106-01 cells have recognized characteristics of 
osteoblasts and they both express IBSP.  The high levels of IBSP mRNA and the absence 
of osteocalcin expression suggest that UMR 106-01 cells model newly formed 
osteoblasts, whereas the lower expression of IBSP and high osteocalcin in ROS cells 
model a more mature osteoblast phenotype (288, 292).  The investigator examined both 
osteocalcin and IBSP gene expression in this study.    
Glycoprotein IIb [ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of 
IIb/IIIa complex, antigen CD41) [Homo sapiens] 
       The glycoprotein IIb gene (ITGA2B) was chosen as a marker of platelet presence 
and expression would hopefully diminish with time.  The PRP treatments done in this 
dissertation were for a 24-hour period only and therefore should be removed with 
aspiration of the PRP medium after 24 hours and what did remain would be removed 
with successive growth medium changes.  The ITGA2B gene encodes for the protein 
integrin α-chain 2b portion of the glycoprotein IIb/IIIa. This integrin α-chain 2b is part of 
a heterodimeric integral membrane protein receptor composed of an alpha chain and a 
beta chain.  The α-chain 2b undergoes post-translational cleavage to yield disulfide-
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linked light and heavy chains that join with beta 3 to form the fibronectin receptor 
expressed in platelets that plays a crucial role in coagulation.  In addition to adhesion, the 
glycoprotein IIb/IIIa receptor is known to participate in cell-surface mediated signaling 
(293).  The glycoprotein receptor and its expression are discussed in detail in the platelet 
membrane glycoprotein section of this paper.  
       In the mouse and murine embryo, Cd41 is the initial and most explicit surface 
marker that distinguishes cells that are committed to the hematopoietic lineage from 
endothelial and other mesodermal cell types (294-299).  However, Cd41 is expressed 
only in nascent hematopoietic mouse stem cells (HMCs), whereas mature HMCs lose 
Cd41 expression, with the exception of megakaryocytes and platelets which maintain it 
(294, 300-302).   In humans, ITGA2b gene expression is thought to be limited to 
megakaryocytes and platelets (293).  
GAPDH (glyceraldehyde-3-phosphate dehydrogenase; G3PD; GAPD) 
       Glyceraldehyde-3-phosphate dehydrogenase was chosen as the “housekeeping” 
gene for this study because it is not regulated by PRP treatment.  Glyceraldeye-3-
phosphate dehydrogenase catalyzes an essential energy-yielding step in carbohydrate 
metabolism, the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in 
the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD
+
).   
GAPDH is a tetramer of four identical chains.  GAPDH is expressed in hMSCs, 
differentiating osteoblasts, mature osteoblasts, leukocytes, and platelets (303-306).  
 
Osteogenesis – Developmental Pathways for Bone Formation 
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       Osteogenesis is the process of bone formation.  Bone is an organ that is 
comprised of mineralized calcium phosphate matrix and a variety of cell types that 
provide structural support for the body and play a role in bone metabolism.  Bone 
develops as osteoblasts - cells that produce and secrete mineralized matrix - mature and 
then differentiate into osteocytes or bone lining cells or undergo apoptosis. 
 
Maturation of 
osteoblasts is coupled with the breakdown of damaged bone by osteoclasts.  Bone is 
therefore a continually remodeled structure.  The site of remodeling is the mineralized 
matrix, which is also the location of the osteoclasts and osteoblasts. 
Osteoclasts are large, multi-nucleated cells that are of hematopoietic origin, 
differentiating from the monocyte-macrophage lineage (307).  These cells are responsible 
for bone resorption at sites within the osteiod of microdamage. The maturation and 
differentiation of osteoclasts is directly linked with that of osteoblasts, as a balance 
between bone resorption and matrix production must exist. 
Osteoblasts develop from mesenchymal stem cells (MSCs) and are responsible for 
secreting the calcium phosphate matrix, or osteiod found in bone (308).  There are four 
stages in the osteoblast life span (309, 310).  The first stage is the preosteoblast, which is 
located within bone one or two cell layers apart from mature bone forming osteoblasts.  
For preosteoblasts to become active, they must locate to the bone surface.  This is 
achieved by osteoclast-induced bone breakdown.  Once in position, the preosteoblast 
begins to produce and secrete bone matrix proteins and is identified as an osteoblast.  
After an osteoblast has ceased synthesis and mineralization of new bone, it is fated to one 
of three states: osteocyte, bone-lining cell, or apoptosis.  A small fraction of the 
osteoblasts are ultimately embedded in the mineralized matrix of the bone and termed 
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osteocytes.  Osteocytes represent the final differentiation stage of the osteoblast lineage  
(309, 311).  Osteocytes regulate bone turnover by detecting microdamage of the bone 
 
(309).  Inactive bone surfaces are covered with post-proliferative osteoblastic cells known 
as bone-lining cells.  It is thought that bone-lining cells are not involved in matrix 
formation, but play a role in initiating remodeling and other functions (312). 
Interestingly, the total population of osteocytes and bone-lining cells does not equal the 
total population of once active osteoblasts, thus suggesting that the third fate, apoptosis, 
may be of importance (309, 313-316).  
  Other cell types that develop from mesenchymal stem cells include chondrocytes 
and adipocytes (317).  The osteogenic protein BMP-2 and the cytokine TGFβ1 are 
examples of regulatory molecules that help mediate the commitment of the progenitor 
cells to the osteoblast lineage (317).  Osteoblasts are under the control of many factors 
including paracrine, autocrine, and endocrine compounds that influence cell replication, 
recruitment, and differentiation.  These factors include bone morphogenetic proteins 
(318), cell growth factors and cytokines (IGF-I, TGF-β, others) (319), hormones (GH, 
insulin, glucocorticoids, 1,25 (OH)2-vitamin D3) (320), and biomechanical forces (321).  
Genetic Aspects of Bone Development 
     Bone formation is directed by multiple genes (322).  The transcriptional cascade that 
regulates osteoblastogenesis is initiated by developmental signals that recruit MSCs to 
organize embryonic bone via osteoblast differentiation (intramembranous bone), or MSC 
condensation into a cartilage template for endochondral bone formation (323).  Primary 
intramembranous bone is formed from mesenchymal cells that develop directly into 
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osteoblasts and is responsible for the formation of the cranial vault, facial bones, and, in 
part, the clavicle and mandible (324, 325).  Endochondral bone formation is responsible 
for the formation of the axial and appendicular skeleton (325, 326).  Endochondral bone 
development is a complex process that involves a highly specific temporo-spatial pattern 
in which undifferentiated MSCs differentiate into chondrocytes, and then undergo well-
ordered and controlled phases of proliferation, hypertrophic differentiation, death, blood 
vessel invasion, and finally replacement of cartilage with bone.  Fibroblast growth factors 
(FGF) and parathyroid hormone/parathyroid related protein (PTH/PTHrP) are regulators 
of proliferation for expansion of progenitor cell populations and growth plate maturation 
during bone development (323, 324, 326).  Secreted factors that have a significant impact 
on bone development include the BMP/TGFβ type factors.  
Several members of the TGF-β superfamily, the bone morphogenetic proteins 
(BMP 2, 4, and 7) have potent osteogenic effects.   It should be noted that PRP contains 
TGF-β1 and BMP2 (327).   Graziani et al. (328) found that various concentrations of  
leucodepleted PRP activated with calcium gluconate and autologous thrombin had an 
effect on hMSC proliferation and osteoblast expression of, osteocalcin, and 
osteoprotegerin.  In 2005, Kanno found that bovine thrombin activated PRP enhanced 
both osteoblast cell proliferation and differentiation (329).  This dissertation differs from 
these two works because the BC PRP used in this technique was not activated with 
thrombin.   
      The mechanism for BMP signaling is through heteromeric formation of BMP 
transmembrane receptors that phosphorylate specific receptor Smad proteins resulting in 
translocation to the nucleus with DNA binding Smad4 (figure 12) (323, 330-332).  While 
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BMP-Smad signaling is a major pathway for induction of osteoblast differentiation, it 
should be noted that BMPs induce other kinase-dependent signaling pathways (e.g., p38, 
MAPK, PKC, and JNK) that also contribute to Smad phosphorylation and mediate the 
effects of BMP on bone formation (323, 333-340).  
 
 
Figure 12.  Bone Morphogenetic Protein Signaling Cascade 
Bone morphogenetic protein (BMP) ligands bind to the BMP receptors BMPRI and 
BMPRII.  Once binding has occurred, BMPRI becomes phosphorylated and activated.  
Phosphorylated BMPRI in-turn phosphorylates receptor-activated Smad proteins (R-
Smads), which combine with common mediator-Smad (co-Smad) and enter the nucleus.  
Once in the nucleus they regulate gene expression by either transcriptional co-activators 
or co-repressors (332).   
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Human Mesenchymal Stem Cells (hMSCs)    
       Human mesenchymal stem cells (hMSCs), also referred to as marrow stromal 
cells, mesenchymal progenitor cells, or colony forming-unit fibroblasts, are multipotent 
cells with a long columnar or fibroblastic appearance that are present in bone marrow.  
They can replicate as undifferentiated cells and then differentiate to lineages of 
mesenchymal tissues that include bone, nerve, cartilage, fat, tendon, muscle, and marrow 
stroma (341-344).  Human MSCs’ non-hematopoeitic adult stem cells have the capacity 
for renewal after trauma, disease, or aging and can be expanded ex vivo (341-344).  
Expanded culture populations of hMSCs are comprised primarily of a single phenotypic 
population (95% and 98% homogenous at passages 1 and 2 respectively) that can be 
differentiated with high fidelity into the various tissue cell types (341, 342).  These cells 
can also be obtained via culture from other tissues, such as the periosteum, fat and skin 
(345).   
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Figure 13. A hypothesized lineage progression for MSCs from 
Caplan et al. (346) 
      Typically, various supplements are added to stimulate the differentiation of MSCs 
into the various cell types.  For osteogenic differentiation, the supplements ascorbate-2 
phosphate, dexamethasone, and β-glycerophosphate are added to the cell culture medium 
(343).  Following treatment, within 21 days the cultured cells form alkaline phosphatase 
(ALP)-positive granules.  Osteoblast specific genes such as Runx2, bone morphogenic 
protein-2 (BMP-2), BMP-6, osteocalcin (BGLAP), bone sialoprotein (IBSP) and 
osteoprotegerin are expressed as the osteoblasts mature (309).    
Pittenger (341) has extensively analyzed the expression of cell-surface receptors 
on hMSCs by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of 
mRNA and confirmed the results by fluorescent antibodies and flow cytometry (342).  
Table 4 provides examples of some hMSC surface markers.  
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hMSC Surface Markers 
Receptor Type  Receptors 
Cytokine  IL-1R, IL-3R, IL-4R, 
IL-6R, IL-7R 
Extracellular Matrix ICAM-1, ICAM-2, 
VCAM-1, ALCAM, 
Endoglin, Hyaluonate , 
Integrins α1, α2, α3, αA, 
αV, β1, β2, β3, β4 
Growth Factor BFGFR, PDGFR 
Others Thy-1, IFNγR, TGFβR, 
TNFR 
 
Table 4. Human Mesenchymal Stem Cell Surface Markers (342). 
 
Dissertation Outline 
      This dissertation includes both in vitro and clinical studies.  It is divided 
into 4 studies.   
      Study 1 is an in vitro study that validates the use of a simple clinical 
table top centrifuge that creates 1150 x g.  Platelet and white blood cell 
concentrations with optimal centrifugation times are tested.  Platelet 
morphology changes with centrifugation and bench set time are examined.  
The presence of key growth factors PDGF-BB, VEGF, EGF, and TGF-β1 
are confirmed and the effect bench set time has on their presence is  studied.  
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      Study 2 examines the effect of a gelled BC has on the incidence of dry 
socket formation with mandibular molar tooth extractions.  Individual 
patient factors for AO formation are considered and the effect PRP 
application has on each of them.  Combination of factors is considered and 
the effect PRP had on these combinations.  
      Study 3 is an in vitro analysis of the effect BC PRP application has on 
hMSC proliferation and differentiation.  
      Study 4 is a blinded prospective clinical trial that examines the effect of 
BC PRP on bone density changes following the removal of bilateral 
mandibular 3
rd
 molars.        
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
Study I: Preparation and Characterization of PRP 
A.  Introduction 
     Review of the medical and dental literature supports the use of autologous PRP in 
clinical practice (347, 348).   There are a number of procedures by which platelets can be 
concentrated to produce PRP in a clinical office setting by dental personnel for 
immediate post-operative use (7, 197).  However, techniques that ensure the production 
of large quantities of autologous PRP can be time- and labor-intensive, and expensive.  In 
contrast, techniques that produce small quantities of PRP can be time- and cost-efficient 
and easily accomplished by dental auxiliaries.    
     A variety of systems are available for use by dental practitioners that involve basic 
protocols for blood collection, platelet concentration via centrifugation, and delivery to 
the surgical site via a syringe.  One such generic system utilizes a single speed (1150 x g) 
clinical centrifuge known as the Clinaseal Centrifuge™ (Salvin Dental Specialties, 
Charlotte, NC).  Use of this type of clinical centrifuge is a simple and cost-effective 
method of concentrating platelets and the desired growth factors contained within them.  
While Eby reported an average platelet yield increase of 356% versus whole blood using 
this method (349),
 
there is only limited analysis on the use of this centrifuge for 
concentrating intact platelets that also includes confirmation of the presence of GFs.  If 
this research can provide scientific evidence that supports this technique as a method for 
enhancing soft and hard tissue healing and provide mechanistic reasoning for its success, 
then patients and clinicians will benefit.    
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     In this section of the dissertation, results of our investigation into the use of the 
clinical centrifuge to obtain PRP are reported.  Platelet and WBC enrichment as a 
function of centrifugation time are evaluated.  Western blot analysis reveals that three key 
GFs are present after centrifugation for 10 minutes at 1150 x g.  The effect of bench-
setting time on PRP platelet enrichment, platelet microscopic morphology, and GF 
content (PDGF-BB, EGF, VEGF, NGF, and TGFβ1) using enzyme-linked 
immunosorbent assays (ELISAs) are also reported.  Collection of this data and its 
analysis will answer the question if this technique can effectively concentrate platelets, 
WBCs, GFs, and does bench set time affect the concentration of GFs.  
B.  Materials and Methods 
Collection of PRP   
    For platelet and WBC concentration studies seven different subjects (4 male, 3 female) 
were used and values were done in triplicate.  For the GF studies there was an N of 3 with 
each sample run in triplicate.  Whole blood was drawn using a 21 gauge 1.5 inch latex-
free needle (EXELINT Int. Co., Los Angeles, CA),  and 4.5 mL BD Vacutainer™ tubes 
containing 0.45 mL of the anticoagulant trisodium citrate (9:1) (Becton Dickinson & Co., 
Franklin Lakes, NJ) to prevent clotting of the blood in the Vacutainer™ tube.  For each 
experiment, one Vacutainer™ tube was used to acquire baseline whole blood platelet and 
WBC values as a reference.  Dependent upon the experiment, the required number of  
additional  Vacutainer™ tubes were centrifuged for various times at 1150 x g to assess 
the optimal spin time for the recovery of platelets in PRP.  After centrifugation, the tubes 
were removed and placed in a test tube rack on the bench for various time intervals to 
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ascertain whether bench set time affected the recovery of platelets in PRP.  The red blood 
cell/plasma interface was allowed to set for 3 minutes.  Pre-made labels were placed on 
the outside of the tube to reproducibly delineate the PRP layer to be harvested.  Labels 
possessed a center dotted line positioned at the blood cell/plasma interface, a solid line 3 
mm above the dotted line, and a second solid line 2 mm below the dotted line (Figure 
14).  Figure 13 displays the label used during the course of this study on a Vacutainer™ 
tube filled with water (for illustration purposes only).  
 
 
Figure 14: Placement of Custom Label for Consistent Retrieval 
of PRP (Buffy Coat, BC).  
The dotted line is placed at the interface of the RBCs and the PPP – between these two 
layers is the PRP layer. The PPP is removed down to the top solid line.  The PRP layer is 
between the top solid line and the bottom solid line.   
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Figure 15.  Anticoagulated Whole Blood After Centrifugation 
Close-up of pelleted anticoagulated whole blood separated into the 3 layers.  Note the 
placement of the label on the outside of the tube is dictated by matching the dotted line to 
the plasma/cell pellet interface. 
 
 
      The upper plasma layer (platelet poor plasma, PPP) was aspirated to the 3 mm mark 
(top solid line) using a sterile aluminum blunt end 20 gauge 1.5 inch needle (Monoject # 
8881202363, TYCO Healthcare Group LP, Mansfield, MA) attached to a 3 mL B-D 
latex-free syringe (Becton Dickinson & Co., Franklin Lakes, NJ).  The PRP was collected 
from between the upper 3 mm mark and the lower 2 mm mark using a beveled 20 gauge 
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1 inch B-D Precision Glide™ needle (Becton Dickinson & Co., Franklin Lakes, NJ) 
attached to a 3 mL B-D latex-free syringe.     
 
Platelet Concentration Determination   
      Platelets were counted using a Cell Dyn 1600™ cell counter (Abbott Laboratories, 
Abbott Park, IL).  Due to the viscosity of PRP it was necessary to dilute the PRP 1:10 
with Streck Diluent™ (Streck Laboratories, Omaha, NE) prior to introducing the sample 
into the cell counter.  The diluted sample was gently mixed by inversion to obtain a 
uniform suspension before aspiration and analysis using the cell counter. 
Platelet Morphology in PRP  
    Smears of PRP were stained with Wright-Giemsa stain, and then examined by oil 
immersion brightfield microscopy at 1000X magnification using a Nikon Eclipse 600 
microscope.  Several fields were examined for each sample, and representative 
photomicrographs were obtained using the SPOT RT-Slider camera and SPOT Advanced 
Digital Image Analysis software (Fryer Co. Inc., Huntley IL).     
 
Partial Purification of Platelets from PRP  
In order to remove red blood cells from PRP, the Histopaque 1077 cell separation 
medium was used.  Briefly, PRP was diluted ten-fold with Hank’s Balanced Salt Solution 
(HBSS); Mediatech, Inc. Herndon, VA) and overlaid onto 5 mL Histopaque 1077 density 
gradient medium (Sigma-Aldrich St. Louis, MO).  The overlaid PRP was then 
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centrifuged at 1150 x g for 20 minutes. The band containing platelets, lymphocytes and 
monocytes was aspirated using a sterile polypropylene pipet, then, diluted with HBSS, 
and centrifuged for 20 minutes at 1150 x g.  Platelet-rich pellets were then resuspended 
and washed two times in HBSS for 5 minutes at 1150 x g and platelet counts performed 
as before.  To lyse platelets, the washed pellets were suspended in 0.5% Triton X100, and 
gently rocked on an Ocelot shaking platform (Fisher Scientific, Pittsburgh PA) for 40-60 
minutes.  Lysis was verified by microscopic examination and by subjecting the lysate to 
centrifugation as before, with no visible pellet observed.  The lysate was then used for 
analysis by immunoblotting to indicate the presence of specific growth factors (GFs), or 
by ELISA to quantify specific GFs. 
Western Blotting   
    Pre-cast 5-20% polyacrylamide gradient gels (Jule Biotechnologies, Inc. Milford, CT) 
were loaded with either Kaleidoscope molecular weight standards (Bio-Rad, Chicago, 
IL), positive control purified human recombinant growth factors (US Biologicals, 
Swampscott, MA), or partially purified PRP platelet samples.  The samples were 
subjected to electrophoresis for approximately 75 minutes at 150 v, 35 mA, and 8 watts.  
Transfer of proteins to nitrocellulose paper was performed at 100 v at 3
o
C for 1 hour.  
Blots were then placed in Tris-buffered saline (20mM Tris, 150 mM NaCl, TBS) with 
0.5% v/v Tween 20 (TBST) and 3% BSA to block nonspecific binding for 8 hours or 
overnight.  The blots were then removed and washed three times with TBST and placed 
in a sealed storage bag with the appropriate primary antibody (US Biologicals 
Swampscott, MA) at the manufacturer’s specified concentration for Western blotting (20 
ng/mL TGF-β1, 0.2 μg/mL PDGF, 0.2 μg/mL NGF) in TBST for 4 hours at 3oC. The 
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blots were removed and washed three times with TBST, then placed in anti-rabbit IgG 
alkaline phosphatase conjugate (US Biologicals, Swampscott, MA) as the secondary 
antibody for one hour.  The blots were then removed, washed three times with distilled 
water, and placed in a solution of 5-bromo-4-chloro-3-indolyl phosphate nitro blue 
tetrazolium (Sigma Fast Tablets, Sigma Aldrich, St. Louis MO).  Color development was 
allowed to proceed until positive control growth factor bands were readily apparent, then 
stopped by immersing the blot in distilled water.  The blots were then photographed using 
a Sony Digital Mavica
™ 
camera (Sony Corporation, NY, NY). 
ELISAs   
      Enzyme-linked immunosorbent assays (ELISAs) were employed to determine the 
quantity of various growth factors.  Lysed platelet samples were prepared for ELISA with 
Quantikine kits (R&D Systems Minneapolis, MN).  The manufacturer’s protocol was 
followed with the following modifications.  To fully release TGFβ, it was necessary to 
use a 3-fold higher volume (600µL) of 1 N HCl with incubation of lysates at room 
temperature for the specified time.  This change required that the lysate was subsequently 
neutralized using 600µL 1.2 N sodium hydroxide.  It was also necessary to dilute samples 
10-fold before adding to the anti-TFGβ1-coated wells because the residual 0.5% Triton 
X-100 used for lysis interfered with the ability of TGF-β1 to bind to the wells.  PDGF-
BB samples were diluted 5-fold to ensure that the absorbance was in the range of the 
standard curve.  After color development, quantification was performed using a BIO-
TEK Kinetic Microplate Reader Model EL312E (Winooski, VT).  
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Statistical Analysis 
       Statistical analysis was performed using one-way ANOVA with post-hoc Newman-
Keuls analysis for the platelet and white blood cell concentrations, effect of bench set 
time on platelet concentration, and effect of bench set time on growth factor content per 
10
5
 platelets data.  Analysis was performed using GraphPad Prism
®
 3.0 (La Jolla, CA) 
computer software. 
C.  Results 
     The first objective was to determine the optimum time of centrifugation in a table-top 
clinical centrifuge to obtain the most consistent and greatest enrichment of the PRP. The 
enrichment of platelets in PRP over whole blood using this centrifuge is displayed in 
Figure 16.  A greater than 6-fold enrichment of platelet concentration was obtained 
consistently using a 6, 8, or 10-minute centrifugation time.  Newman-Keuls analysis 
showed that compared to whole blood baseline platelet counts, a 2- and 20-minute 
centrifugation time did provided a significant increase (p < .05) in platelet concentration, 
but there was greater significance (p < .001) for 6, 8 and 10 minutes.   There was no 
significant (p > .05) difference in platelet concentrations between 2- and 20-minute 
centrifugation times.  Newman-Keuls analysis also found no significant difference (p > 
.05) in platelet concentrations between the 6, 8, and 10 minute centrifugation times.  
Centrifugation times greater than 20 minutes were not considered because these longer 
times would not be time efficient in the clinical setting and there was concern that too 
long a centrifugation time (> 20 minutes) might cause complicating factors such as 
damage to the platelets.  The value of these findings is that centrifugation times between 
6, 8, and 10 minutes do provide significant (p < .001) concentration increases in 
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comparison to whole blood, yet there is no significant difference (p > .05) in platelet 
concentrations between 6-, 8-, and 10-minute centrifugation times.  These data suggest 
equivalent platelets would be harvested between 6- and 10-minute centrifugation times.   
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             Figure 16.  Platelet Concentration Fold Increase  
                 Over Whole Blood By Centrifugation Time 
     The effect of various centrifugation times on platelet concentration in comparison to 
whole blood that had not been centrifuged (0 minutes).  Each bar represents the ± S.E.M. 
of 7 different specimens performed in triplicate.  All data were analyzed with a one way 
ANOVA followed by a Newman-Keuls post-hoc test where significance was defined as p 
< .05, where a = p < .001when 6, 8, and 10 centrifugation times compared with 0 
centrifugation time (whole blood); b = p < .05 when 2 and 20 centrifugation times 
compared with 0 centrifugation time; c = p < .01 when 6 minute centrifugation time 
compared with 2 minutes; d = p < .05 when 8 and 10 minute centrifugation times 
compared with 2 minutes; e = p < .001when 6 minutes is compared with 20 minutes; f = 
p < .05 when 8 and 10 minutes are compared with 20 minutes.  The importance of these 
findings is that centrifugation times between 6, 8, and 10 minutes do provide significant 
(p < .001) concentration increases in comparison to whole blood, yet there is not a 
significant difference (p > .05) between 6, 8, and 10 minutes. 
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     In the second study, WBC counts for various centrifugation times were determined.  
As seen in Figure 17, there was a slight increase in WBC counts even with a 2 minute 
centrifugation but the concentration continued to rise, peaking at 10 minutes before 
declining.  One-way ANOVA with a Newman-Keuls post-hoc statistical analysis verifies 
that there is a significant difference (p < .001) in WBC concentrations when 2 through 20 
minute centrifugation times are compared with whole blood that has not been centrifuged 
(0 time).  Newman Keuls post-hoc analysis did not reveal a significant difference (p > 
.05) between any of the centrifugation times (2- through 20-minutes).   
     When considering that platelets contain the wanted GFs and WBCs contain 
macrophages plus factors such as thrombin that are involved in clotting, the 10-minute 
centrifugation time was chosen as the optimal time and used for the duration of the study.  
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Figure 17.  White Blood Cell Fold Increase Over  
             Whole Blood by Centrifugation Time 
     The effect of various centrifugation times on white blood cell (WBC) concentration in 
comparison to whole blood that had not been centrifuged (0 minutes).  Each bar 
represents the ± S.E.M. of 7 different specimens performed in triplicate.  All data were 
analyzed with a one way ANOVA followed by a Newman-Keuls post-hoc test where 
significance was defined as p < .05, where a = p < .001when 2 – 20 centrifugation times 
are compared with 0 centrifugation time (whole blood).  There was no significant 
difference in WBC concentration when 2-20 minute centrifugation times are compared 
with each other.  The importance of these findings is that centrifugation times between 2 
and 20 minutes do provide significant (p < .001) concentration increases in comparison to 
whole blood, yet there is not a significant (p > .05) change in WBC concentrations with 
centrifugation times from 2-20 minutes.    
  
     The final objective of this investigation was to determine whether bench set time (time 
between centrifugation of the whole blood and application in the patient) at room 
temperature affected the recovery and enrichment of platelets in PRP.  Figure 18 shows 
that after a 10-minute centrifugation, the enrichment did not vary as a function of bench 
set time for up to 6 hours.  One-way ANOVA with a Newman-Keuls post-hoc test 
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showed that the fold enrichment of platelets vs. baseline platelet count of whole blood 
was statistically significant (p < .001) for all times examined.  When comparing all bench 
set times (0 through 360 minutes) with each other there was not a significant difference 
(p > .05) in platelet enrichment as bench set time progressed.  This confirmed that PRP 
still contained platelets even if the blood was collected up to 6 hours prior to application.   
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Figure 18.  Platelet Fold Increase of Centrifuged Blood  
         Over Whole Blood with Bench Set Time 
The effect of various bench set times at room temperature on platelet concentration when 
compared to whole blood that had not been centrifuged or experienced bench set time.  
Bench set time began after the whole blood was centrifuged and before removal of the 
PRP layer.  At completion of the prescribed bench set time the PRP layer was removed 
and analyzed.   Each bar represents the ± S.E.M. of 7 different specimens performed in 
triplicate.  All data were analyzed with a one way ANOVA followed by a Newman-Keuls 
post-hoc test where significance was defined as p < .05, where a = p < .001when 0 – 360 
minute bench set times are compared with whole blood that did not experience bench set 
time.  There was no significant difference between the 0 to 360 minute bench set times. 
The importance of these findings is that bench set times of centrifuged whole blood 
between 0 and 360 minutes did maintain significant (p < .001) platelet concentration 
increases in comparison to whole blood, yet there is not a significant (p > .05) change in 
platelet concentrations with bench set time up to 360 minutes.    
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      While the number and concentration of platelets did not appear to change as a 
function of bench set time, platelets in the PRP may change in other ways and, thereby, 
become less active in promoting healing.  The fourth objective was to determine whether 
the morphology of platelets changed as a function of bench set time.  Figure 18A shows 
the components of a typical stained whole blood smear.  Figure 18B-F shows the changes 
that occurred in platelet morphology from 0-6 hours bench set time.  From 0-2 hours, 
platelets appeared to be normal, much as they appear in whole blood: discoid and lightly 
stained with the blue Giemsa dye. The platelets displayed little to no aggregation.  
However, after 2 hours of bench set time, platelets began to appear smaller, and more 
densely stained, forming small clusters.  These effects were more dramatically evident by 
6 hours, indicating a change in their morphology as a function of bench set time. 
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Figure 19. PRP Platelet Morphology with Bench Time.  
  
 The morphology of platelets in platelet-rich plasma (PRP) changed as a function of 
bench set time.  Centrifuged blood was allowed to set on the bench for up to 6 hours, and 
then PRP was harvested at various times.  Samples were smeared, stained with Wright-
Giemsa, and viewed/photographed using brightfield microscopy.  All fields are x1000 
magnification.  (A) Whole blood; note that very few platelets were present relative to the 
number of red blood cells (RBCs).  (B) A 0-time bench set time; note that the platelets 
are higher in number relative to the RBCs, indicating that platelets have been enriched 
using the procedures described previously.  Also note that the platelets possess a normal 
morphology (discoid, light blue staining, with little to no adherence to one another 
(aggregation).  (C) A 30-minute bench set time: concentrated platelets continue to appear 
intact and healthy.  (D) A 1-hour bench set time; platelets begin to aggregate but they are 
still ovoid and lightly stained.  (E) A 2-hour bench set time; platelets form larger 
aggregates and have begun to lose ovoid shape developing bleb-like structures on the 
plasma membranes.  (F) A 6-hour bench set time; note the aggregation that occurred with 
prolonged bench set time and more than 100 platelets per aggregate.  Platelets appear 
shrunken and distorted, suggesting aggregation, possible activation and a loss of 
functional capacity.  
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     PRP's effectiveness in wound healing and other responses is thought to be due to the 
presence of GFs present in the platelets.  Western blots shown in Figure 19 demonstrated 
that the PRP obtained using the above protocol contains growth factors, including PDGF-
BB, TGF-β1, and NGF.   
 
Figure 20.  Platelets in Platelet-Rich Plasma (PRP) Prepared 
using the Clinaseal CentrifugeTM Method Contained Intact 
Growth Factors.   
Western blotting was used to qualitatively assess whether platelets in PRP prepared using 
the methods described contained platelet-derived growth factor-BB (PDGF-BB), 
transforming growth factor-β1 (TGFβ1), or nerve growth factor (NGF).  Lane 1: 
molecular weight markers that flank the growth factor protein bands of interest.  Lane 2: 
purified recombinant human growth factors that serve as positive controls.  Lane 3: 
lysates from 5-7 X 10
6
 partially purified platelets contained within the PRP.  Note the 
presence of bands in Lane 3 that correspond in migration and immunoreactivity to the 
standard growth factors in Lane 2.  Also note that the bands in Lanes 2 and 3 migrate to 
the known molecular weight range for each growth factor monomer (PDGF-BB = 15kD, 
TGF-β1 = 12. kD, nerve growth factor =14 kD).  
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     Since GFs are small proteins (5-30 kDaltons) and their structure and activity may be 
sensitive to hydrolytic or proteolytic degradation over time, the next objective was to 
investigate whether the platelet morphological changes that occurred with increasing 
bench set time were accompanied by changes in GF content of the PRP.  ELISAs were 
used to measure the content of TGF-β1, EGF, VEGF, and PDGF-BB in PRP as a function 
of bench set time.  Table 5 shows that levels of these GFs were comparable to the levels 
reported by others who used more complicated techniques for preparation of the PRP 
(238, 350, 351).  While there was some variation observed in the data collected, the effect 
of bench set time did not have a significant effect (p > .05) on the concentration of select 
growth factors found in the platelets.  These findings suggest that platelets, even when 
they undergo morphological changes and possible activation, retained significant growth 
factor concentrations over time. 
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Table 5:  Growth Factor Content of Platelets with Bench Set 
                                                 Time 
 
Growth factor content pg per 10
5 
platelets after 10-minute centrifugation time at 1150 x g 
force as measured by enzyme linked absorbant assay (ELISA).  All samples were run in 
triplicate.  PDGF-BB N=4, EGF N=3, TGF-β1 N=4, VEGF N=3, OPG N=3.  BDL = 
below detectable limits.  All data were analyzed with a one-way ANOVA followed by a 
Newman-Keuls post-hoc test where significance was defined as p < .05.  There was not a 
significant change in GF content over a 6-hour bench set time when compared with a 0 
bench set time (p > .05) 
 
 
 
 
Bench Set Time (hours) 
 0 3 6 
Growth 
Factor 
Content* 
(pg/10
5
 
platelets) 
Mean (SE) Mean (SE) Mean (SE) 
PDGF-BB 2.877 (±0.6492) 2.135 (±0.8093) 2.432 (±0.8932) 
EGF 0.1865 (±0.1440) 0.2826 (±0.2085) 0.2930 (±0.2659) 
TGFβ1 5.257 (±0.5959) 4.043 (±0.6095) 4.525 (±1.024) 
VEGF 2.474 (±0.5702) 3.052 (±0.5845) 3.202 (±0.9860) 
OPG BDL BDL BDL 
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D. Discussion 
     The goal of this study was to determine whether a simplified, inexpensive procedure 
to obtain platelet-rich plasma (PRP) by the buffy coat (BC) method would yield intact 
platelets and GFs  in concentrations similar to those reported in the literature to facilitate 
clinical healing.   
     The investigation showed that platelet recovery and enrichment in PRP prepared using 
a clinical centrifuge creating 1150 x g force was optimal, consistent and significant (p < 
.001) between 6 and 10 minutes of centrifugation (Figure 16).  This is of importance to 
the clinician because if time were limited in the clinical setting, then a centrifugation time 
of 6 minutes will provide optimal platelet concentrations.   WBC concentration was also 
significantly (p < .001) increased with a 10-minute centrifugation time using the clinical 
centrifuge.  It was also shown that platelet recovery and enrichment did not change 
significantly after centrifugation for up to six hours of bench set time at room temperature 
(Figure 18). Thus, this method of PRP preparation provides platelet concentrations and 
recoveries that match or exceed the PRP preparations obtained through more expensive 
and elaborate methods (178, 238). 
    However, it was found that platelet morphology did change over a period of six hours 
bench set time (Figure 18).   Even with two hours of bench set time, platelets in PRP 
began to appear less normal and as an example, small aggregates formed indicative of 
platelet activation and possible growth factor release. In western blots, at 0 hour bench set 
time, detectable levels of the growth factors PDGF-BB, TGF-β1, and NGF were present 
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in partially purified platelets using this BC method of PRP preparation.  PDGF-BB, EGF, 
TGFβ1, and VEGF levels did not significantly change over 6 hours of bench set time 
(Table 5).    
    There are a variety of explanations for why the time between blood draw and PRP 
harvest might exceed two hours.  One obvious reason is that different methods of PRP 
collection vary in the length of time required to obtain the PRP for use; another is that if 
the blood is drawn from the patient upon arrival at the practice, some simple dental 
surgical procedures may require less than 30 minutes until PRP application while other 
more complex surgeries may require more than 3-4 hours.  In practice, it is easiest to 
draw blood from the patient initially, centrifuge the Vacutainer™ immediately after draw, 
but then harvest the PRP layer just prior to administration.  The centrifuged blood 
therefore will vary in the length of time it remains on the bench top prior to collection of 
PRP and use. The results suggest that bench set time does not influence the activity of 
PRP and therefore its effectiveness in promoting bone formation and wound healing, 
despite there being platelet morphology changes.    
     It is known that TGF-β1 stimulates osteogenesis (7, 352, 353), therefore the loss of the 
bioactivity of TGF-β1 in PRP preparations may account for the disparity among 
clinicians concerning the effectiveness of PRP.  The current results suggest that TGF- 
β1concentration in PRP prepared by the BC method is not affected by bench set times of 
up to 6 hours.   
     A decrease in TGF-β1 concentration in PRP prepared with bovine thrombin and excess 
calcium has been noted (238).
  
The loss of this factor over time with when bovine 
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thrombin is added could be due to three factors including: 1) natural hydrolysis, 2) 
degradation by proteases, or 3) specific irreversible binding by molecules that may be 
present in the PRP.  TGF-β1 is normally found in a latent form within platelets.  When 
TGF-β1 is in the latent form it is either bound to latency associated peptide (LAP) or 
latent TGF-β binding protein (LTBP) and release from these proteins is required before it 
can bind to receptors on target stem cells and trigger the formation of osteoblasts and 
ultimately new bone tissue (354).  If TGF-β1 were released from LAP or LTBP before 
reaching its receptor, it could be rapidly degraded by hydrolysis (354, 355).  Therefore, 
hydrolysis is one explanation for the loss of TGF-β1 over time in the bovine thrombin 
induced PGEL (gelled PRP).   
  Another explanation for the potential loss of TGF-β1 with these other methods is via the 
action of proteases.  If thrombin and Ca
2+
 are used in conjunction with PRP, the clotting 
cascade and platelets will become activated resulting in the secretion of a variety of 
granule components and growth factors.  Two types of proteases found within platelet 
granules are matrix-metalloproteinase-2 (MMP-2) and thrombospondins-1 and -2 (TSP2, 
TSP2).  One effect of these proteases is the release of TGF-β1 from its bound form 
rendering it active (355, 356).  MMP-2 is found as a constituent of PRP, but MMP-2 
must be activated in order to proteolytically cleave its substrates (357).  
 
Activation of 
MMP-2 depends upon other enzymes (MMP-14, -16) that are found in monocytes, also 
present in PRP preparations.  Monocytes may be triggered to release MMP-2 activating 
proteases by platelet factors released during the clotting cascade initiated by thrombin 
and Ca
2+ 
(355).  Interestingly, monocytes and neutrophils, also found in PRP, contain 
TSP1 and 2, protease 3, and cathepsin G that may be released during the clotting cascade.  
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These proteases could act in concert with active MMP-2 to release TGF-β1 resulting in 
its rapid degradation (358).  Zimmermann et al. (359) found that when thrombin and 
calcium were added to platelets prepared by plateletpheresis and leukaphoresis under 
various conditions and bench set times, the concentration of TGF-β1 decreased by 
approximately 60-65%. This study found that by not activating the platelets, TGF-β1 
concentrations did not significantly change over six hours.  Since the PRP in this current 
study was not used in conjunction with thrombin and Ca
2+
 hydrolysis of TGF-β1 via a 
protease cascade may not have occurred, this may explain why higher levels of TGF-β1 
were detected when using the current protocol compared with the others (238, 269). 
     Recent evidence suggests another route whereby osteogenic TGF-β1 can be lost from 
PRP preparations.  Alpha-2-macroglobulin (α2M) a protein that can bind active TGF-β1 
is found in high concentrations (2-4 mg/mL) in PPP.  Initially, active TGF-β1 non-
covalently associates with α2M but this loose association leads to the formation of a 
covalent bond between the molecules (356).  Once the TGFβ1/α2M complex is 
irreversibly formed, TGF-β1 becomes inactive, and incapable of binding to receptors.  
Therefore, the less PPP is present in PRP preparations, the greater the free TGF-β1 is 
available to bind to receptors triggering osteogenesis. 
    Growth factor levels in this PRP preparation were generally higher than those reported 
by other researchers (238).  These findings may result from diluting the 0.5% Triton X-
100 (TX-100) platelet lysates prior to adding the samples to the ELISA plate. Preliminary 
experiments showed that concentrations greater than 0.05% TX-100 interfered with 
stoichiometric measurement of this growth factor using the manufacturer's protocol.  
Diluting the TX-100 lysates allowed for lower binding interference by this detergent and 
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allowed the maximal TGF-β1 signal from the samples during ELISA analysis.  Also, the 
ELISA kit for TGF-β1 analysis employed a monoclonal capturing antibody, whereas 
other researchers used kits employing Type II TGF-β1 receptor or polyclonal anti-TGF-
β1 capturing antibodies to detect the growth factor.  These differences may also account 
for the higher TGF-β1 yields in our study.  
    Because there are many methods to prepare PRP, and since forming a PRP gel by 
inducing clot formation with Ca
2+
 and thrombin appears to decrease the amount of TGF-
β1 in PRP preparations, the clinical effects of PRP application with and without thrombin 
and Ca
2+
   over time need to be investigated.  Future plans include experiments assessing 
the neutralizing activity of α2M by combining PRP with PPP in various quantities to 
examine whether immunoprecipitation of α2M from PPP allows higher levels of TGF-β1 
to persist in PRP.  Future studies will also address the in vitro efficacy of PRP on 
mesenchymal stem cell differentiation into osteoblasts. 
E.  Conclusion 
     This simple and inexpensive procedure for obtaining PRP by the BC method 
effectively recovers and concentrates platelets after a 10 minute centrifugation time at 
1150 x g.  Moreover, this technique did not alter platelet morphology during preparation 
of the BC.  Platelet morphology did change after 2 hours of bench set time, but the 
concentration of GFs (PDGF-BB, EGF, TGF-β1, and VEGF) contained within the 
platelets was not altered significantly with bench set time.  Therefore, the efficacy of this 
preparation condition will be assessed in Study III (in vitro) and Study IV (prospective 
clinical study).  
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Study II: The Effect of PRP on the Frequency of 
Alveolar Osteitis Following Mandibular Tooth 
Extraction 
A.  Introduction 
     Alveolar osteitis (AO) is a complication that occurs with variable frequency (0.49% – 
68.1%) following the removal of permanent teeth (360-368).  AO is characterized by 
severe throbbing pain that begins within 3 to 5 post-operative days and is usually 
refractory to NSAIDs and/or narcotic analgesics (369, 370).
 
 The clinical presentation of 
AO demonstrates a partial or total disintegration of the intra-alveolar sanguine clot, 
resulting in a denuded bony crypt with surrounding debris (371, 372).  Suppuration is not 
evident but the patient usually complains of an acute throbbing pain emanating from the 
extraction site, frequently radiating to the ipsilateral ear and side of the head.  Although 
rare, AO can affect the jugulodigastric lymph glands on the affected side as well. 
     A definitive etiology for AO has not been universally accepted, but is commonly 
thought to include clot fibrinolysis as a result of bacterial invasion (373).  Smoking, 
female gender, oral contraceptive use, surgical trauma, operator experience level, poor 
oral hygiene, gingivitis, periodontitis, and pericornitis have all been reported in the 
literature to be associated with AO formation (374-382).  Increased age and systemic 
conditions such as diabetes and immunosuppression have also been associated with a 
greater incidence of AO (383).
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     Treatment for AO is typically preventative in nature, and is based on two theories of 
etiology: 1) control of fibrinolysis at the time of extraction and during healing and 2) 
control of bacterial populations (371, 384).  Due to potential adverse reactions to 
antifibrinolytic agents, most treatment has been directed towards control of bacterial 
colonization.   
     More recently, platelet rich plasma (PRP) has been used to facilitate healing in various 
oral surgical procedures such as soft and hard tissue grafting (7).  PRP has been placed in 
the sockets of lower wisdom teeth to decrease the incidence of AO (385).  This section of 
the dissertation reports on retrospective studies of the effect of PRP on AO incidence and 
its relationship with other patient factors.  
     Platelet-rich plasma was employed as a gelled autologous fibrin clot to enhance post-
operative healing in conjunction with the removal of teeth.  Anecdotal clinical 
observations suggest a decrease in the incidence and severity of AO, compared to the 
previous techniques used for tooth removal.  The purpose of this study was to examine 
the effect of PRP on the incidence of AO following mandibular molar tooth removal.  
The study examined the incidence of AO formation and its correlation with immediate 
placement of platelet rich plasma gel in the extraction alveolus socket.  In addition to the 
efficacy of PRP in patients without independent risk factors for AO, the effectiveness of 
PRP in patients with potential risk factors was examined.  Factors considered included:    
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 gender 
 age 
 smoking status 
 systemic antibiotic therapy 
 concurrent use of other oral medications 
 oral contraceptive use  
 presence of oral clenching/grinding habits (bruxism) 
 tooth eruptive state 
 tooth position, and  
 concurrent restorative treatments provided at the time of surgery 
 
B. Materials and Methods 
Patient Information 
     This study was reviewed and approved by the Investigational Review Board for the 
Protection of Human Subjects in research of Duquesne University.  Data were obtained 
by retrospective chart reviews of 904 mandibular molar extraction sites from 499 
patients.  A total of 506 patients had been treated, but 7 patients (all non-PRP treatment) 
were excluded because of missing data on one or more variables.  All molar tooth 
positions and eruptive states (erupted, partially erupted, and complete bone impaction) 
were included in the study.  Tooth removals done without PRP were performed between 
June 1996 and December 2000.  Tooth removals done with PRP were performed between 
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January 2001 and August 2003.  Demographics for the data collection set are presented in 
Table 6.   
 
Demographic 
Treatment Total 
No-PRP 
N = 272 
PRP 
N = 227 
 
N = 499 
Race:    
African-American 7 (2.6%) 4 (1.8%) 11 
Asian 0 (0%) 1 (0.4%) 1 
Caucasian 265 (97.4%) 222 (97.8%) 487 
Age Groups:    
15-20 161 (59.2%) 146 (64.3%) 307 
21-30 47 (17.3%) 47 (20.7%) 94 
31-40 22 (8.0%) 9 (4.0%) 31 
41-50 18 (6.6%) 10 (4.4%) 28 
51-60 12 (4.4%) 10 (4.4%) 22 
61-70 7 (2.6%) 4 (1.8%) 11 
71-80 4 (1.5%) 1 (0.4%) 5 
80+ 1 (0.4%) 0 (0.0%) 1 
 
Table 6. Demographic Profile of Data Collection  
Demographic profile of database used in study by race and age of participants. 
Protocol for Obtaining and Applying PRP 
     The procedure used is similar to that described in the Materials and Methods section 
of the Procedure portion of the Preparation and Characterization of PRP study but with 2 
differences: 1) whole blood was drawn through a catheter, and 2) the PRP was gelled by 
the addition of a calcium chloride/platelet poor plasma (PPP) mixture.  The reasons for 
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these variations is that whole blood obtained through the catheter eliminated an additional 
venipuncture site for the patient and at the time of this study the clinician performing the 
surgery preferred to use a gelled form of the BC as it was easier to place in the extraction 
site.  Steps were performed using aseptic techniques and sterile materials.  
Statistical Analysis  
     Statistical investigation for AO formation by treatment group was chi square analysis.  
When analyzing the effect of individual patient factors bivariate tests for independence of 
categorical data were performed and when analyzing the combination of factors 
multivariate analysis with multiple logistic regressions were performed using SPSS 
software (SPSS Inc., Chicago, IL).  Values of p < 0.05 were considered significant.  The 
Mantel-Haenszel test for equality of population odds ratios was used to investigate 
interaction effects among factors.   
C.  Results 
       The results of this study will provide information that will be of value to clinicians 
by revealing the patient factors that have an increased incidence of AO associated with 
them and the effect PRP administration has on decreasing that incidence.  The 904 
extraction sites were assumed to be independent from one another.  The test for equality 
of proportions revealed a significantly greater proportion of AO cases occurring among 
the non-treated sites (n=491) compared with sites in the PRP treatment group (n=413); (p 
= .00043).  The odds ratio (OR) was 2.81 (95% CI, 1.54 to 5.10), indicating an almost 
threefold increase in the odds of AO occurring in the control sites compared to the PRP-
treatment group.  Figure 20 illustrates the difference in AO formation for non-PRP 
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treatment sites and sites receiving PRP treatment at the time of surgery.  Table 7 lists a 
comparison of non-PRP treatment and PRP treatment for the various patient factors. 
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Figure 21.  Percent AO Formation by Treatment Group 
 
Alveolar Osteitis (AO) formation in extraction sites with or without PRP treatment. All 
data were analyzed with a chi square analysis with SPSS software.  Significance was 
defined as p < .05, where 
a
p < .001.  
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 Non-PRP Treated Sites PRP Treated Sites Change in 
% 
Occurrence 
of AO with 
PRP 
% ↓ in 
AO 
with 
PRP 
Patient Factor # of AO 
formations/ 
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population %
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(%) (%) 
Sex (d ) 
    Male 
    
 
 Female 
 
21/231 9.10 5
.4
-1
2
.8
 
4/191 2.10 0.1-
4.1 
7.00  76.90 
26/260 10.00 6.4-
13.6 
11/222 4.95 2.1-
7.8 
5.05  50.50 
Age (d) 
<40 yrs 
 
≥40yrs 
 
42/436 9.63 6.9-
12.4 
14/380 3.68 1.8-
5.6 
5.95 61.79 
5/55 9.09 1.5-
16.7 
1/33 3.03 -2.8-
8.9 
6.06 66.67 
1
st
 molar (d) 0/23 0.00 0.0 0/8 0.00 0.0 NC NC 
2
nd
 molar (d) 1/22 4.55 -4.2-
13.3 
0/12 0.00 0.0 4.55 100.0
0 
3
rd
 molar (d) 46/446 10.31 7.5-
13.1 
15/393 3.82 1.9-
5.7 
6.49 62.95 
Erupted (d) 6/93 6.45 1.5-
11.74 
1/55 1.82 -1.7-
5.4 
4.63  71.78 
Partially 
impacted (d) 
6/130 4.62 1.0-
8.2 
4/100 4.00 0.2-
7.8 
0.62  13.42 
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 Non-PRP Treated Sites PRP Treated Sites Change in 
% 
Occurrence 
of AO with 
PRP 
% ↓ in 
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(%) (%) 
Full impaction 
(c) 
35/268 13.06 9.0-
17.1 
10/258 3.88 1.6-
6.5 
9.18 70.29 
Bruxism (a) 24/105 22.86 14.8-
30.9 
6/41 14.63 3.8-
25.4 
8.23  36.00 
Prophylactic 
antibiotics (d) 
6/60 10.00 2.4-
17.6 
1/40 2.50 -2.3-
7.3 
7.50 75.00 
Oral 
Contraceptives 
(b) 
8/45 17.78 6.6-
29.0 
5/49 10.20 1.7-
18.7 
7.58 42.63 
Other meds (d) 7/88 7.95 2.3-
13.6 
3/95 3.16 -0.4-
6.7 
4.79 60.25 
Tobacco 
Smoking (d) 
10/59 16.95 7.4-
26.5 
0/37 0.00 0.0 16.95 100.0
0 
Other operative 
procedures (d) 
7/48 14.58 4.6-
24.6 
1/12 8.33 -7.3-
24.0 
6.25 42.87 
 
Table 7. Comparison of Non-PRP Treatment and PRP Treatment 
for Each Patient Factor 
 
Table 7 lists all 10 patient factors considered in this study along with the corresponding 
proportions experiencing AO for both PRP and non-PRP treated sites.  All data were 
analyzed with a chi square analysis with SPSS software.  Significance was defined as p < 
.05, where 
a
p < .001; 
b
p < .01; 
c
p < .05; 
c
p > .05.  PRP treatment decreased AO incidence 
for all subpopulations in which AO occurred.  When examining individual risk factors for 
AO formation, significance was found with only 4 factors.  Three are listed in this table 
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bruxism, oral contraceptive use, and complete impaction.  The fourth significant factor 
was not using PRP (Figure 21 and 22).  AO formation was not observed with first molar 
extraction sites and was seen in only one second molar extraction site (which did not 
receive PRP treatment).  The remaining 61 sites that developed AO formation were all 
third molar extraction sites.  Note that bruxism and oral contraceptive use display the 
greatest likelihood of AO formation for both PRP and non-PRP groups. 
 
     Multiple logistic regression (multivariate) analysis revealed four significant risk 
factors for AO: complete impaction, oral contraceptive use, bruxism, and failure to use 
PRP.  Figure 22 lists the expected probability of AO formation for each of these 
significant risk factors alone and in combination.  The individuals most at risk for AO 
were those presenting with a combination of complete impaction, use of oral 
contraceptives, bruxism, and no treatment with PRP.  With each risk factor combination, 
the use of PRP significantly reduced the probability of AO by approximately one half (p 
< .05, Figure 22).  Multiple logistic regression analysis revealed that when PRP was not 
administered the other examined factors (gender, age, tooth position, smoking status, 
prophylactic antibiotic use, other operative procedures performed at the same 
appointment, and concurrent use of other medications) were not associated with an 
increase or decrease in the probability of AO.   
    Analysis of potential interactions between the use of PRP and identified risk factors 
were examined using the Mantel-Haenzel test for OR equality.  The results revealed no 
significant interactions between PRP and other risk factors for AO.  Thus, the 
effectiveness of PRP in reducing the incidence of AO is not dependent upon the presence 
or absence of other risk factors for this complication.   
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D.  Discussion 
           Multivariate analyses revealed that PRP significantly reduced the incidence of AO, 
with the odds of AO formation 2.37 times higher for extraction sites without PRP 
treatment (95% CI, 1.3 to 4.4).  In addition to the absence of PRP administration, this 
multivariate analysis revealed exactly three other significant risk factors for AO: bruxism, 
oral contraceptive use, and complete impaction.  Figure 22 shows the expected AO 
probabilities for patients presenting with any combination of these four significant risk 
factors.  Notice that when PRP is administered, the AO probability is reduced by roughly 
½ for patients in any partition.  Therefore, we can conclude that the administration of 
PRP following mandibular tooth extraction is beneficial in decreasing the incidence of 
AO.  PRP use should be considered by the clinician especially for patients who have an 
impaction, take oral contraceptives, or brux (grind) their teeth, however all patients 
having a mandibular tooth removed would benefit from the application of PRP.    
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Figure 22. Alveolar Osteitis (AO) Formation by Partition 
Alveolar osteitis (AO) formation for various partitions found to be significant risk factors 
(multivariate analysis).  Statistical significance: p < .05 for all of the above combination 
of variables.  PRP indicates platelet-rich plasma.  Complete impaction N=526 (no PRP 
N=268; PRP N=258), oral contraceptive use N=94 (no PRP N=45; PRP N=49), bruxism 
N=146 (no PRP=105; PRP=41), Non-PRP N=491; PRP N=413).  Partition A:  N=904; 
Partition B:  N=526; Partition C: N=94; Partition D: N=146; Partition E: 620; Partition F:  
N=672; Partition G: N=240; Partition H: N=766.  
 
 
  Furthermore, this analysis did not find an association between smoking status and the 
occurrence of AO (p = 0.3).  However, this study did not take into account smoking 
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quantity.  Moreover, smoking status is subject to a possible response bias.  It was 
interesting that none of the smoking PRP-treated patients (n=37) experienced AO.  
Sorensen et al., (386) showed that smoking induced significant reductions in cutaneous 
and subcutaneous tissue blood flow (p < .001), oxygen tension (p < .05), and aerobe 
metabolism (p < .01).  Sufficient oxygen supply is fundamental for normal healing, and 
tissue hypoxia has been shown to impair the reparative processes of wound healing (387), 
decrease the neutrophil defense against pathogens (388, 389), and increase the incidence 
of wound infection (390)  These factors have  been implicated in AO formation (391-
393).  Nicotine, a component of cigarette smoke, is known to increases tissue oxygen 
(386) and induce angiogenesis (394).  The increased oxygen and angiogenesis induced by 
nicotine in combination with the growth factors in PRP may explain the 100% remission 
in AO formation found with the application of PRP in cigarette smokers. 
      Patients taking oral contraceptives also had a significant increase (p < .05)   in AO 
formation.  The particular oral contraceptive taken by each of the patients was not 
recorded, but a similarity for each of these agents is an estrogen component.  A possible 
reason for the significant increase in AO formation for patients taking oral contraceptives 
is that estrogen is known to induce fibrinolysis (395).  Fibrinolysis is thought to be a 
mechanism for AO formation (373).  A feasible explanation for how PRP reduces the 
incidence in AO formation for these patients is the induced angiogenesis and soft tissue 
formation by VEGF, PDGF-AB, and PDGFD-BB growth factors found in the platelets of 
PRP.     
     The participants in this study were, overall, young (15 to ≤ 30 years of age, 80.5%) 
and white.  However, statistical analysis did reveal that the effectiveness of PRP in 
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reducing the occurrence of AO was significant and independent of all confounding 
factors, including age.  Patients younger than 40 years of age and those older than 40 
years of age both had AO formation reduced by approximately two thirds.  Race was not 
considered a variable in the study because of the small number of nonwhite participants.   
     Placing PRP in surgical sites, particularly in the elderly and/or medically 
compromised patient, is a rational approach to treatment.  This is supported by the in 
vitro work of Cei et al, who found that, irrespective of age, bone marrow stromal cells 
responded similarly to platelet-released supernatant and bone morphogenetic protein 6, 
both of which are found within PRP (396). Moreover, it is known that TGF-β1 enhances 
mineralization on dental implant materials in osteoblast cultures from elderly human 
subjects (397).   
      Mesenchymal stem cells decrease in number early during aging in humans (398).
 
  
The stem cells can differentiate into osteoblasts when stimulated by the proper growth 
factors contained within platelets.  However, the bone marrow microenvironment 
changes with maturity and may possibly be unfavorable for mesenchymal stem cell 
(MSC) proliferation or may favor MSC maturation toward a different cell lineage such as 
adipocytes (399-401).  Adipogenesis can be inhibited by TGF-β1, which again is 
contained in PRP (402).  Therefore, gelled PRP (PGEL) techniques that utilize bovine 
thrombin and have decreased TGF- β1 levels (238) could induce hMSCs to go down the 
adipogenic pathway and not the osteogenic pathway.  This may be an additional reason 
for clinicians not witnessing the anticipated bone formation with bovine thrombin PGEL 
techniques.  Ultimately, since stem cell numbers decrease with age but still retain their 
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juvenile potential, it is reasonable to suggest that PRP, with increased concentrations of 
growth factors, would be beneficial in treating elderly patients.  
     Many practitioners prescribe systemic antibiotics to prevent dry socket, but this study 
found no significant effect of prophylactic antibiotics on the incidence of AO.  This result 
supports the position that using prophylactic antibiotics to prevent AO is without benefit, 
unless the patient has a systemic pathology that indicates the need for pre-medication 
with antibiotics.  This study did not examine the effect of localized intra-alveolar post-
extraction antibiotic administration.  Sanchis et al, found that intra-alveolar placement of 
tetracycline did not affect the incidence of dry socket (403). 
     The beneficial effects of PRP for decreasing the incidence of AO may be related to a 
number of signaling proteins found in the platelets, including multiple growth factors 
such as insulin-like growth factor, vascular endothelial growth factor, epidermal growth 
factor, nerve growth factor, transforming growth factors β1 and β2 (TGF-β1,-β2), 
platelet-derived growth factors, and cytokines such as angiopoietin-2, and interleukin-1 
(404, 405).
 
 These factors stimulate cell mitosis and differentiation (406), increase 
collagen production, recruit leukocytes and other cells to the surgical site, and initiate 
vascular in-growth.  Growth factors promote both soft and hard tissue healing and 
angiogenesis.  In addition, platelets promote clot formation, which is beneficial in 
healing.  Aside from platelets, PRP also contains white blood cells that can inhibit 
bacterial growth.  Therefore, PRP application mitigates the currently accepted causes of 
AO by facilitation of clot and soft tissue formation and inhibition of bacterial 
colonization.   
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E.  Conclusion  
     This study found a substantial reduction in the incidence of AO following treatment of 
the extraction site with PRP. The results of this study also demonstrated that complete 
impaction, oral contraceptive use, and especially bruxism are associated with significant 
increases in AO incidence and PRP significantly (p < .05) reduced its incidence.  This is 
the first time that a simple and cost-effective technique has been reported that provides a 
viable methodology by which dental practitioners can decrease the incidence of AO 
formation in patients.  This study supports the use of PRP in mandibular extraction sites 
as a method for reducing patient postoperative discomfort and the need for multiple 
postoperative visits that can be associated with AO.   
  
104 
 
Study III: Effect of Platelet Rich Plasma on Human 
Mesenchymal Stem Cell Growth, Differentiation, and 
Gene Expression 
A.  Introduction 
     Use of autologous PRP in tooth extractions decreases the incidence of AO (8) and this 
benefit may be achieved by facilitating clot formation and decreasing the incidence of 
infection.  Clinicians have anecdotally found that the use of PRP also seems to stimulate 
bone (re)modeling and jawbone density in dental patients prepared for tooth replacement 
with a dental implant.  Alveolar bone development is fundamental to restoring dental 
patients to full function and, therefore is of great interest to clinicians.  One way that PRP 
might trigger bone formation in these patients is to stimulate the proliferation and 
subsequent differentiation of resident hMSCs into osteoblasts.  
     The most conspicuous function of the osteoblast is the formation of bone.  
Clinically, bone formation is a multistep process that begins with the chemotaxis and 
attachment of hMSCs (407).  Following this initial step, the initiation of bone induction is 
primarily regulated by bone morphogenetic proteins, PDGF, TGFβ1, ILGF, and FGF 
which are all found in platelets of PRP (407).  During phases of active bone formation, 
osteoblasts synthesize bone matrix and prime it for subsequent mineralization.  Active 
osteoblasts in vivo are plump, cuboidal cells rich in organelles involved in the synthesis 
and secretion of bone matrix proteins.  Osteoblasts are polarized, allowing for the 
secretion of matrix onto the underlying bony substratum, which results in bone growth by 
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apposition.  Some osteoblasts become trapped in matrix during bone formation and are 
entombed in lacunae.  These cells are referred to as osteocytes and remain in the bone 
matrix in a state of low metabolic activity.  At the completion of bone formation, those 
osteoblasts that avoid entombment in lacunae, lose their important matrix synthesis 
function and become bone-lining cells.  In mature bone, these bone-lining cells cover 
most of the bone surfaces. Osteocytes and bone-lining cells should not be thought of as 
senescent, because they play a major role in the regulation of bone modeling and 
remodeling in addition to aiding in calcium homeostasis (408).  
     Bone development is dependent upon the proliferation of hMSCs and the controlled 
differentiation of those cells into osteoblasts.  Therefore, hMSCs were chosen for this 
study because they are known to contribute to bone regeneration (341, 409).  They are 
also essential for the growth and differentiation of primitive hemopoietic cells within the 
bone marrow microenvironment (341, 409-411) and are significant to bone development 
and remodeling.  Human MSCs are primary cells that can be successfully cultured 
through approximately eight passages (412).  Techniques are now available to isolate 
hMSCs and control their expansion in vitro under controlled culture conditions without 
change of phenotype or loss of function (409).   
     The effect of PRP on hMSCs is of interest because it provides a mechanism for 
explaining the clinical effects observed in the previous retrospective study.  By studying 
the effects of PRP on hMSCs, clinicians may gain greater understanding of the 
mechanisms for PRP actions and apply the improved knowledge base to further improve 
clinical treatments.  Studies have demonstrated the feasibility of transplanting hMSCs 
clinically to provide crucial new cellular therapy.  The hMSCs are harvested and cultured 
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from normal human bone marrow obtained primarily from the posterior iliac crest of the 
pelvis (341, 413) and the tibial and femoral marrow compartments (414, 415).  These 
cells are used in regenerative medicine, immune modulation, and tissue engineering. 
Since PRP is thought to induce earlier and enhanced bone formation in the jaw, then 
the question arises to “Whether PRP induces earlier and enhanced proliferation of hMSCs 
as well as inducing their subsequent differentiation into osteoblasts?”.  It is known that 
hMSC cultured in growth medium will proliferate (grow in number) (341).  This study 
examines if hMSC in growth medium with PRP exposure induces earlier and enhanced 
proliferation of hMSCs when compared to growth medium alone.  Knowing  if PRP does 
increase proliferation of hMSCs at an earlier time point would provide a partial 
mechanistic explanation for what is observed clinically in Studies II and  IV of this 
dissertation.  PRP proliferation effects were assessed by three accepted methods: cell 
counts, MTT assay, and total RNA analysis (416-418).  We also examined if hMSCs in 
osteogenic differentiation medium with PRP exposure induced differentiation into 
osteoblasts at an earlier time point when compared to the osteogenic differentiation 
medium alone.  The PRP differentiation effects were assessed by two known and 
accepted methods: alkaline phosphatase assay and examination of key gene expression by 
real time RT-PCR that confirm differentiation down the osteoblastic (osteogenic) 
pathway (419-422).  This molecular study may improve mechanistic understanding of 
how PRP improves the bone modeling and remodeling in vivo.   
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Materials and Methods 
Collection of PRP 
     PRP was collected as described in the Preparation and Characterization of PRP section 
(page 68), except that all Vacutainer™  tubes were centrifuged for 10 minutes at 1150 x 
g, and the PRP was used in these studies between a minimum of 3 minutes and a 
maximum of 30 minutes after collection from the Vacutainer™ tubes.  Three to thirty 
minutes is the most typical time that elapses between completion of centrifugation and 
PRP application in clinical practice.  The protocol for PRP collection in the Preparation 
and Characterization of PRP study is also the same protocol that is used in the 
prospective clinical study, therefore that protocol is used in this study.  A new blood draw 
was performed for each cell culture flask.  All PRP was collected from the same 
individual. 
Cell Culture 
     Human mesenchymal stem cells were purchased from Lonza Biosciences 
(Walkersville, MD). Cell purity had been tested by the supplier with flow cytometry and 
for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages.  
As per the manufacturer’s specification, these stem cells were positive for CD105, 
CD166, CD29, and CD44 expression and were negative for CD14, CD34 and CD45 
expression.  Upon arrival, cells were initially seeded at a density of approximately 7500 
cells/cm
2
 in a T-75 flask.  Human mesenchymal stem cells when assessed by proliferative 
ability, morphological appearance, and surface antigen, gene and protein expression have 
been found to maintain a stable phenotype through the first 6-8 passages of culture (423).  
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Di Girolamo et al. found that early passages of hMSCs would most likely be the most 
useful in identifying samples that would provide the consistent and appropriate cell 
characterization (413).  Therefore, for the experiments in this dissertation cells passaged 
3 to 4 times were chosen.  For each experiment, cells were seeded at an initial density of 
2500 cells/cm
2
 inT-25 flasks.  Cells were cultured in growth medium alone [comprised of 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum, 2mM L-Glutamine, and 0.5% gentamicin 
(10mg/mL)] and incubated at 37°C in a 5% CO2 atmosphere for 24 hours.  This initial 24-
hour incubation was performed so the cells could attach to the flask.  After the 24-hour 
attachment period all medium was removed and replaced with the appropriate medium 
for each experimental group.  Cells displayed the typical morphology of growing MSCs 
in that they were long, columnar, and spindle-shaped (413, 424) following this initial 
attachment period.  Growth medium was refreshed every third day.  Differentiation 
studies relied on the use of supplemented DMEM medium containing 100 nM 
dexamethasone, 0.2 mM ascorbic acid, and 10 mM β-glycerophosphate (osteogenic 
medium) (425-427).  Osteogenic medium will be referred to as differentiation medium in 
this manuscript.  All differentiation medium supplements were purchased through Sigma 
(Sigma Aldrich, St Louis, MO).  Cells cultured in differentiation medium displayed the 
typical characteristics associated with osteoblastic differentiation, i.e., they became 
flattened or broadened in appearance with a much more prominent cytoplasm that 
eventually became hardened or dense in appearance after thirty days in culture (424).  
Differentiation medium was refreshed every third day.  For PRP treatment, PRP (375 µL) 
was collected as discussed above and added to the flasks containing 10 mL growth or 
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differentiation medium for 24 hours and incubated at 37°C in a 5% CO2 atmosphere, after 
which all medium was aspirated and replaced with fresh growth or differentiation 
medium as per experimental group.  Adding 375 µL of PRP to each flask containing 
10mL of medium resulted in a 3.75% v/v concentration.  PRP treatment for 24 hours was 
chosen because we felt it was more clinically relevant.  When placing the BC PRP at the 
surgical site, it is uncertain how long it is retained in place, but it is known that when 
platelets are present in a blood clot, retraction is thought to occur within hours and 
extrudes a very large fraction of serum and its contents (15).  Therefore, it seems 
reasonable that a 24-hour PRP treatment would be similar to what is occurring in the 
body at the surgical site.  It should be noted that once the PRP was placed in the culture 
flask it would form a clot signifying platelet aggregation and activation.  Upon 
aggregation and activation, granules within the platelets release their contents (cytokines, 
and GFs) (41).    
     For proliferation studies, cultures of hMSCs were passaged in growth medium until a 
sufficient number of flasks were obtained.  Cells were then seeded in T-25 flasks at a 
density of 2500 cells/cm
2
 in growth medium.  Cells were incubated for 24 hours at 37
o
C 
in a 5% CO2 atmosphere to allow cells to attach to the flask.  After this initial 24 hour 
period, all medium was removed and replaced with: either growth medium or growth 
medium with 3.75% (v/v) PRP.  All media were changed after the initial 24 hours.  
Samples cultured in growth + PRP were incubated thereafter in growth medium (no 
PRP).  Media were changed every 3 days thereafter and cells were incubated for various 
times.  
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     Human MSCs for differentiation studies were cultured as per the following protocols.     
For qualitative alkaline phosphatase assays, the cells were seeded on collagen-coated 
coverslips (Biocoat® Franklin Lakes NJ) at 2000 cells/cm
2 
and were placed into each 
well.  Three mL of growth medium were placed into the wells for 24 hours, after which 
all media were changed and replaced with either growth medium only, growth medium 
plus PRP 112 µL (3.75% v/v), differentiation medium only, or differentiation medium 
plus PRP 112 µL (3.75% v/v).  After 24 hours, all medium were removed growth 
medium and growth medium + PRP groups had their medium replaced with growth 
medium (no PRP),  and the differentiation and differentiation + PRP groups had their 
medium replaced with differentiation medium (no PRP) for 5 and 15 days.  From this 
time forward, none of the cells for the experiment were exposed to PRP.  All media were 
changed every 3 days.   
      For total RNA and  real time reverse-transcriptase polymerase chain reaction (real 
time RT-PCR) studies, the cells were cultured in their respective test group medium for 
the initial 24 hours to allow cell attachment to the flasks then 3.75% v/v PRP was added 
to flasks that were to receive the PRP treatment.  Following this 24-hour exposure, all 
media were removed from the flasks and replaced with their respective media without 
PRP for 5, 10, or 21 days.  All media were changed every 3 days. 
Cell Counts 
     Cell counts were performed to evaluate the proliferation effects of a 24-hour exposure 
of PRP on hMSCs growth medium in comparison to growth medium alone.  Changes in 
cell morphology, an indication of differentiation, were also noted.  Cell counts were done 
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in three microscopic fields for days 1, 3, 4, 5, 7, 10, and 12 using a grid.  Days 1, 4, 5, 
and 7 were examined in triplicate, while days 3, 10, and 12 were analyzed in duplicate.    
MTT Assay 
 The (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  (MTT) 
assay (R&D Systems, Minneapolis, MN) was carried out as indicated by the 
manufacturer’s instructions. The MTT colorimetric assay is well accepted as a measure 
of hMSC proliferation (419) and therefore, chosen for this study.  This is a colorimetric 
assay that determines the ability of viable cells to convert a soluble tetrazolium salt- [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT)- into an insoluble 
formazan precipitate.  Tetrazolium salts accept electrons from substrates such as NADH 
or NAPDH. Specifically, MTT is reduced at the ubiquinone and cytochrome bc1 sites of 
the mitochondrial electron transport system.  Figure 23 summarizes the reaction that 
transforms the yellow soluble salts to purple or dark blue-colored formazan crystals that 
can be dissolved in an organic solvent and concentration can be spectrophotometrically 
determined (412).  
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Figure 23.  Conversion of Soluble MTT Salt to Insoluble MTT 
Formazan Crystals (428) 
     Briefly, cells were trypsinized from the flask and placed in a sterile 15 mL conical 
tube. The cells were re-suspended in two volumes of media.  From this, 200 µL of cell 
suspension were added to each of the wells, five wells in total.  Negative controls were 
used- three in total- and controls for PRP were used.  This plate was placed in a 37° C 
incubator at 5% CO2 overnight to allow the cells to reattach.  The following day, 10 µL 
of the MTT reagent were added to each of the wells and placed in the incubator for 3 
hours, until a purple, punctuate precipitate was visible under magnification. When this 
condition was visible, 100 µL of detergent were added to each of the wells and the plates 
incubated at room temperature for 4 hours.  When the crystals had dissolved, the plate 
was quantified using a BIO-TEK Kinetic Microplate Reader Model EL312E (Winooski, 
VT) at 570 nm. 
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RNA Preparation 
     Total RNA formation can be collected in preparation for use in the subsequent RT-
PCR experiments.  Changes in total RNA production over baseline can be measured and 
are reflective of metabolic changes in the hMSC’s functions of proliferation and 
differentiation(422).    All cells were cultured in their respective media and grown to a 
50% confluent monolayer. The PRP treatment was applied and flasks were placed back in 
the incubator for 24 hours. Following the 24-hour incubation, all cell flask media were 
aspirated and replaced with new media that was without PRP.  At this point all cells, 
including PRP treated cells, were grown in their respective medium without PRP for the 
set time of 5, 10, and 21 days.  All media changes were completed every third day after 
this point.  The groups examined were (1) growth medium, (2) differentiation medium, 
(3) growth medium + PRP treatment for 24 hours followed by growth medium only, and 
(4) differentiation medium + PRP treatment for 24 hours followed by differentiation 
medium only. 
     The procedure for the isolation of RNA and reagent preparation was done as specified 
by manufacturer’s (Qiagen, Valencia, CA) instructions.  Briefly, all media from the cell 
culture flasks were completely aspirated and 650 µL of lysis Buffer RTL
TM
 were added 
directly to the flask.  This flask was then placed on a rotator and periodically visualized 
until no cell structures were evident.  At this point, the flasks were shaken and the 
homogenized cell lysate was placed into a gDNA spin column and spun at 8000 x g for 
15 seconds.  The spin column was discarded and one volume of 70% ethanol was added 
to the flow through and mixed by pipetting.  From this, 700 µL were taken and placed 
into an RNeasy
®
 spin column and centrifuged at 8000 x g for 15 seconds and the flow 
114 
 
through was discarded. Seven hundred µL of Buffer RW1
TM
 were added to the spin 
column and spun at 8000 x g for 15 seconds and the flow through was discarded. Five 
hundred µL of Buffer RPE
TM
 were added to the spin column and spun at 8000 x g for 15 
seconds and the flow through was discarded. Five hundred µL of Buffer RPE
TM
 were 
again added to the spin column and spun at 8000 x g for two minutes. The RNeasy
® 
spin 
column was placed in a new 1.5 ml collection tube and 100 µL of 37°C RNase-free water 
were added to the column and spun for one minute at 8000 x g to elute the RNA.  Total 
RNA was measured with spectrophotometry at 260nm and quality assessed with 280 nm. 
Quantitative Alkaline Phosphatase Assay  
    The alkaline phosphatase (ALP) assay was chosen as one method to determine 
hMSC differentiation.  Alkaline phosphatase expression is an early marker of  osteoblast 
differentiation (429).  ALP catalyzes the hydrolysis of phosphate esters found in 
nucleotides, proteins, and alkaloids resulting in the formation of an organic moeity and 
inorganic phosphate (430).  It is known that ALP activity increases during bone 
development (431).  For this project ALP activity is detected by using p-nitrophenyl 
phosphate (pNPP) as an effective chromogenic substrate for alkaline phosphatase.  This 
assay is highly sensitive with a detection limit that is less than 3 ng with a wide linear 
range (432).  The assay measures ALP activity as it hydrolyzes pNPP into a yellow 
colored product (p-nitrophenol) with a reaction rate that is directly proportional to the 
enzyme activity.   
                
 p-nitrophenyl phosphate                p-nitrophenol (yellow) + phosphate 
ALP 
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     Alkaline Phosphatase (ALP) assays (Anaspec, San Jose, CA) were performed as per 
manufacturer’s directions. Briefly, the p-nitrophenyl phosphate (pNPP) reaction mixture 
was diluted 1:100 with dH2O. The ALP dilution buffer was prepared by diluting the 10X 
lysis buffer with dH2O and adding 1% bovine serum albumin to yield a 1X working 
solution. The ALP standard was diluted 1:25 with dilution buffer. Diminishing serial 
dilutions were prepared, with final concentrations ranging from 0.2 to 0 ng/µL. To each 
of the wells, 50µL of samples and 50 µL of the serial dilution were added. The plate was 
mixed by gentle shaking for 30 seconds. The plate was incubated at room temperature for 
30 minutes immediately followed by quantification using a BIO-TEK Kinetic Microplate 
Reader Model EL312E (Winooski, VT) at 405nm. 
RT-PCR 
 Real-time RT-PCR has become the preferred method for quantifying changes in gene 
expression (433).  This project examined two genes (bone sialoprotein and osteocalcin) 
that represent hMSC differentiation into osteoblasts.  The bone sialoprotein gene (IBSP) 
was chosen because it is expressed at 14 days when cells are grown in differentiation 
medium (434).  IBSP expression occurs prior to the mineralization phase and represents a 
functioning osteoblast (287, 435).  The osteocalcin gene (BGLAP) expression is a 
definitive marker for functioning osteoblasts grown in differentiation medium at 21 days 
(276, 277, 279, 434).  Two other genes were chosen as control markers.  The housekeeper 
gene studied was glyceraldehyde-3 phosphate dehydrogenase (GAPDH) (303-306).  The 
glycoprotein-IIb(GPIIb) gene was chosen because it is expressed in developing 
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megakaryocytes and is thought to be found only in platelets and therefore should not be 
expressed in the non-PRP treatment groups (294, 300-302).  Glycoprotein-IIb gene 
expression was examined to assure that all platelet influence was removed following the 
medium change after the 24-hour PRP treatment.  
     The genes of interest were selected based upon their appearance in platelets and 
differentiating mesenchymal stem cells (MSCs) (into osteoblasts). The gene for 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) is a well-characterized 
housekeeper gene for differentiating MSCs.  The gene for bone sialoprotein was chosen 
because it is expressed during the differentiation of MSCs, prior to the mineralization 
phase, but represents a mature functioning osteoblast. The gene BGLAP (osteocalcin) 
was chosen because it is definitive marker for functioning osteoblasts at 21 days in 
differentiation medium.  The gene for glycoprotein-IIb (GPIIb) was chosen because it is 
expressed in developing megakaryocytes and found in platelets.  Table 8 lists the forward 
and reverse primer sequences used for this study. 
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Gene Forward Primer Reverse Primer 
Glyceraldehyde-3 
phosphate 
dehydrogenase 
(GAPDH) 
5’GAGTCAACGGATTTGGTCGT CATTGATGACAAGCTTCCCG 
Bone sialoprotein 
(IBSP) 
5’CTATGGAGAGGACGCCACGCCTG CATAGCCATCGTAGCCTTGTCCT 
Osteocalcin(BGLAP) 5’ TACCTGTATCAATGGCTGGG ATGTGGTCAGCCAACTCGT 
Glycoprotein-IIb 
(GPIIb) 
5’GTCAGCTGGAGCGACGTCA CTGAATGCCCAAAATACGACG 
 
Table 8 Primer Sequences for Genes of Interest  
Official abbreviations for the genes are listed in parenthesis in the first column.   
      The real time RT-PCR reaction protocol was completed in a Bio-Rad Chromo4 Real 
Time Detection System using the iScript One-Step RT-PCR Kit (Bio-Rad, Hercules, 
CA). Each reaction mixture contained 100 nM RNA.  The 50 μL reaction mixture was 
placed in the thermal cycler and incubated at 55°C for 10 minutes, 5 minutes at 95°C for 
cDNA synthesis and reverse transcriptase inactivation.  The PCR cycling was completed 
after 45 cycles; 10 seconds at 95°C, 30 seconds at 57°C.  A melt curve analysis was 
completed; 1 minute at 95°C, 1 minute at 55°C, and 10 seconds at 55°C for 80 cycles, 
increasing 0.5°C each cycle.  Data were analyzed using MC Opticon
®
 software.    
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Statistical Analysis 
     Statistical analysis was performed using GraphPad Prism
®
 3.02.  Cell count analyses 
and MTT analysis were performed using a two-way ANOVA with Newman Keuls post-
hoc tests and unpaired two tailed t tests for comparison of growth ± PRP at specific time 
points or between time points for a specific medium.  Total RNA and ALP were analyzed 
using one-way ANOVA with Newman Keuls post-hoc tests.  Newman Keuls was chosen 
because it will compare between each of the groups.  Real time RT-PCR data was 
analyzed by a two-tailed paired t test when two sample data sets were analyzed and a 
One-way ANOVA with Newman Keuls post-hoc tests were used when more than two 
sample data sets were being analyzed.   
A. Results 
Experimental Rationale: 
      For proliferation studies, cells cultured in growth medium and growth medium + 
PRP were compared.  Cells are expected to proliferate when cultured in growth medium 
with a limited number of cells undergoing differentiation as the cells reach 100% 
confluence (341).  When culturing hMSCs in growth medium ± PRP exposure for 24 
hours, the effect of PRP on proliferation should be discerned.  By culturing cells in 
growth medium only, it is possible to determine the rate of cell proliferation and if there 
is spontaneous differentiation.  If differentiation is occurring in growth medium alone, 
differentiation studies will determine the time point that it does occur in growth medium 
alone.  Cells cultured in growth medium will be compared to cells cultured in growth + 
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PRP.  If PRP does induce differentiation, it should be observed at an earlier time point or 
at an increased level than differentiation seen in growth medium alone.   
      For differentiation studies, cells were cultured in growth medium, growth medium + 
PRP, differentiation medium, and differentiation medium + PRP.  Culturing cells in 
differentiation medium is a control for known differentiation markers to confirm that 
osteoblastic differentiation is occurring (419-422).  Culturing hMSCs in differentiation 
medium + PRP should determined if PRP has an effect on the normal differentiation 
process.  PRP may be found to have one of three effects on the normal differentiation 
process, PRP may either 1) delay or inhibit normal differentiation  2) enhance 
differentiation, that is induce differentiation at an earlier time point, or 3) have no effect 
on the normal differentiation process.    
      It should also be noted that the effects observed in each of these studies is the result 
of a 24-hour buffy coat (BC) PRP exposure.  Buffy coat PRP contains concentrated 
platelets and WBCs therefore; the effects seen are the result of platelets, WBCs, and their 
contents. 
Proliferation Studies 
Cell Microphotographs 
       To assess proliferation effects of PRP, hMSCs were cultured in either growth 
medium alone or growth medium with PRP.  Cell counts were performed at 1, 3, 4, 5, 7, 
10, and 12 days.  Observations from representative photomicrographs are presented in 
Figure 24.  Photomicrographs were done independently of the cell counts (Figure 25).  
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The growth medium control group represents the normal and expected growth patterns 
for cultured hMSCs in vitro.  After a 24-hour PRP exposure, cells demonstrated an 
increase in cell number when compared to cells not exposed to PRP.  Some variation 
exists between the photomicrographs and the cell counts because they were done 
independently of each other.  It should be remembered that PRP contains concentrated 
platelets and WBCs.  When observing the photomicrographs, PRP related cells (platelets 
and WBCs) can be observed in the growth + PRP (24-hour exposure) groups up to and 
including Day 5.  The number of Platelets and WBCs decreases from Day 1 to Day 5 
because of medium change after PRP exposure for the initial 24 hours and then again on 
Day 4.  Medium was changed every 3 days thereafter.     
Day Growth Medium 
   Growth Medium + PRP 
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Figure 24.  Photomicrographs of Cell Cultures at Various Time 
Points 
Representative photomicrographs of cell cultures:  Cells were seeded 3 x10
3
 cells/cm
2 
in 
a T-25 flask containing 10 mL of growth medium and allowed to attach to the cell flask 
for 24 hours.  Following this 24-hour attachment period, 375 µL or PRP was added to the 
PRP treatment groups.  Day 1 represents the cell proliferation after 24 hours of either 
growth medium alone or growth + PRP treatment.  Several PRP related cells (platelets 
and WBCs) can be observed as small round dots in the Day 1 growth + PRP group 
photomicrograph.  All media were removed and Day 1 photomicrographs taken.  
Subsequent microphotographs show the growth of cells in control (growth medium) and 
growth medium + PRP treatment for 24 hours.  After this 24-hour PRP treatment, all 
media were removed from all flasks and replaced with growth media only.  Media were 
changed every 3 days and replaced with growth media only.  Day 3 photomicrographs 
demonstrate that both groups had achieved approximately 15% confluence and there are 
still several WBCs present in the growth + PRP treated group.  On day 4, cells cultured in 
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growth medium had reached 25% confluence; growth + PRP had reached 80% 
confluence with no morphological changes and several WBCs are present.  On day 5, 
growth group demonstrated no change in confluence, but the growth + PRP group 
increased to 100% confluence with noticeable changes in morphology.  Fewer WBCs are 
present because this group had gone through two media changes.  Day 7 growth group 
reached 40% confluence and the growth + PRP group demonstrated further 
morphological changes with a slight decrease in number.  It is difficult to determine if 
any WBCs are still present in the growth + PRP treated group because of the large 
number of hMSCs present and morphological changes (cells spreading out and 
potentially overlapping).  On day 10, the growth group had increased to 45% confluence 
with the growth + PRP group demonstrating greater morphological changes (cells are 
larger, layered, decreased number and crowding each other out).  At Day 10 and beyond, 
it is difficult to determine the presence of WBCs in the growth + PRP treatment group.  
By day 12, the growth group reached 55% confluence with no changes in morphology, 
yet the PRP treated group demonstrated considerable morphological change and a 
continual decrease in cell number.  Photomicrographs have varying colors due to the use 
of different cameras at different time points.  
 
Cell Counts 
       Human mesenchymal stem cells were counted using phase contrast microscopy at 
these specified time points.  Several fields were counted and photomicrographs were 
obtained.  It should be noted that PRP contains concentrated platelets and WBCs.  
Therefore, the effects seen here are from PRP and all of its contents, not just the platelets, 
or the growth factors contained within them, although platelets and WBCs were not 
included in cell counts.  Cell counts will be correlated with two other proliferation 
studies: MTT assay and total RNA expression. 
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Figure 25. Proliferation Confirmation with Cell Counts 
hMSC counts per field after exposure to either growth medium (control) or growth 
medium with an initial 24-hour exposure to PRP (growth + PRP).  Days 1,4,5,and 7 - 
N=3; Days 3, 10, and 12 - N=2.  Cells were seeded at a density of 3 x 10
3
 cells/cm
2
 in a 
T-25 flask (represents a 1 to 6 split of an 80% confluent T-25 flask.  All cell in this study 
were 3
rd
 or 4
th
 passage.  Each bar represents the ± S.E.M. of 2 or 3 different tests 
performed in triplicate.  All data for individual specific time points were analyzed with a 
two-tailed paired t test where significance was defined as p < .05, where a = p < .01 for 
Days 4, 7, 10, and 12 and b = p < .05 for Day 5.  Examination of the actual cell counts at 
each individual time point (Days 1, 3, 4, 5,7, 10, and 12) with a two-tailed paired t test 
the PRP treatment had a significant effect (p < .01) on cell number for days 4, 7, 10 and 
12 in comparison to cells that did not receive the 24-hour PRP treatment.  There was also 
a significant increase on cell number with the 24-hour PRP treatment on day 5 (p < .05).  
Two-way ANOVA revealed that for the entire 12-day time, PRP treatment had a 
significant effect (F=583.1, p < .0001) on cell proliferation; total 12 day time elapsed also 
have a significant effect (F=206.2, p < .0001) on proliferation; PRP treatment and time 
elapsed were related to each other (F=53.68, p < .0001).  Therefore, not only does PRP 
treatment affect cell proliferation, but also time elapsed from the start of the experiment 
has a significant effect on proliferation.   
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MTT Analysis 
     The MTT analysis was used as a measure of cell proliferation.  The MTT assay 
monitors changes in mitochondrial activity, whereby increases in mitochondrial activity 
are associated with increased numbers of cells.  Figure 26 illustrates increased 
mitochondrial activity with PRP-treated cells up to Day 5, after which the control cells 
demonstrated greater activity.  Again, it should be noted that PRP contains concentrated 
platelets and WBCs.  Therefore, the effects observed are from PRP and all of its contents, 
not just platelets, or the growth factors contained within them.  Platelets and WBCs 
contain mitochondrial reductase that may be presenting a confounding factor for 
interpretation of the MTT data (15).  There was significantly less activity in the PRP-
treated cells in comparison to the non PRP-treated cells on Days 6 and 10, which 
corresponds to the decrease in platelet and WBC numbers observed in the 
photomicrographs (Figure 24).  The mitochondrial reductase from the platelets and 
WBCs would reduce the soluble tetrazolium salt (MTT) into an insoluble formazan 
precipitate and therefore, prevented a portion of the MTT from entering the hMSCs.  This 
decreased uptake of the soluble tetrazolium salt would mute the actual mitochondrial 
reductase activity of the hMSCs.  There may have been more hMSCs, but there was 
insufficient concentration of the tetrazolium salt to record the true viability (number) of 
hMSCs.  Figure 26 illustrates that MTT absorbance is significantly greater in the PRP-
treated cells for the first 5 days (except Day 2), but these values may be artificially low in 
comparison to what should have been observed.  Even though muted, significantly 
greater MTT activity was seen with PRP-treated cells in comparison to non-PRP-treated 
cells.  This corresponds with the initial 5day significant increase in cell number observed 
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with growth + PRP (Figure 25).  The finding of less MTT activity for PRP-treated cells in 
comparison to non PRP-treated cells after Day 5 is not surprising when compared with 
the cell count data (Figure 25), where the non PRP-treated cells continued to proliferate 
and the PRP-treated cells had reached a post-mitotic state.  It would appear that after Day 
5 the PRP-treated cells are not proliferating at the same rate as the non PRP-treated cells, 
possibly because the cells are beginning to become differentiated, and thus post mitotic.  
This indicates that the PRP exposure had a significant effect on proliferation in 
comparison to non PRP-treated cells for the initial 5 days, but when considering the 
entire10-day time, the effect of PRP treatment was lost over the time.  Interestingly, the 
MTT activity did continue to increase for both non PRP-treated cells and PRP-treated 
cells.  The significant increase in MTT activity between days 6 and 10 for non PRP-
treated cells is due to continued proliferation as which correlates with cell count data 
(Figure 25).  A possible explanation for the significant increase in MTT activity between 
days 6 and 10 for PRP-treated cells may be due to the decreased number of platelets and 
WBCs in the flask due to successive media changes that facilitate removal of any PRP 
residual PRP cells after the initial 24-hour PRP exposure.  There is the possibly a portion 
of the tetrazolium salts may have been reduced prematurely by the mitochondrial 
reductase present in residual platelets or WBCs mixed in with the hMSCs or osteoblasts 
particularly at the earlier time points, therefore, producing an artificially low MTT 
absorbance for the initial 5 days.  If a portion of the tetrazolium salts had been reduced by 
platelet or WBC mitochondrial reductase the full amount of MTT would not have been 
available for hMSCs uptake, therefore providing an artificially low MTT absorbance 
value for the initial 5 days.  There may be other explanations for the increase in MTT 
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absorbance observed at Day 10.  The Day 10 MTT reported value may be the more 
accurate representation of total number of viable hMSCs that received PRP exposure, 
than are earlier time point values.  From this data, it is now known that a different 
methodology to confirm cell viability is necessary for future experiments involving PRP 
treated cells.     
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Figure 26.  MTT Measured Cell Proliferation Effects of 
         Growth and Growth + PRP Media  
Mitochondrial reductase activity in cells cultured in growth medium and cells 
cultured in growth medium with an initial 24-hour PRP exposure.  All cells in this study 
were 3
rd
 or 4
th
 passage.  Each bar represents the ± S.E.M. for N=3 with tests performed in 
triplicate.  All data for individual specific time points were analyzed with a two-tailed 
paired t test where significance was defined as p < .05.  Where a = p < .0001, PRP-treated 
cells had significantly greater activity on day one (p < .001) when compared with cells 
not receiving the 24-hour PRP treatment.  For b = p < .05, PRP-treated cells had 
significantly greater activity on day three when compared with cells not receiving the 24-
hour PRP treatment.  Where c = p < .01, PRP-treated cells had significantly greater 
activity on day five when compared with cells not receiving the 24-hour PRP treatment.  
Where d = p < .01, non PRP-treated cells had significantly greater activity on day six 
when compared with cells receiving the 24-hour PRP treatment.  For e = p < .0001, non 
PRP-treated cells had significantly greater activity on day ten when compared with cells 
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receiving the 24-hour PRP treatment.  Where f = p < .0001 as an unpaired two-tailed t 
test found a significant difference between Day 6 and Day 10 MTT activity for cells not 
treated with PRP.  For g = p < .0001 as an unpaired two tailed t test found a significant 
difference between Day 6 and Day 10 MTT activity for cells receiving the 24-hour PRP 
treatment.  Two-way ANOVA analysis for the initial 5 days revealed that both treatment 
(F = 832.48, p < .0001) and time (F = 48.33, p < .0001) were significant.  The interaction 
between treatment and time was significant (F = 5.686, p < .05).  However, there was 
significantly less MTT activity in the PRP-treated cells on Days 6 and 10 when compared 
to non-PRP treated cells.  For the entire 10 day period treatment was not significant (F = 
0.7060, p > .05), and time was significant (F = 278.9. p < .0001).  The interaction 
between treatment and time was significant (F = 21.68, p < .0001).  This indicates that 
the PRP exposure had a significant effect on MTT activity for the initial 5 days, but when 
confluence was reached due to contact inhibition, continued benefits of PRP-treatment in 
comparison to non-PRP treated cells was not evident.    
 
Total RNA Production 
      Another indicator of cell proliferation that was examined is global (total) RNA 
production on Days 5, 10 and 21.  De novo biosynthesis of pyrimidine nucleotides is an 
indicator of DNA synthesis, metabolic activity, and cell proliferation (419, 421, 422).  
Total RNA evaluation results are shown in Figure 27 A-C.   
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Figure 27. Total RNA Yield Days 5, 10, and 21 
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RNA yield measured with spectrophotometry at 260:280 ratio demonstrated all RNA 
preparations were of good quality.  All cells in this study were 3
rd
 or 4
th
 passage.  Each 
bar represents the ± S.E.M. for N=3 with tests performed in triplicate.  All data were 
analyzed with a one-way ANOVA with a Newman Keuls post-hoc test where 
significance was defined as p < .05, where a = p < .001; b= p < .01.  Newman Keuls 
analysis represents the comparison between each of the groups. Growth + PRP and Diff 
(differentiation) + PRP represent a 24-hour exposure of 3.75% v/v PRP followed by 
growth or differentiation medium only.  All media was changed every 3 days.  Note: Y-
axis scale changes between A-C for illustrative purposes.  For Day 5 (A) where a = p < 
.001 analysis revealed a significant difference between all groups; where b= p < .01 there 
was a significant difference between cells cultured in growth medium and cells cultured 
in differentiation medium.  Growth + PRP and differentiation + PRP groups showed the 
greatest yield of total RNA.  For Day 10 (B) where a = p < .001 analyses showed a 
significant difference between all groups with the PRP treated groups having the greatest 
RNA yield.  The RNA yield for these two groups is approximately 1/3 of that seen on 
Day 5.  For Day 21 (C) where a = p < .001 there is a significant difference between all 
groups except for cells cultured in growth and differentiation media where there was no 
significant difference.  Total RNA yield for the growth and differentiation media groups 
remained similar to those of Days 5 and 10. PRP-treated groups maintain a signficant 
increase in RNA yield over the growth and differentitation media groups.  The difference 
between the PRP-treated groups is also significant with the Growth + PRP yielding the 
most RNA.  The total RNA yield for the Growth + PRP group is again highest, but the 
level is only 2/3 that of Day 10 and only 1/5 that of Day 5.  This again demonstrates that 
PRP treatment does have some effect on total RNA yield, but the effect diminishes with 
time.   This effect may be due to continual removal of residual platelets and WBCs with 
media changes every 3 days.   
    
      For Day 5 (Figure 27 A), one-way ANOVA with a post-hoc Newman Keuls analysis 
revealed a significant difference between all the groups.  The growth + PRP group had 
the greatest global RNA yield - approximately 5 times that of control and twice that of 
differentiation + PRP.  Cells cultured in differentiation medium demonstrated the lowest 
level of RNA production at day 5.  This is expected because in differentiation medium 
the total number of cells does not increase significantly.  Figure 27 A clearly shows the 
PRP-induced positive effect on RNA yield on Day 5.  These results correlate with the 
MTT data and cell count data offering additional support for the early positive 
proliferative effects of PRP on hMSCs.  This day 5 specific time point is also the time 
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when PRP-treated cells reached 100% confluence.  Cell counts for the PRP-treated group 
increased by 3.2 fold at day 5 and MTT data had a 2-fold increase, yet the total RNA 
yield was increased  by 5-fold.  This large discrepancy in cell count and total RNA values 
may not represent only an increase in hMSC cell number as PRP contains platelets and 
WBCs that may be contributing to the RNA levels.   
       Figure 27 B illustrates the continual PRP-increase in total RNA as seen at day 10.  
RNA yield in the PRP-treated groups was again significant (p < .001) when compared to 
the non-treated groups.  The Growth + PRP group had approximately twice the RNA 
level compared to the other 3 groups.  It is also noteworthy that the RNA levels from the 
PRP-treated groups is about 1/3 that of Day 5 values, possibly due to the reduction in 
platelets and WBCs remaining in the culture.  RNA yield levels for the non-PRP treated 
groups remained similar to those on Day 5 despite an increase in cell number.     
        Day 21 (Figure 27 C), illustrates that the PRP-treated groups still maintain a 
signficant (p < .001) increase in RNA yield over the growth and differentitation media 
groups.  The difference between the PRP-treated groups is also significant (p < .001) with 
the Growth + PRP yielding the most RNA. The non-treated groups have maintained 
approximately the same level of RNA production as found on Days 5 and 10, despite 
increases in cell number (Figure 25).  The total RNA yield for the Growth + PRP group is 
again highest, but the level is only 2/3 that of Day 10 and only 1/5 that of Day 5.  This 
again demonstrates that PRP treatment does have some effect on total RNA yield, but the 
effect diminishes with time.   This effect may be due to continual removal of residual 
platelets and WBCs with media changes every 3 days.   
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Differentiation Studies   
     Differentiation of hMSCs into osteoblasts was measured by the alkaline phosphatase 
assay (ALP) and examination of expression of specific mRNAs markers that would 
signify osteoblast formation.  It should be remembered that these studies were performed 
by the application of 375 µL of BC-PRP for 24 hours following an initial cell attachment 
to the flask in either growth or differentiation medium.  Therefore, the effects seen are for 
PRP and its constituents, platelets and WBCs and the cytokines and GFs contained within 
them.  For growth medium, it is expected that ALP levels would remain unchanged 
between Day 5 and 15 because differentiation is not expected.  For differentiation 
medium, it is anticipated that there will be a significant increase in ALP in comparison to 
growth medium alone.  If PRP does induce differentiation, it would be expected to 
increase ALP expression on either Day 5 or 15 for cells cultured with growth + PRP or 
differentiation + PRP media.   
      The rationale for using growth ± PRP is to determine if PRP can induce 
differentiation without the aid of ingredients of differentiation medium, which is known 
to induce differentiation.  Differentiation ± PRP is examined to determine if PRP alters or 
impedes the differentiation that is normally seen with differentiation medium.  The in 
vivo environment more closely resembles the environment of differentiation medium than 
it does growth medium. 
       When hMSCs differentiate into bone-forming osteoblasts, the intracellular levels of 
ALP increase (436).  Aubin et al. (431) found that as hMSCs became committed to 
mature osteoblasts that these cells became characterized by loss of proliferative capacity 
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and sequential increased markers of expression, specifically, alkaline phosphatase, 
followed by bone sialoprotein, and osteocalcin.  This enzyme is used to dephosphorylate 
target proteins at specific sites that induce cellular consequences leading to cellular 
differentiation (437).   Cells (Figure 28) were incubated in growth medium with and 
without PRP, and in differentiation medium with or without PRP as described previously.  
PRP treatments occurred in the first 24 hours.  ALP was quantified by standard assays as 
described in the Materials and Methods section on page 114.  ALP evaluation was 
performed with N=2 among small coefficients of variation.  Since ALP expression was 
not normalized with cell number or total protein and there were, varying cell numbers 
present depending upon the culture medium of the treatment group, the ALP increases 
may reflect increased cell number.  For Day 5, the growth medium cells had achieved a 
45% confluence, differentiation medium cells had a 20% confluence, differentiation + 
PRP medium cells had a 55% confluence, and growth + PRP had achieved a 100% 
confluence.  At Day 15, growth and growth + PRP media cells had reached 100% 
confluence, differentiation medium cells were at 85%, and differentiation + PRP medium 
cells had reached 90% confluence.  Future examination of ALP levels will use equivalent 
cell number or normalize to protein to allow direct comparison to all the groups and 
different time points.  Different time points will be examined because PRP may shift 
differentiation of hMSCs either earlier or later than what is normally observed.   
      ALP results are reported in Figure 28.  It should be noted that with the small sample 
size (N=2) and lack of normalization for cell number statistical analysis cannot be 
performed on these data (Figure 28 A, B).  
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Figure 28. Alkaline Phosphatase Activity on Days 5 and 15 
Alkaline Phosphatase activity (µg/mL) was quantified using spectrophotometry at 405nm 
for days 5 (A) and 15 (B) in the various media.  Cells were seeded on collagen-coated 
coverslips (Biocoat
®
 Franklin Lakes NJ) at 2000 cells/cm
2
.  All cells in this study were 
3
rd
 or 4
th
 passage.  Growth + PRP and Diff (differentiation) + PRP represent a 24-hour 
exposure of 3.75% v/v PRP followed by growth or differentiation medium only.  All 
media was changed every 3 days.  Each bar represents the ± S.E.M. for N=2 with tests 
performed in triplicate.  Statistical analysis cannot be performed because of the small 
sample size.  ALP expression is not normalized to cell number or total protein.  At Day 5 
(A), there is a baseline level of ALP in growth medium.  In differentiation ± PRP 
medium, the levels increased 4-fold when compared to growth medium.  Additionally, 
growth + PRP-treated cultures reveal a 3-fold increase at Day 5 when compared to 
growth medium alone.  This suggests that at Day 5 PRP can induce differentiation in 
growth medium that does not contain the differentiation inducing factors dexamethasone, 
ascorbic acid, and β-glycerophosphate found in differentiation medium.  All cell 
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treatment groups began with the same number of cells, but as time progressed each of the 
flasks experienced proliferation of cells at individual rates depending on the medium.  
Panel B illustrates ALP levels in cultures at day 15.  Differentiation medium increased 
ALP 3-fold over the growth groups and differentiation medium + PRP induced a 4-fold 
increase ALP over the cells receiving growth medium with or without PRP at Day 15.  It 
should be noted that the ALP levels in differentiation medium alone at Day 5 are higher 
than that seen on Day 5 for cells cultured in growth medium + PRP, however, ALP 
expression for differentiation medium on Day 15 is similar to that seen on Day 5 for 
growth + PRP medium.  This suggests that a shift in the time of differentiation may be 
occurring with PRP treatment.      
 
      Figure 28 A illustrates, as expected, that there is only a baseline level of ALP in 
control cells (growth medium) at day 5.  In differentiation medium, the levels increased 
4-fold with or without PRP.  However, PRP-treated cultures in growth medium also show 
a 3-fold increase in ALP at 5 days.  There is a substantial difference between 
differentiation medium and differentiation + PRP medium at Day 5.  This suggests that at 
Day 5 PRP can induce differentiation in growth medium that does not contain the 
differentiation-inducing factors that differentiation medium contains (dexamethasone, 
ascorbic acid, and β-glycerophosphate), therefore PRP contents (platelets and/or WBCs) 
contain the factors necessary for the early steps of differentiation.  However, the increase 
in ALP levels for PRP-treated cells in growth medium is substantially less than that 
observed with differentiation or differentiation media.  Differentiation + PRP treatment 
had substantially less ALP expression than differentiation medium alone, suggesting the 
PRP may delay differentiation.  
       Figure 28 B illustrates ALP levels in cell cultures at day 15.  It should again be noted 
that the ALP levels in differentiation medium alone at Day 5 are higher than that seen on 
Day 5 for cells cultured in growth medium with PRP, however, ALP expression for 
differentiation medium on Day 15 is similar to that seen on Day 5 for growth + PRP 
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medium.  In a study by Jaiswal et al. (438) using the same differentiation media, ALP 
activity was present on Day 4, doubled on Day 8, peaked at day 11, and then decreased as 
bone sialoprotein and osteocalcin mRNA markers were expressed.  Therefore, it appears 
that in differentiation medium alone the Day 5 ALP levels may be earlier than ALP’s 
normal expression peak and the Day 15 ALP levels may be beyond the peak and 
decreasing.  Since, in the differentiation + PRP medium ALP activity is less than 
differentiation medium at Day 5, but more than differentiation medium at Day 15, this 
suggests that PRP does not stop the differentiation process.  However, it may delay 
differentiation due to the initial 5 day proliferation period that is seen in cell count 
(Figure 25), MTT activity (Figure 26) and total RNA yield (Figure 27).  The 
differentiation process appears to be delayed until the proliferation is complete.  This 
suggestion is supported by Parsons et al. (439) who found that platelet rich concentrate, 
when added to the culture medium as a clot, induced an earlier onset of proliferation 
followed by a sustained increase in the  key osteogenic transcription actor RUNX2.   
      Figure 29 reflects graphs that correct for the differences in cell density for the various 
treatment groups as Days 5 and 15.  These data demonstrate that ALP activity is highest 
in the differentiation medium on Day 5, which correlates with previous reports (438).  
PRP addition to differentiation medium reduced ALP activity, possibly due to an initial 
period of proliferation preceeding differentiation.  Differentiation + PRP is higher than 
growth medium alone suggesting some level of differentiation has begun.  On Day 15, 
differentiation + PRP is similar to differentiation alone, suggestin that both treatments are 
past the peak times for ALP activity (438).  Additional time points are also required to 
assess whether PRP addition to differentiation medium modifies the differentiation 
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capacity of the cultured hMSC cells.  However, since cell density was estimated based on 
visual inspection and adjustments to ALP activity based on cell density may not be 
equivalent at varing levels of confluence, these trends will need to be confirmed in future 
studies by quantifying cell number.  
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Figure 29. Alkaline Phosphatase Activity Corrected for Cell 
Density on Days 5 and 15 
Alkaline Phosphatase (ALP) expression observed in Figure 28 is corrected for cell 
density variations between media at Day 5 (A) and Day 15 (B).  Calculations were made 
by taking the actual ALP expression and multiplying it by the recorded cell density 
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(percentage confluence) for each medium at the respective time points.  These values are 
then represented by the bars.  This data cannot be analyzed for statistical significance 
because the data is corrected by individual interpretations of confluence and not actual 
cell counts and the small sample size.  Panel A illustrates that as expected differentiation 
medium has the greatest ALP expression and growth medium has the least.  It also 
appears that differentiation + PRP medium decreased the expression of ALP when 
compared to differentiation medium at Day 5, but at Day 15, differentiation and 
differentiation + PRP are similar.  Differentiation medium has ALP expression similar to 
that observed with growth + PRP at Day 5 (A).  Base on the time points examined this 
data suggests that PRP may not have the necessary factors to induce differentiation in 
growth media.  When PRP is added to differentiation medium, differentiation still occurs, 
but it is suppressed at Day 5.  It is difficult to say if differentiation is suppressed or if 
differentiation is shifted to an earlier or later time point.  Most likely it would be to a later 
time point because it enhances proliferation at the earlier time point.  Differentiation 
follows proliferation.   
      PRP contains the factors necessary to increase proliferation in growth medium 
(Figures 25-27).  PRP may not induce differentiation in growth medium; however, 
because of the small sample size (N=2) and cell number was not normalized for the ALP 
assay, these data cannot be analyzed for statistical significance.  Therefore, no definitive 
conclusions about PRP’s effects on differentiation are possible from the current study.  
However, after normalizing ALP activity by correcting for cell density (Figure 29) there 
does not appear to be enhanced ALP activity in growth + PRP medium when compared 
to growth medium alone at either Days 5 or 15.  Other time points may reveal different 
hypothesis, but at Day 5 and 15 enhanced ALP activity with PRP treatment in growth 
medium does not appear to occur.  The decreased ALP activity with differentiation + 
PRP medium when compared to differentiation medium alone at Day 5 suggests that PRP 
may affect the differentiation process when differentiation signals are present.  At Day 
15, differentiation + PRP medium ALP activity is similar to that observed with 
differentiation medium.  Therefore, at this one specific time point (Day 15) it appears that 
PRP did not affect differentiation.  However, it cannot be clearly stated if differentiation 
+ PRP medium reached the same peak of ALP activity at any time when compared to 
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differentiation medium.  In addition, this study we cannot conclude when the peak in 
ALP activity with differentiation medium occurred.  From this data, it can be suggested 
that PRP does not stop differentiation.  However, it does not effectively address to what 
degree it affects differentiation.  These data suggest that it may either delay and decrease 
differentiation, but this does not match what is seen clinically.  Clincally early bone 
development occurs; therefore, in the in vivo environment it does not appear to 
substantially alter the differentiation process in a negative manner.   Perhaps, the 
differentiation process is delayed until after proliferation has ended.  Future studies to 
examine the effect of PRP on the early differentiation marker ALP will include a larger 
sample size and normalization with either cell number or protein levels and additional 
time points to determine if a shift in the differentiation process does occur.    
Real time RT-PCR     
       Finally, differentiation was examined by looking at expression of key genes that are 
known to be switched on during osteogenesis.  These genes are bone sialoprotein (IBSP) 
and osteocalcin (BGLAP).  As a baseline control, expression of the housekeeper gene for 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was monitored.  The glycoprotein 
IIb gene (ITGA2B) was chosen because it is expected to be expressed in platelets 
specifically and would serve as a method of monitoring platelet mRNA contribution (59, 
60, 294, 300).  It was predicted that with a 24-hour PRP exposure and successive medium 
changes that all platelets would be removed and, therefore, ITGA2B expression would be 
non-existent after Day 5.  Unexpectedly, ITGA2B was found expressed in all of the 
treatment groups, not just those that had been exposed to PRP (Table 8).   
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      Real-time RT-PCR experiments were done in triplicate with 3 readings taken for each 
sample.  For normalizing the tested osteoblast markers, a housekeeper gene, GAPDH, 
was also monitored.  Gene expression was measured as a threshold cycle (CT) value.       
      The analysis revealed that the housekeeper gene (GAPDH) was expressed 2-3 cycles 
sooner at the 5- and 10-day time points in the cells that had been exposed to PRP versus 
cells that had not received PRP treatment (Table 9).  For accurate normalization, GAPDH 
expression should be consistent across all groups.  In the PRP-treated groups, GAPDH 
expression is likely higher due to the presence of WBCs and other cellular constituents 
present in PRP.  Therefore, CT values for the PRP treated groups at Days 5 and 10 may 
not reflect effects observed only in hMSCs.  However, GAPDH mRNA expression (CT 
values) at Day 21were consistent between all groups (growth, growth + PRP, 
differentiation, and differentiation + PRP) and therefore analysis could be performed for 
all groups at this specific time point.  At Days 5 and 10, GAPDH CT values were 
consistent for the non-PRP groups; therefore, analysis could be performed for these 
groups on Days 5 and 10, unlike the PRP treated groups.  Examining the CT values for 
the non-PRP-treated groups at these time points provides confirmation that these genes 
are expressed as expected and therefore, confirms that differentiation medium does 
induce differentiation and growth medium alone results in little expression of these 
osteoblast markers.      
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Gene  Treatment  Day 5 Day 10 Day 21  
GAPDH Growth 
a
 15.35 17.71 19.92 
Growth + PRP 
b
 12.11 14.91 21.13 
Differentiation  
a
 14.94 16.67 21.51 
Differentiation + PRP 
b
 12.17 15.57 22.54 
IBSP Growth  16.19 15.94 14.77 
Growth + PRP 16.44 15.85 14.91 
Differentiation  16.24 15.70 14.66 
Differentiation + PRP 17.34 15.46 14.92 
Bglap  Growth  25.07 24.02 24.30 
Growth + PRP 24.54 23.43 25.03 
Differentiation  25.51 23.87 24.90 
Differentiation + PRP 23.78 23.40 24.60 
ITGA2B Growth  30.37 29.39 29.18 
Growth + PRP 30.29 28.87 29.07 
Differentiation  30.72 28.79 28.83 
Differentiation + PRP 30.69 28.68 29.15 
 
Table 9.  CT Values for Genes of Interest  
CT values for the genes of interest with the various treatment conditions.  It should be 
noted that the lower the CT value the greater the expression of the gene(s) and conversely, 
the higher the CT value the lower the expression of the gene(s).  The target genes (IBSP, 
BGLAP) and the platelet gene (ITGA2B) from the various treatment groups were 
normalized to the housekeeping gene found in the same RT preparation for which the 
target gene was evaluated.  Note
 a
 consistency of CT values for GAPDH on Days 5 and 10 
(groups not exposed to PRP).  Note 
b
 consistency of CT value for GAPDH on Days 5 and 
10 (groups were exposed to PRP).  Note that CT values for other genes in all treatment 
groups were consistent within each time point (meaning gene expression began at similar 
cycles of the real time RT-PCR process).   
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      The question of whether differentiation occurred was addressed by the expression of 
the IBSP (bone sialoprotein) and BGLAP (osteocalcin) mRNAs for cells cultured in 
differentiation media as measured by real time RT-PCR.  The IBSP gene expression has 
been reported to increase during middle to late stages of differentiation (14-21 days) and 
occurs prior to BGLAP gene mRNA expression at 21-28 days for hMSCs cultured in 
differentiation medium (275, 282, 287, 288).   Table 10 examines the expression of IBSP 
and BGLAP mRNAs on Days 10 and 21 relative to Day 5 for growth and differentiation 
media.    
       The relative quantification (fold changes) in expression for the genes of interest 
(∆∆CT) for Days 10 and 21 relative to Day 5 in its medium were calculated and 
summarized in Table 10.  The relative quantification calculation was performed by 
examining the gene of interest’s ∆CT expression for Day 10 or 21in medium of interest 
(growth or differentiation media) and comparing this value to Day 5 (control) ∆CT 
expression for the gene of interest in the same medium.  ∆∆CT values were calculated by 
subtracting the target gene’s ∆ CT from the medium of interest (growth or differentiation) 
on Day 5 (control) from the ∆ CT value for the target gene in the medium of interest on 
Day 10 or 21.  The final calculation (fold increase in expression) involved raising the 
efficiency value (2) to the negative ∆∆CT value for the target gene.  Calculations were 
done by raising the efficiency (e) of the gene to the negative power of the average target 
gene ∆ CT minus the average control gene ∆CT for medium of interest (growth or 
differentiation medium).  The formula used is: e
-(target ∆ C
T
-control ∆ C
T
).  An efficiency of “2” 
was used for all calculations.  Table 10 lists the relative fold changes for IBSP and 
BGLAP gene expression on Days 10 and 21 compared with Day 5 for medium of interest 
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(growth medium or differentiation).  These data are of importance because they confirm 
that differentiation medium is inducing the hMSCs to induce the expression of 
differentiation markers.  Therefore, suggesting that osteogenic differentiation is taking 
place.   
 
Gene Treatment Day 5  Day 10  Day 21  
IBSP 
Growth 1 8.09 84.16 
Differentiation 1 1.74 413.96 
BGLAP 
Growth 1 12.91 49.12 
Differentiation 1 3.39 188.92 
 
Table 10. Relative Quantification of Gene Expression for Days 10 
and 21 When Compared with Day 5 for Growth and 
Differentiation media Using the Comparative CT Method 
The relative quantification of IBSP and BGLAP gene expression over time is shown for 
growth and differentiation media.  There are 3 CT readings for each sample.  N=3 and 
each sample was run in triplicate.  The average CT was calculated for each day followed 
by averaging the three daily averages together.  Method of calculation is presented in the 
text.   IBSP and BGLAP gene expression for Days 10 and 21 relative to Day 5 for growth 
and differentiation media illustrate that the relative IBSP gene expression at Day 21in 
differentiation medium is 413.96 times that of Day 1.  This is expected because the IBSP 
mRNA is expressed at 14 to 21 days after initiation of the differentiation process.  IBSP 
mRNA gene expression also precedes the expression of the BGLAP mRNA that is 
normally expressed at 21 to 28 days.  BGLAP mRNA gene expression at Day 21 is 
188.92 times that of Day 1.  For both of these genes the mRNA gene expression of Day 
21 exceeds that of Days 1 and 10 by several fold; therefore suggesting that these hMSCs 
are differentiation process of becoming osteoblasts.     
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      Bone sialoprotein gene (IBSP) mRNA ∆ CT values for growth and differentiation 
media are illustrated in Figure 30 A-C.  ∆ CT values relate to the cycle at which the gene 
is expressed after normalization to the housekeeper (GAPDH) for each sample.  Because 
these are ∆CT values, the more positive or higher the values (bars) represent less 
expression of the mRNA for that particular gene.  Therefore, the lower, or more negative, 
the ∆CT values, the greater the gene mRNA expression.  To find the relative expression of 
the gene between treatment groups versus the control, one must examine the ∆∆CT value.  
To determine the ∆∆CT value, the average ∆CT values for the gene of interest in the 
medium of interest is compared to the average ∆CT values for the same gene in the 
control (growth) medium.  ∆∆CT values are calculated by raising the efficiency of the 
primer to the negative power of the growth medium target genes average ∆CT value 
minus the target gene average ∆CT value for the medium of interest.  The fold changes 
between treatment groups for each time point are represented in Table 11.  As sample 
variation for calculating statistical significance is determined from the ∆CT, these values 
and not the ∆∆CT or fold changes are graphed in Figures 30-32. 
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Figure 30.  Bone Sialoprotein gene (IBSP) ∆CT mRNA Expression 
for Days 5, 10, and 21 in Growth and Differentiation Media 
146 
 
Bone Sialoprotein gene (IBSP) ∆CT expression as determined by real time RT-PCR 
reactions.  It should be noted that the lower the CT value the greater the expression of the 
gene(s) and conversely, the higher the CT value the lower the expression of the gene(s).  
The target gene (IBSP) from growth and differentiation media were normalized to the 
housekeeper gene found in the same RT preparation for which the target gene was 
evaluated.  All cells in this study were 3
rd
 or 4
th
 passage.  Panels A, B, and C report only 
cells cultured in growth and differentiation media due to the interference of the WBCs 
with the PRP treated cells.  All media was changed every 3 days.  Each bar represents the 
± S.E.M. for N=3 with tests performed in triplicate.  All data for Panels A, B, and C were 
analyzed with a two-tailed unpaired t test where significance was defined as p < .05.  
Panels A-C shows the relative changes (∆CT) in IBSP expression at days 5, 10, and 21 in 
growth and differentiation media.  There was no significant difference (p > .05) in IBSP 
gene expression at the Days 5 or 10, but there was significantly increased (p < .01) IBSP 
gene expression on Day 21.      
     PRP-induced expression of IBSP at Day 5 was low and not significantly different 
between the growth and differentiation media (Figure 30 A).  The fold change for IBSP 
with differentiation medium was 0.73 times (Table 11) that of IBSP expression in growth 
medium.  It was expected that IBSP expression in differentiation medium would not be 
significantly different from growth medium on Day 5 because IBSP is known to have 
middle to late expression during the differentiation process.  Day 10 IBSP expression was 
not significantly different (p >.05) for differentiation medium when compared to growth 
medium.  The fold increase for IBSP on Day 10 with differentiation treatment was 0.57 
times (Table 11) that of IBSP expression observed in growth medium.  Again, this was 
expected for Day 10 IBSP expression.  For Day 21, there is a significant increase in IBSP 
gene expression in differentiation medium when compared to growth medium.  IBSP 
mRNA expression for differentiation medium was 3.26 times (Table 11) that of growth 
medium.   
       Osteocalcin gene (BGLAP) mRNA expression for growth medium and 
differentiation medium is illustrated in Figure 31 Panels A-C.   
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Figure 31.  Osteocalcin (BGLAP) ∆CT mRNA Expression for Days 
5, 10, and 21 in Growth and Differentiation Media 
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Osteocalcin (BGLAP) ∆CT expression as determined by real time RT-PCR reactions.  It 
should be noted that the lower the CT value the greater the expression of the gene(s) and 
conversely, the higher the Ct value the lower the expression of the gene(s).  The target 
gene (BGLAP) from growth and differentiation media were normalized to the 
housekeeping gene found in the same RT preparation for which the target gene was 
evaluated.  All cells in this study were 3
rd
 or 4
th
 passage.  Osteocalcin (BGLAP) ∆CT 
expression as determined was real time RT-PCR reactions.  All cells in this study were 
3
rd
 or 4
th
 passage.  Panels A, B, and C report only cells cultured in growth and 
differentiation media due to the interference of the WBCs with the PRP-treated cells.  .  
All media was changed every 3 days.  Each bar represents the ± S.E.M. for N=3 with 
tests performed in triplicate.  All data for Panels A, B, and C were analyzed with a two-
tailed unpaired t test where significance was defined as p < .05.  Panel A shows the 
relative changes (∆CT) in BGLAP expression at day 5.  There was no significant 
difference (p > .05) in BGLAP expression between the differentiation and growth 
medium group ∆CT values.  Expression of BGLAP as measured by ∆CT for either group 
at Day 5 was low with the fold change for IBSP with differentiation medium  0.55 times 
(Table 11) that of BGLAP expression in growth medium.  Day 10 BGLAP expression as 
measured by ∆CT and analyzed with a two-tailed unpaired t test was not significantly 
different (p > .05) for differentiation medium when compared to growth medium.  The 
BGLAP fold increase for Day 10 with differentiation treatment was 0.54 times (Table 11) 
that of BGLAP expression observed in growth medium.  For Day 21, there is no 
significant difference between any of the ∆CT values when comparing differentiation 
medium to growth medium.  Differentiation medium BGLAP gene expression was 2.00 
times (Table 11) that of growth medium expression.   
 
Figure 31 A-C illustrates the relative changes in BGLAP gene expression in growth 
medium and differentiation medium at days 5, 10, and 21.  When using a two-tailed 
unpaired t test, there was no significant difference found in BGLAP gene expression at 
days 5, 10, or 21 when comparing differentiation medium to growth medium.  It was 
expected that there would not be a significant difference between differentiation and 
growth media at days 5 and 10, because BGLAP gene expression occurs late in the 
differentiation cycle (21-28 days).  On Day 21, there was a 2-fold increase in BGLAP 
expression in differentiation medium when compared to growth medium (Table 11) as 
expected for this late stage differentiation marker.   
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Figure 32.  Bone Sialoprotein (IBSP) and Osteocalcin (BGLAP) 
∆CT mRNA Expression for Day 21 in Growth ± PRP and 
Differentiation ± PRP Media 
Bone sialoprotein (IBSP) and osteocalcin (BGLAP) ∆CT expression as determined by 
real time RT-PCR reactions.  It should be noted that the lower the CT value the greater 
the expression of the gene(s) and conversely, the higher the CT value the lower the 
expression of the gene(s).  The target genes (IBSP and BGLAP) from growth ± PRP and 
differentiation ± PRP media were normalized to the housekeeping gene found in the same 
RT preparation for which the target gene was evaluated.  All cells in this study were 3
rd
 
or 4
th
 passage.  IBSP and BGLAP ∆CT expression were determined by real time RT-PCR 
reactions.  All cells in this study were 3
rd
 or 4
th
 passage.  Panels A and B report both 
genes in all media because the interference of the WBCs with the PRP-treated cells 
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appears to be removed by Day 21.  All media was changed every 3 days.  Each bar 
represents the ± S.E.M. for N=3 with tests performed in triplicate.  All data for Panels A 
and B were analyzed with a two-tailed unpaired t test where significance was defined as p 
< .05.  Panel A shows the relative changes (∆CT) in IBSP expression.  There was no 
significant difference (p > .05) in IBSP expression between the differentiation ± PRP and 
growth medium ± PRP groups ∆CT values.  The fold change for IBSP at Day 21 with 
differentiation + PRP medium was 4.52 times (Table 11) that of IBSP expression in 
growth medium (control).  The fold change for IBSP at Day 21 with differentiation 
medium was 3.56 times (Table 11) that of IBSP expression in growth medium (control). 
Panel B represents Day 21 BGLAP expression as measured by ∆CT and analyzed with a 
two-tailed unpaired t test.  There was not significantly different (p > .05) between any of 
the media groups.  The BGLAP fold increase for Day 21 with differentiation + PRP 
medium was 4.08 times (Table 11) that of BGLAP expression observed in growth 
medium.  Differentiation medium BGLAP gene expression was 2.00 times (Table 11) 
that of growth medium expression.   
      The relative quantification (fold changes) in expression for the genes of interest 
(∆∆CT) was calculated and summarized in Table 11.  ΔΔCT values were calculated by 
subtracting target gene’s ΔCT from the medium and day of interest from the ΔCT value 
for the target gene in growth medium (control) on the day of interest.  The final 
calculation (fold increase in expression) involved raising the efficiency value (2) to the 
negative ΔΔCT value for the target gene.  Table 11 lists the relative fold changes for each 
treatment compared with growth medium for each gene and time point.   
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Gene  Treatment Day 5 
 
 
Day 10 Day 21 
IBSP Growth  1 1 1 
Gwth + PRP n/a n/a 2.11 
Differentiation  0.73 0.57 3.26 
Diff + PRP n/a n/a 4.52 
BGLAP  Growth  1 1 1 
Gwth + PRP n/a n/a 1.39 
Differentiation  0.55 0.54 2.00 
Diff + PRP n/a n/a 4.08 
ITGA2B Growth  1 1 1 
Gwth + PRP n/a n/a  2.50 
Differentiation  0.59 0.73 3.85 
Diff + PRP n/a  n/a  5.12 
 
Table 11. Relative Quantification Using the Comparative CT 
Method 
The relative quantification calculation for all four genes in the medium of interest relative 
to growth medium (control) are presented.  There are 3 CT readings for each sample.  
N=3 and each sample was run in triplicate.  The average CT was calculated for each day 
followed by averaging the three daily averages together.  Standard Error of Measures is 
reported in Figures 30 and 31.  Delta CTs were calculated by subtracting the 
housekeeping gene average CT value for the gene of interest in growth medium from the 
target gene average CT value for the treatment of interest.  Delta-delta CT values were 
calculated by subtracting the growth medium target genes Delta CT value from the delta 
CT value for the target gene in the medium of interest.  The final calculation (fold 
increase in expression) involved raising the efficiency value (2) to the negative delta-
delta CT value for the target gene.  Note: n/a= not available, this data was not able to be 
calculated because the housekeeper gene (GAPDH) was not consistent across these 
groups at Days 5 and 10 due to a possible WBC interference for PRP treated groups at 
Days 5 and 10.   
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            There was no relative increase in IBSP (bone sialoprotein) or BGLAP 
(osteocalcin) expression compared to growth medium for Days 5 or 10 with non-PRP 
treatments (PRP treatments not reported).  By Day 21, IBSP expression had a 2.11 fold 
increase for the growth + PRP medium, 3.26 fold increase for the differentiation medium 
and a 4.52 fold increase for the differentiation + PRP medium.  The results were similar 
for Bglap expression with the growth + PRP having the lowest fold increase (1.39), 
followed by differentiation (2.00) and differentiation + PRP again having the greatest 
fold increase (4.08).  However, additional studies will be required to establish if these 
PRP-induced increases are significant.  
     The ITGA2B expression showed the same trend as the IBSP and BGLAP genes.  
Differentiation + PRP medium at Day 21 had the greatest fold increase (5.12).  The 
expression of the ITGA2B gene mRNA in the non PRP treated groups at all time points 
and its expression in the PRP treated groups at Day 21 was unexpected as ITGA2B gene 
was reported to be expressed only in megakaryocytes and platelets (294, 300-302).      
D.  Discussion 
     Based on the premise that PRP will enhance bone formation by stimulating 
proliferation of hMSCs (and not interfere with hMSCs differentiation into osteoblasts) 
via platelet activation, it is important to consider whether the platelets are activated in the 
in vitro conditions.  Platelets have several methods of activation in vivo, but a concern 
when working with platelets in vitro is, will the platelets be activated?  When platelets 
become stagnant, the platelets enter a second stage where they rapidly convert  into their 
active form with filopodia and lamellipodia that derive from a remodeled actin skeleton 
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and a sophisticated assembly of new actin filaments (36).  This change in physical state 
allows platelets to interact with each other and adhere to each other.  Platelet aggregation 
or coagulation occurs when platelets adhere to each other by adhesion receptors, with 
glycoprotein IIb/IIIa being the most abundant adhesion receptor (15, 59).  Once the 
glycoprotein IIb/IIIa receptor is activated, it initiates cell-surface signaling, resulting in 
activation of the platelet (15).  Upon activation, platelets release the contents of their α-
granules.  Alpha granules contain coagulation factors, platelet activating factors, adhesion 
molecules, cell-activating molecules, cytokines, integrins, inflammatory molecules, and 
growth factors.  Therefore, it is believed that the platelets are activated in vitro.   
Another concern is that PRP is processed from whole blood that is collected in 
BD Vacutainer™ tubes that contain the anticoagulant trisodium citrate (9:1).  The reason 
for concern is that trisodium citrate may block the coagulation (aggregation) and 
subsequent platelet activation.  However, in the BC PRP preparation process the whole 
blood in the Vacutainer™ tube undergoes centrifugation at 1150 x g for 10 minutes.  The 
trisodium citrate is present in an ionic state in the whole blood and would rise to the 
supernatant (PPP) portion of the tube with centrifugation.  Therefore, the trisodium citrate 
would be removed from the BC PRP.  This is confirmed by the findings of the Study I: 
Preparation and Characterization of PRP (page 67).  With bench set time, it became 
evident that platelets were aggregating (Figure 18) and therefore activation would follow.  
Additionally, when the BC PRP was applied to the culture flask the BC PRP would form 
a clot, again signifying aggregation and subsequent platelet activation and release of the 
α-granule contents.  
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      The results of each of the proliferation studies (cell growth photomicrographs/ cell 
counts, MTT analysis, and total RNA) appear to correspond with each other.  It is readily 
apparent that 24-hour PRP exposure does have an early effect on proliferation and that 
effect is seen most dramatically within 5 days and then appears to taper off after that time 
point.  The reason for the decline in proliferation response at this time point may not be 
due to a loss of proliferative effects of PRP, but may be due to PRP promoting osteoblast 
differentiation into a post mitotic phenotype.   At the time of PRP removal, it was noted 
there were actually fewer cells present than had been seeded.  It appeared that some cells 
had been lost with the PRP removal.  Cells normally attach to the flask within 24 hours of 
placement.  PRP administration occurred after this initial 24-hour attachment period.  The 
cytokines in PRP are known to be chemotactic to hMSCs and therefore, a portion of the 
cells may have detached from the flask and attracted to the PRP.  The PRP that was 
aspirated was placed in a new T-25 flask and cells were found to be growing in these 
flasks over the subsequent days (data not reported).  This observation further enforces the 
proliferative effects of PRP.  This finding warrants additional investigation in future 
studies.  The cell count study is the only proliferation study done in this study that is not 
confounded by the constituents of PRP and therefore the most reliable.  The MTT assay 
may be compromised due to the mitochondrial reductase found in the residual platelets 
and WBCs and total RNA yield may be challenged by the presence of WBC RNA.      
      The MTT results correlate with those of Lucarrelli et al. (106).  Lucarrelli found the 
PRP-induced increase in MTT values was PRP dose dependent.  Stromal stem cells were 
exposed to thrombin plus calcium gluconate-activated PRP for 3, 6, and 9 days in a 1% or 
10% concentration.  Their experimental design differs from our work in that our exposure 
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was for 24 hours only and in a 3.75% v/v concentration.  Lucarrelli et al. found that at 
day 3 (10% concentration) there was a 1.5-fold increase in MTT absorbance.  In our 
study, there was a 1.34-fold increase.  The difference between the two studies is that 
platelets in our study were not subjected to exogenous thrombin and calcium gluconate 
and we had 1/3 the concentration with 1/3 of the PRP exposure time.  Many clinicians 
feel that PRP must be activated and in a gel form for PRP benefits to be realized and that 
is the thought behind using bovine thrombin and calcium gluconate.  However, the BC 
PRP technique had a positive effect on proliferation without the addition of bovine 
thrombin and calcium gluconate.  Future work should include examining similar 
concentrations of thrombin/calcium gluconate-activated PRP vs. our buffy coat PRP 
technique.  With continuous exposure, Lucarrelli et al. found the same fold increase 
present at days 6 and 9.  Their 1% concentration had a modest 1.1-fold increase at day 6.   
     In another study, Graziani et al. (328) examined leucodepleted thrombin/calcium 
gluconate-activated PRP (via negative-charged Pall™ filter) at various concentrations.  
Concentrations for the Graziani study were determined by recording baseline platelet 
values and then measuring the platelet count in the PRP samples.  These samples were 
then diluted to give a range of 100% (PRP1x), 250% (PRP 2.5x), 350% (PRP 3.5x), and 
550% (PRP 5.5x - undiluted) PRP concentrations over baseline values.  PRP exposure 
was for either 24 or 72 hours.  MTT measurements were taken for each of these time 
points.  At the 24-hour time point, the maximal MTT absorbance occurred with the PRP 
1x concentration and higher concentrations of PRP resulted in decrease proliferation.  
However, at the 72-hour mark, the PRP 2.5x had the highest MTT absorbance with a 
70% increase in cell number compared to the negative control.  Interestingly, in the 
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leucodepleted thrombin/calcium gluconate-activated PRP studies, none of the PRP-
treated groups surpassed the control group, which was growth medium (328).  In contrast, 
in our study, the PRP treated group surpassed growth medium until Day 6.  The main 
difference in the techniques was the activation of the platelets with thrombin and calcium 
gluconate and that their preparation was leucodepleted and therefore may not have the 
degree of interference from the WBCs that our MTT assays do.  Platelets were 
continuously applied in the Graziani study, therefore the platelets may have compromised 
their data also.  This brings into question if leucodepleted thrombin/calcium gluconate-
activated PRP retains the same proliferative qualities as PRP containing WBCs and not 
activated with bovine thrombin/calcium gluconate.  Future work should include 
comparing various concentrations of leucodepleted thrombin/calcium gluconate-activated 
PRP with our buffy coat PRP technique.  
     At day 5, growth + PRP treated groups demonstrated a total RNA increase of 6.5-fold 
over growth medium alone (Figure 27).  This represents a much greater increase than is 
seen with cell counts (3.2 fold increase) (Figure 25) or MTT assay (2-fold increase) 
(Figure 26).  At day 5, total RNA expression is twice that of the cell count increase.  Part 
of this excessive total RNA increase may be due to the 24- hour PRP exposure.  PRP 
contains platelets and white blood cells (WBCs).  Platelets contain mRNA carried over 
from megakaryocytes, but it cannot synthesize mRNA due to the lack of a nucleus and 
with time, mRNA undergoes progressive decay (136-139).  Therefore, it is unlikely that 
platelet mRNA is responsible for the additional total RNA seen in Figure 27.  WBCs 
contain ribosomal RNA (440) and this is most likely causing the excessive increase in 
total RNA at day 5.  This marked increase in total RNA was present in both PRP treated 
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groups (growth + PRP and differentiation + PRP).  The control groups (growth and 
differentiation media) did not display these large increases in total RNA.  Differentiation 
medium alone had a significant (p < .001) decrease in expression of total RNA in 
comparison to growth medium.  At Day 10, the total RNA difference between growth 
medium and growth + PRP treatment was much less.  The growth medium total RNA 
was unchanged from day 5 and the differentiation medium total RNA had increased 
slightly.  Interestingly, on day 10, the growth + PRP and the differentiation + PRP 
treatments had approximately 1/4 to 1/3 of the total RNA that these groups had on day 5.  
This drop in total RNA may not be due to a proliferation or differentiation effect, but 
rather the decreased presence of WBCs in the PRP.  The PRP was removed after 24 
hours, but WBCs can be adherent to the flask and therefore retained in the flask, even 
with successive medium changes every 3 days.  The life expectancy of a WBC depends 
upon the cell type and can range from hours to weeks (441, 442).  The decrease in WBCs 
either because of media changes every 3 days or apoptosis of existing WBCs could 
explain the drop in total RNA.  Since the cell numbers increased by 3.2-fold with growth 
+ PRP treatment over growth medium counts, we could take the total RNA value for the 
growth medium and multiply it by 3.2 to get the approximate total RNA value for the 
growth + PRP treatment effect.  The difference would represent the WBC effect beyond 
the proliferative effect seen with the MTT assay (Figure 26).  The potential WBC effect 
appears to be approximately 52% of the total effect seen with the growth + PRP 
treatment.  
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Figure 33.  White Blood Cell Effect on Total RNA Yield - Day 5  
Gth (growth) + PRP treatment bar is marked with the proposed effect WBCs may have 
upon the total RNA levels.  Approximately 52% of the effect seen in this example may be 
due to ribosomal RNA from WBCs, 48% of the effect may be due to a true proliferative 
effect induced by PRP.  Proliferative effect was measured by taking the growth medium 
total RNA production and multiplying it by 3.2, which represents the fold increase 
growth + PRP treatment cell counts were beyond growth medium alone cell counts.    
 
 
 This potential WBC effect will be reviewed again with the real time RT-PCR discussion.  
Despite this WBC effect, it appears that PRP has an enhancing effect on proliferation.  
This finding is supported by the cell count and MTT data.  At day 10, the RNA 
expression for growth + PRP treatment had decreased by 67% of the day 5 level.  This 
may be due in part to the decrease in the number of WBCs.  Even with this drop in 
growth + PRP treatment total RNA, the total RNA level is still twice that of growth 
medium alone.  The effect of PRP on proliferation at day 10 is additive for growth 
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medium, but is sub-additive for differentiation medium.  It is interesting to note that at 
day 10 the total RNA level for differentiation + PRP treatment had decreased by 70%, but 
still exceeded the differentiation or growth media.  In this case, PRP is sub-additive for 
differentiation medium.  It is obvious that the PRP effect is decreasing and the non-
treatment groups are approaching the PRP treatment groups.  At day 21, the growth + 
PRP treatment level had diminished by 80% of the total RNA occurring at day 5.  Again, 
despite this continual drop, it still exceeded all other groups for RNA production by a 
significant amount (p <0 .001).  At day 21, the differentiation only group had 
significantly exceeded the growth medium and differentiation + PRP treatment groups.  
This would occur because of the continual hMSC differentiation that is taking place in 
this medium.  Notwithstanding the WBC effect, there is robust total RNA expression that 
may be due to the presence of TGF-β1 in PRP.  TGF-β1 is known to control growth in 
hMSCs (443).  By day 21 PRP is sub-additive for growth medium, but now interferes 
slightly with differentiation medium, which may be due to down-regulation of protein 
synthesis or differentiation signals. 
      Figure 34 A and B illustrate the total RNA yield for Days 5, 10, and 21 for growth 
medium and differentiation medium.   
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Figure 34 Total RNA Yield for Growth and Differentiation Media 
Days 5, 10, 21 
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RNA yield measured with spectrophotometry at 260nm and quality assessed with 280 nm 
for growth medium (Panel A) and differentiation medium (Panel B) expressed as total 
RNA yield ng/μL.  These graphs are extractions from Figure 27 with all conditions being 
the same.  All data were analyzed with a one-way ANOVA with a Newman Keuls post-
hoc test where significance was defined as p < .05, where a = p < 0.05 when compared to 
Day 5, b = p < 0.05 when compared to day 10.  Newman Keuls analysis represents the 
comparison between each of the Days.  Panel A (growth medium) analysis revealed that 
there was no significant difference (p > .05) in RNA yield between Days 5 and 10.  Day 
21 did have a significantly greater (p < .01) total RNA yield when compared to Days 5 or 
10.  Differentiation medium shown in Panel B did have a significant difference (p < .001) 
for each of the time points.  Total RNA yield in differentiation medium continued to 
increase throughout the time span.    
     For growth medium there was no significant difference (p > .05) between Days 5 or 
10 in total RNA yield, but there was a significant increase (p < .01) between Day 21 and 
these earlier time points.  Neither of the other cell proliferation studies (cell count or 
MTT assay) was extended to Day 21.  Cell count data (Figure 25) suggests that 
proliferation in growth media doubled between Days 5 and 10.  MTT data (Figure 26) 
suggests that cell proliferation increased three fold in this time for cells cultured in 
growth medium.  Therefore, total RNA may not be a good indicator of cell proliferation 
and the entire total RNA yield effect seen with growth + PRP medium and differentiation 
+ PRP medium at Days 5 and 10 may be due to the WBCs.   
       In the future,  proliferation studies should be performed with cell counts and the use 
of the CellTiter-Glo
®
 Luminescent Cell Viability Assay that is a homogeneous method of 
determining the number of viable cells in culture based on quantification of ATP present 
(444, 445).   
      Total RNA levels will increase with differentiation as well as proliferation.  For 
differentiation medium, there was a significant increase (p < .001) in RNA yield as time 
passed from Day 5 to 21.  This most likely signifies that differentiation was taking place 
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to account for the increase in total RNA.  Proliferation of hMSCs in vivo is of great 
importance clinically because there is an age-related decrease in hMSCs and the 
generation of osteoblasts.  Additionally, the time for doubling of hMSC is increased by 
1.7 fold for older patients (446).  Therefore, these aging issues may compromise the 
healing response and PRP application may help negate these factors.   
       For the alkaline phosphatase assay our results (Figure 28) for differentiation medium 
without PRP correspond with those of Jaiswal et al. (438).  Jaiswal et al. used the same 
differentiation media and found that on Day 4 ALP, expression was present and at day 8 
ALP expression had doubled and peaked at day 11.  However, over time there was a 
decrease in ALP activity beyond Day 12 that correlated with  bone sialoprotein and 
osteocalcin mRNA expression and terminal osteogenic cell differentiation as hMSCs 
become osteocytes (438).  Although our time points varied from Jaiswal et al., there was 
a greater ALP expression at Day 5 than at Day 15.  For growth + PRP medium, ALP 
results suggest that PRP-treatment does induce this early differentiation marker in 5 days.  
A valid question is does the presence of WBCs affect these results.  The WBCs may not 
be causing the increased ALP levels seen with the alkaline phosphatase assay, because 
there is not an additive effect with the differentiation + PRP treatment.  There was an 
enhancing effect of PRP exposure to differentiation medium in the total RNA study for 
Days 5 and 10.  This same effect was not observed with the ALP assay at Day 5.  To 
answer the question if this 5-day ALP increase is truly due to platelets and not WBCs, the 
study would need to be repeated with a WBC-free PRP treatment in comparison to this 
BC method of PRP preparation.  At Day 15, the differentiation + PRP treatment had 
significantly (p < .001) higher ALP expression than the other groups.  At Day 15, PRP 
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may interfere with the normal effect of differentiation medium ALP production.  
Interestingly Day 15 differentiation medium ALP expression (average 0.07972 µg/mL 
±SEM 0.0001383) was similar to that seen at Day 5 for growth + PRP medium (average 
0.07194 µg/mL ±SEM 0.0006543).  This may suggest that PRP treatment induces ALP 
formation, but at a lower level than does differentiation medium.  At Day 5, 
differentiation medium ALP expression was substantially higher than that of growth + 
PRP medium.  There was no sizeable difference between differentiation medium and 
differentiation + PRP induced expression of ALP.  The reason that PRP treatment may 
not be as effective for inducing differentiation is that differentiation medium has 
signaling mechanisms (dexamethasone, β-glycerophosphate, and ascorbic acid) that are 
specific to differentiation, while PRP has signals that appear to enhance proliferation and 
differentiation.  Owen et al. (447) found that a temporal relationship exists between 
proliferation and differentiation; therefore, maybe PRP-treatment must initially perform 
proliferation before progressing to differentiation.  Since PRP-treatment induces 
proliferation initially, this may lead to a shift in the differentiation process to a different 
time point than what is normally observed.  The Day 5 ALP activity for differentiation + 
PRP medium was less than that of differentiation medium alone; however, Day 21 ALP 
activity for differentiation + PRP medium was greater than that of differentiation medium 
alone.  Also the growth + PRP medium had less ALP activity at Day 5 than 
differentiation medium, but the Day 15 differentiation medium ALP activity was similar 
to that of growth + PRP on Day 5.  This suggests that PRP does have the following 
effects on differentiation: 1) it does not stop the differentiation process, 2) it may not 
have the factors necessary to induce differentiation in growth medium, and 3) it may 
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delay the differentiation process when the necessary differentiation signals are present to 
a later time point because of its initial influence on proliferation.    
      Further evaluation of the differentiation effect of PRP was performed by examining 
specific genes known to be markers of middle to late differentiation.  Cells cultured in 
PRP treatment media had approximately a 3 cycle earlier expression of the GAPDH 
housekeeping gene at day 5 in comparison to cells cultured in media that did not have 
PRP exposure and each cycle represents a doubling in the expression of the gene of 
interest.  At Day10, this difference had decreased to 1 or 2 cycles.  The housekeeper gene 
is used as the internal standard and used to normalize and quantify target mRNA 
expression.  The housekeeper expression should be stable within each cell regardless of 
the treatment (448, 449).  These differences raised concerns about the validity of using 
this housekeeper for the study.  The GAPDH expression was very consistent across all 
treatment groups with the day 21 samples.  It was observed that the other osteoblast 
(IBSP) or platelet (BGLAP) specific genes were also consistent in their expression across 
all of the treatments.  Therefore, the question is what was different about these PRP 
groups at the 5 and 10-day time points?  As mentioned earlier in the introduction section, 
PRP contains platelets and WBCs.  The possibility of platelets being the confounding 
factor was considered.  Platelets were ruled out as the cause for the over expression of 
GAPDH in the 5- and 10-day samples because the ITGA2B gene that was thought to be 
expressed only in platelets did have consistent expression (albeit at low levels) in all 
treatment groups.  WBCs express GAPDH that could be increasing the housekeeper gene 
expression.  This housekeeper gene was selected because it had been reported as the 
housekeeper gene by Kanno et al. in a similar semiquantitative RT-PCR study examining 
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the differentiating effects of PRP (329).  It was also thought that if the PRP were 
removed after 24 hours and new medium placed that the effects of PRP and its contents 
would be removed and therefore not a confounding factor for these studies.   
      At Day 21, IBSP expression (Table 11) was at a higher level than BGLAP expression 
for all media with differentiation + PRP having the greatest expression.  It is expected 
that IBSP expression preceded BGLAP mRNA expression (276, 277, 279, 287).  Gene 
expression for PRP treated groups is reported for the Day 21 samples because the 
housekeeper gene was stably expressed.  This suggests that influence of the WBCs was 
gone by the Day 21 time point.  Ingrwoth + PRP at Day 21, PRP may somewhat enhance 
differentiation of growth medium alone because, IBSP (2.11 fold) and BGLAP (1.39 
fold) expression were higher than growth medium alone and approached that of 
differentiation medium.  PRP exposure also demonstrated an enhancing effect on 
differentiation medium for IBSP (4.52 fold) and BGLAP (4.08 fold) expression at Day 
21.  Further studies will be required to confirm these proposed effects of PRP.     
     This dissertation is suggesting that BC PRP enhances hMSC proliferation and 
suggests that it may not stop their differentiation into osteoblasts.  Proliferation seems to 
be occuring in a shorter time than what is normally observed in vitro with growth 
medium for proliferation.  PRP does not appear to induce differentiation in growth 
medium, nor does it stop the differentiation process for cells cultured in differentiation 
medium.  Parsons et al. (439) found that platelet rich concentrate, when added to the 
culture medium as a clot, PRC induced an earlier onset of proliferation and stimulated a 
transient enhancement of bone morphogenetic protein-2 mRNA that peaked after 12 
hours and induced an earlier and a sustained increase in the  key osteogenic transcription 
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actor RUNX2.  After 3 days of treatment, PRC enhanced alkaline phosphatase activity 
more than 2-fold compared to donor-matched serum, and at 23 days, the increase in 
osteoblastic commitment translated to enhanced calcified matrix deposition.  Our studies 
found that cells cultured in growth + PRP medium had ALP activity increased by 2.5 fold 
at Day 5 (Figure 28) when compared to growth medium alone, but when ALP activity 
was corrected for cell density, there did not appear to be a difference in ALP activity 
between cells cultured in growth or growth + PRP media.  We also found that by Day 5, 
cell counts (Figure 25) were 3.2 fold greater for cells cultured in growth + PRP in 
comparison to cells cultured in growth medium alone.  It is at Day 5 we also found that 
the MTT assay showed a drop in MTT activity (Figure 26), signifying that proliferation 
was ending.  Therefore, it appears that proliferation discontinues and differentiation 
begins immediately thereafter.  A possible explanation for this may be found in the work 
of Owen et al. (447).  They found a relationship existed between fetal rat hMSC growth 
and differentiation-related gene expression during the in vitro cultivation of osteoblasts.  
They found a temporal, functional relationship between the decline in proliferative 
activity and the subsequent induction of genes associated with osteoblast differentiation, 
matrix maturation, and mineralization.  Initially, proliferating cells express cell cycle and 
cell growth regulated genes that lead to the production of a fibronectin/type I collagen 
extracellular matrix.  Immediately following a sequence of events occurs in which there 
is an enhanced expression of ALP and later an increased expression of osteocalcin at the 
onset of mineralization.  Additionally, it was demonstrated that there is enhanced 
expression of the osteoblast markers as a function of ascorbic acid-induced collagen 
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deposition.  This suggests that the extracellular matrix contributes to both the shutdown 
of proliferation and the development of the post mitotic osteoblast phenotype.   
E. Conclusion   
      This molecular-based study examining the effects of the buffy coat method of 
preparing PRP supports the hypothesis that PRP obtained by this simple and cost-
effective method enhances proliferation.  It also suggests that BC PRP does not interfere 
with hMSC differentiation down the osteogenic pathway.  Proliferation was confirmed 
with cell count and MTT assays.  Evidence of  PRP not stopping the differentiation 
process was suggested by the unaltered ALP activity at Day 15 for differentain+ PRP 
medium when compared to differentiation medium .  Additionally, evidence of  
differentiation was supported by the increased expression of the bone sialoprotein gene 
mRNA and the osteocalcin gene mRNA in differentiation +PRP medium.  This study 
also supports the concept that PRP initially accelerates proliferation of hMSCs and it 
does not stop differentiation with the possibility of inducing differentiation at a late time 
point.  PRP may induce a shift in the differentiation chronological framework.  PRP 
causes the hMSCs to proliferate before differentiation into osteoblasts begins.  These 
effects may promote bone healing and formation.  This molecular study provides a 
mechanistic basis for the clinical use of PRP in osseous surgery.   
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Study IV: The Effect of PRP on Wound Healing 
Following Tooth Extraction: 
A Prospective Clinical Study 
A. Introduction  
     Immediately following the removal of one or several teeth, a healing process begins 
that affects the eventual alveolar bone volume and architecture of the alveolar ridge.  
Proper and timely healing are essential in order to obtain the ideal functional 
reconstruction for the patient.  Improper traumatic removal of a tooth or a poor healing 
response may lead to excessive bone loss delaying tooth replacement, may necessitate 
expensive and time-consuming alveolar bone reconstructive surgeries, or create a 
situation that is impossible to correct, leaving the patient severely compromised (450).  If 
a cost-effective, simple technique were available that would decrease bone-healing time 
and increase the predictability of having a favorable result, patients and clinicians would 
benefit.  The intent of this study was to determine whether the application of PRP to a 
tooth extraction site would facilitate healing. 
     Following tooth extraction, a cascade of inflammatory reactions begins immediately, 
and the extraction socket is temporarily closed by clotting blood.  Epithelial tissue 
proliferation and migration start within the first week and the disrupted tissue integrity is 
quickly restored.  Histological evidence of active bone formation in the bottom of the 
extraction socket is seen as early as 2 weeks following tooth removal.  The socket is 
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filled with newly formed bone in about 6 months (451, 452).  If the removed tooth is not 
replaced by an intraosseous fixture within 6 months of removal, the residual ridge 
alveolar bone undergoes a life-long catabolic remodeling (451).    
     Radiographic techniques have been used to document the gross morphologic changes 
of the alveolar processes after the loss of teeth (450, 453-455).  A well-established 
method for the detection of subtle bone changes is the use of subtraction radiography.  
We used a variation of the technique reported by Hildebolt et al. in 1998  (456).  To 
determine changes in alveolar bone radiodensity through time, homologous regions of 
interest (ROIs) were identified and compared (456, 457), with one image subtracted from 
the other, the difference representing the change in radiodensity (457-461).  The regions 
of interest were interpreted using a computer program that examined the pixel number 
and converted to grayscale images.  In this study, we used a combination of these 
techniques and normalized radiographs to an ROI (the adjacent tooth).  The extraction 
sockets were evaluated by the same method and normalized to the ROI.  The grayscale 
values of the baseline radiograph were subtracted from the grayscale value for the time 
point radiograph.   
     Macro-structural and micro-structural bone forming information can be acquired with 
advanced imaging techniques rather than with conventional radiography or standard bone 
densitometry (462).  Computerized tomogram scanning technology (CT scan) provides a 
three-dimensional representation of the object in any geometry (463) which can provide 
information about bone healing and define the skeletal response to innovative therapies 
(462, 464-469).  Investigators have employed quantitative CT scans to monitor fracture 
healing in experimental models and clinical studies (462, 464, 465).  Since this 
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technology is expensive and requires more radiation exposure than digital radiography, it 
was used on only three patients in this study.   
B.  Materials and Methods  
      This study was reviewed and approved by the Investigational Review Board (IRB) for 
the Protection of Human Subjects at Duquesne University.  Funding for this study was 
provided for by the American Academy of Implant Dentistry Research Foundation.  The 
appendix contains forms relevant forms to IRB approval.  
Patient Selection  
     All patients (N=6) selected were between ages 18-40 with a negative medical history 
and were non-smokers. Tooth extractions considered in the study were bilateral 
mandibular impacted third molars of equal eruptive states.  Patients were informed 
individually of possible complications and signed study, surgical and IV sedation 
informed consent forms.  Patients were remunerated $250.00 at the completion of the 25 
week evaluation period.   
PRP Collection 
     A venous puncture using a 21 gauge 1.5 inch latex-free needle(EXELINT Int. Co., 
Los Angeles, CA) with an attached vacutainer holder (EXELINT Int. Co., Los Angeles, 
CA) in the ante-cubital fossa, or the dorsal surface of the hand contra-lateral to the IV 
administration site was performed. Whole blood was drawn using two 4.5 mL BD 
Vacutainer™ tubes containing 0.45 mL of the anticoagulant tri-sodium citrate (9:1) 
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(Becton Dickinson & Co., Franklin Lakes, NJ).  PRP was prepared as described 
previously in the Preparation and Characterization of PRP section (Study 1). 
Third Molar Surgical Technique and PRP Placement 
      Intravenous access was obtained using a 22 gauge 1-inch Terumo Surflo™ 
intravenous catheter (Terumo Medical Corporation, Elkton, MD). The vein was kept 
open (KVO) with dextrose 5% in water (Baxter Healcare Corporation, Deerfield, IL). 
Patients were monitored via electrocardiogram (EKG), automatic blood pressure, and 
percent hemoglobin oxygen saturation with a Criticare Systems model 507 E (Criticare 
Systems, Inc. Waukesha WI) anesthesia monitor.  All patients were sedated with a 
combination of intravenous midazolam HCl, diphenhydramine HCl, and fentanyl citrate 
(Ace Surgical, Brockton, MA) as needed to induce a state of conscious sedation.  Once 
the patient was sedated, the blood draw was performed to acquire the PRP for use after 
the teeth were removed.  Depending on allergies, patients were administered either 
cefazolin 2.0 gram (Baxter Healthcare Co, Deerfield, IL) or clindamycin 600 mg (Ace 
Surgical, Brockton, MA) immediately pre-operative via IV.  Following sedation and 
administration of antibiotics, all patients were administered lidocaine HCl 2% with 
epinephrine 1:100,000 (Cook-Waite, Rochester, NY) bilaterally as follows: 1.8 mL (1 
unit-dose carpule) as a Gow-Gates inferior alveolar block, 1 unit-dose carpule as a long 
buccal, buccal infiltration and lingual block.  If anesthesia was deemed to be inadequate, 
additional carpules were administered as needed to a total maximum of 11 unit-dose 
carpules.  Incisions were made in the envelope fashion. The posterior extension of the 
incision diverged laterally to avoid injury to the lingual nerve.  The incision was brought 
anterior in the gingival sulcus to the mesial of the first molar (no vertical releasing 
172 
 
incision was made).   The gingival soft-tissue was reflected exposing bone overlaying the 
impacted tooth.  Bone was removed by the use of a Elcomed 100 electric handpiece 
(W&H Dentalwerk, Burmoos, GMbH, Austria) and a #8 round surgical burr (Henry 
Schein Inc. Melville, NY).  Teeth were sectioned as needed with a 45° High Impact 
handpiece with a #700 Fisher burr (Henry Schein Inc., Melville, NY).  The control 
extraction site was treated immediately post-extraction as follows: 
a. Placement of Gelfoam® (Pharmacia Corporation, Kalamazoo, MI) only (no PRP) 
b. Primary closure was achieved with 3-O chromic gut suture material (Henry 
            Schein Inc., Melville NY 11747 USA).  
c. After removal of the tooth, a small periapical digital radiograph (Dentsply 
Gendex®, York, PA) was taken using an XCP-DS® mount to determine a 
baseline grayscale representing bone density at each extraction site. 
 
The treated site was treated immediately post-extraction as follows: 
a. Injection of 200 μL of PRP into the extraction site   
b. Placement of Gelfoam®, moistened with 175 µL PRP  
c. Primary closure was achieved with 3-O chromic gut suture material (Henry 
Schein Inc., Melville NY 11747 USA).  
 
d. After removal of the tooth, a small periapical digital radiograph (Dentsply 
Gendex®, York, PA) was taken using an XCP-DS® mount to determine a 
baseline grayscale representing bone density at each extraction site. 
      To help prevent excessive post-operative inflammation, patients were administered 
dexamethasone sodium phosphate (Ace Surgical, Brockton, MA) 8 mg IV pre-
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operatively and methylprednisolone suspension Depo-medrol
®
 (Pharmacia & Upjohn Co, 
New York, NY) suspension 40 mg IM immediately post-op.  Patients were also 
administered ketorolac trimethamine 30 mg (Hospira, Lake Forest, IL) IV immediately 
post-op.  Immediately post-operative bilateral Gow-Gates mandibular block injection 
using 1.8 mL of bupivacaine HCl 0.5% with 1:200,000 epinephrine (Hospira, Lake 
Forest, IL) was administered to prevent immediate post-op pain.  Patients were advised to 
take ibuprofen 600 mg every 6 hours for 3 days and then every 6 hours as needed 
thereafter.  They were advised to take acetaminophen 500 – 1000 mg every six hours if 
the ibuprofen did not control the pain.  Patients were dismissed with a grade card for 
notations every 8-hours for 3 days, then notations every 12 hours for the following 6 
days. Each surgical site was graded with a visual analogue scale (VAS) for: 
1. Pain 
2. Temperature (external feeling of warmth) 
3. Facial swelling  
4. Bleeding  
5. Numbness or altered sensation of tongue, face, lip or chin. 
The participants used the instrument in the appendix for post-operative evaluation from 
their perspective.   
     The patients returned post-operatively for observer evaluations plus digital 
radiographs using the same protocol for immediate post-operative radiographs.  These 
evaluations were repeated at the following post-operative time points: 3 days plus weeks-
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1, 2, 3, 4, 6, 8, 12, 16, 20, and 24.  Blinded observers used a VAS to evaluate the 
following: 
1. Dehiscence (surgical soft tissue opening) 
2. Bleeding 
3. Inflammation 
4. Facial edema 
5. Intra-oral edema  
6. Pain 
      Three of the patients had a mandibular computerized axial tomography (CT) scan 
performed by a local hospital.  Each of these three patients had one CT scan taken.  
Patient-1 had theirs taken at 18 weeks post-operative, Patient-2 at 14 weeks post-
operative, and Patient-3 at 10.5 weeks post-operative.  This allowed for verification of the 
grayscale from digital radiography with the bone density Hounsfield units (HUs) of the 
CT scan and percent bone fill of the extraction sites.  
Radiographic Technique and Exposure  
     Radiographs were taken with a Trophy ETX Dental peri-apical X-ray machine 
(Trophy Radiologie, Vincennes, Cedex, France).  X-radiation settings were 70 KV, 8 
mA, for 0.05 second exposure time.  The digital x-ray sensor used was a Gendex GX-S 
sensor (Gendex Dental System, Lake Zurich, IL).  The radiograph sensor was held by a 
Dentsply Sensor Holder XCP-DS® posterior holder and ring (Dentsply International 
York, PA).  Digital radiographs were formatted by VinWix Pro computer software 
(Gendex Dental System, Lake Zurich, IL).  Digital radiographs were used for two 
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reasons: 1) the technique allows for consistent radiographic opacity and evaluation, and 
2) it exposes patients to only 25% of the radiation used with conventional radiography.  A 
correlation of bone density was confirmed during the study with a CT scan and computer 
reformatting for bone density determination via HU for three patients.  Because of the 
need to evaluate the post-operative bone healing, participants were exposed to 22 digital 
periapical radiographs. 
CT Scan Technique and Exposure  
     Mandibles were scanned 1mm inferior to the mandible to the superior surface of the 
mandibular teeth. CT specifics were as follows:   
• Image size: 512 x 512 pixels  
• Gantry tilt: 0.0 degrees 
• Scanner slice thickness: 0.5 – 1.0 mm 
• Scanner step increment: 0.5 – 1.0 mm 
• Field of View: typically 150 – 180 mm  
Images were taken in uncompressed DICOM 3.0 format. KV and MA were kept as low 
as possible with a table pitch 1:1. CT scans were reformatted for quantitative 
measurement using Logic VIPTM Data Conversion
®
 software. 
 
X-ray Analysis  
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     Image J software (downloaded from http://rsb.info.nih.gov/ij/) was used for digital 
radiograph analysis.  The radiographs were assessed by obtaining the average density of 
the third molar extraction socket sites.  Three different readings were taken of each 
socket and averaged.  This average was compared to the average of three density outlines 
of the adjacent tooth.  When all radiographs for a patient were assessed in this manner, 
they were normalized to the original radiograph and the same untouched adjacent tooth.  
The baseline socket average was then subtracted from the normalized radiographic 
average for each of the tooth extraction sockets at the different time points.  This 
accounted for minor radiographic exposure and technique variation with each time point.  
The final normalized socket value differences for each PRP treated and non-treated sites 
for the various time points were compared.  Figure 35 illustrates the outline with ImageJ 
software for outline of adjacent tooth used for normalization of radiographs and the 
outline of the extraction socket.   
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Figure 35.  Example of ImageJ® Software Outline of Adjacent Tooth 
and Extraction Socket   
Example of ImageJ
®
 software outline of adjacent tooth (left photo) used for 
normalization with the baseline radiograph taken of the same site immediately following 
tooth extraction and placement of the Gelfoam® (± PRP) and sutures.  Right radiograph 
illustrates outline of tooth extraction socket that is compared to the same region of 
interest of the baseline radiograph.  All radiographs were taken with the same exposure 
parameters (KV, mA, and time) and similar angles and distance from x-ray source.    
 
All radiographs were taken by a blinded certified X-ray dental assistant or hygienist.  
Radiographs were taken immediately post-op and at the following time points after the 
day of surgery: 3 days, 1 wk, 2 wks, 4 wks, 6 wks, 12 wks, 16 wks, 20 wks, and 24 wks.  
Radiographs were evaluated by 3-blinded dental professionals.   
CT Scan Analysis 
     CT scans were evaluated concerning percent bone fill, formed bone density, and total 
socket formed bone density.  CT scans were reformatted with Logic VIPTM Data 
Conversion
®
 software, which permitted quantitative measurements at 1mm increments of 
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the extraction socket.  Percent bone fill was determined by measuring the quantity of 
bone that had formed in the socket at that time point and dividing this value by the entire 
socket depth and multiplying by 100% .  Representative bone fill measurements for 
Patient-2 at 14 weeks are shown in Figure 36. 
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Figure 36.  Example of CT Scan Evaluated Percent Bone Fill 
Measurements (mm) for Extraction Sites 
Representative CT scan projections of control and PRP-treatment extraction sites are 
illustrated by VIPTM Data Conversion
®
 software for Patient-2 at 14 weeks.  Each 
individual projection represents a 1 mm sagittal cross section slice of the extraction 
socket in a anterior to posterior direction.  Measurements in millimeters (mm) are shown 
using the measuring tool provided by the software.  Two measurements are taken, one 
that measures from the base of the extraction site to the superior aspect of actual formed 
bone (left number in each slice), the second is total socket depth and is measured from 
the base of the extraction socket to what would be the most superior aspect of the socket 
(right number in each slice).  Dividing the actual bone formed bone by the total socket 
depth and multiplying this number by 100% provides the percent bone fill for the socket.  
All bone fill measurements for the multiple 1 mm slices of the respective extraction site 
were averaged together.  Each CT scan was evaluated by 3-blinded observers.  All three 
evaluator average readings were then analyzed by a two-tailed t test.  
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      Newly formed bone density (NFBD) was measured in Hounsfield units (HU) by the 
use of an elliptical drawing tool provided with the software.  Areas of new bone 
formation were outlined and quantified as HUs.  Representative measurements of NFBD 
for Patient-2 at 14 weeks are illustrated in Figure 37.  
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Figure 37.  Example of CT Scan Evaluated Newly Formed Bone 
Density (NFBD) in Hounsfield Units for Extraction Sites 
Representative CT scan projections of control and PRP-treatment extraction sites are 
illustrated by VIPTM Data Conversion
®
 software for Patient-2 at 14 weeks.  Each 
individual projection represents a 1 mm sagital cross section slice of the extraction socket 
in a anterior to posterior direction.  Measurements in Hounsfield units (Hus) are shown 
with the elliptical measurement tool provided by the software.  The elliptical tool was 
used to outline actual bone that had formed in the extraction site as is referred to as newly 
formed bone.  Each measurement provides an average HU that was recorded for each 
1mm slice.  Average HUs represent averaged bone density, therefore these values would 
represent the average newly formed bone density (NFBD) for that 1 mm slice.  All HU 
measurements obtained for the multiple 1 mm slices of the respective extraction site were 
averaged together.  Each CT scan was evaluated by 3-blinded observers.  All three 
evaluator average readings were then analyzed by a two-tailed t test.  
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 Total socket formed bone density (referred to as total formed bone density - TFBD) was 
a measurement of the HUs for the entire socket, regardless of the quantity of bone 
formed.  Representative measurement of TFBD for Patient-2 at 14 weeks is shown in 
Figure 38.  This measurement was done in a similar manner to NFBD (Figure 37) but the 
difference being that the entire height of the socket was considered, not just the areas that 
had actual bone formation.  This measurement could more accurately represent the same 
areas measured by digital radiographs.  Taking this measurement allowed for comparison 
of the two measurement tools.   
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Figure 38.  Example of CT Scan Evaluated Total Formed Bone 
Density (TFBD) in Hounsfield Units for Extraction Sites 
Representative CT scan projections of control and PRP treatment extraction sites are 
illustrated by VIPTM Data Conversion
®
 software for Patient-2 at 14 weeks.  Each 
individual projection represents a 1 mm sagittal cross section slice of the extraction 
socket in an anterior to posterior direction.  Measurements in Hounsfield units (HUs) are 
shown with the elliptical measurement tool provided by the software.  The elliptical tool 
was used to outline the entire vertical height of the extraction site as is referred to as total 
bone formed.  Each measurement provides an average HU that was recorded for each 1 
mm slice.  Average HUs represent averaged bone density, therefore these values would 
represent the average total formed bone density (TFBD) for that 1 mm slice.  All HU 
measurements obtained for the multiple 1 mm slices of the respective extraction site were 
averaged together.  Each CT scan was evaluated by 3-blinded observers.  All three 
evaluator average readings were then analyzed by a two-tailed t test.  
 
      Patients 1 and 2 CT scans were measured in 1 mm cross section planes (anterior to 
posterior).  The CT scan for patient three was measured in panoramic 1 mm sectional 
planes.  The cross sectional planes were preferred, but the topography of the bone after 
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tooth removal for Patient-3 did not permit accurate quantitative measurements with those 
projections.  CT scans were evaluated by 3-blinded evaluators working independently. 
Statistical Analysis 
     Statistical analysis was performed using GraphPad Prism
®
 3.0 (GraphPad Software, 
Inc., La Jolla, CA).  Two-way ANOVA analysis was performed for digital radiographs 
taken over a 0 to 2 weeks, 3 to 12 weeks, 3 to 25 weeks, and 0 to 25 weeks time-periods.  
Two-tailed paired t-tests were performed for individual time points with digital 
radiographs and CT scan analysis.   
C.  Results 
Digital Radiographic Results:   
     Digital radiographs were used to evaluate changes in radiographic bone density for 
each extraction site.  Three blinded dental professionals working independently evaluated 
all radiographs.  All extractions were of bilateral mandibular third molars (wisdom teeth) 
that had similar eruptive states prior to removal.  Each patient had one extraction site 
treated with PRP and the ipsilateral side did not receive PRP treatment.  Three patients 
received PRP treatment on the right side and three received the PRP treatment on the left 
side.  Treatment side was predetermined as follows.  The first, third, and fifth patients 
would receive PRP treatment on the left side and the second, forth, and sixth patients 
would receive PRP treatment on the right side.  This treatment decision was made prior to 
viewing patient radiographs and patient position in the sequence was based on their order 
of scheduling.   
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      Radiographic analysis of the digital radiographs taken for the 6 patients over the 25 
week time period show a significant (p < .0001) effect of localized PRP treatment on 
bone density.  The data represent the percent change in radiographic density for each 
socket and each time point from its corresponding baseline value.  Baseline values were 
determined as the radiographic density of extraction site immediately following tooth 
removal and placement of the Gelfoam
®
 and sutures.  Figure 39 illustrates the mean 
densities for all patients.  The two-tailed paired t test was used to analyze each time point, 
while two-way ANOVA was used to analyze data representing the span of a time-period.  
The two-tailed paired t test showed that there was a significant increase in the 
radiographic bone density for PRP treatment sites compared to control sites for each of 
the time points 1week (p < .01), and 2 weeks (p < .05).  The PRP treatment side had a 
positive effect on bone density immediately following tooth extraction.  Whereas, the 
control side when compared to its corresponding baseline bone density immediately 
following tooth removal (baseline density), showed a decrease in bone density for the 
initial week and by week 2 returned to baseline.  Two-way ANOVA for the initial 2 
weeks showed that treatment was significant (F = 32.16, p < .0001), the time elapsed 
following surgery was not significant (F = 2.874, p > .05) but there was a significant 
interaction between treatment and time (F =7.733, p < .001).  For weeks 3-12, treatment 
was significant (F=21.97, p < .0001), but time was not (F=1.698, p > .05) and there was 
no significant interaction between time and treatment (F=0.1455, p > .05).  Weeks 3, 4, 6, 
and 8 showed parallel density changes from their respective baseline.  The two-tailed 
paired t test revealed at week 12 a significant difference (p < .05) between the density 
changes between the two groups as did week 20 (p < .05).  The intervening week 16 (p > 
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.05) did not show a significant difference nor did week 25 (p > .05.  The PRP treatment 
group had greater bone density changes over baseline immediately following extraction, 
but the differences between the groups were not significant at later time points with the 
exception of weeks 12 and 20.  For weeks 3-25 two-way ANOVA analysis did reveal that 
treatment was significant (F = 15.21, p < .0001), time elapsed was also significant (F = 
5.924, p < .001), but the interaction between treatment and time was not significant 
(F=0.07530, p > .05).  When examining the entire 25-week period, treatment was again 
significant (F = 37.49, p < .0001), time elapsed following surgery was significant (F = 
13.75, p < .0001) but the interaction between treatment and time was not significant 
(F=0.6975, p > .05).    
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Figure 39.  Percent Radiographic Density Change of Surgical 
±PRP Treatment compared to Control Radiograph Taken 
Immediately Following Tooth Removal 
 
All 6 patients are represented in this graph with each time point representing the average 
values of the patients combined.  Percent bone density change on the Y-axis represents 
the change in bone density that has occurred at the extraction site in comparison to the 
extraction site immediately after tooth removal and placement of the Gelfoam
®
 sponge ± 
PRP and suturing.  Digital radiographs were normalized to the immediate post-operative 
film by comparing the unaltered adjacent tooth on the time point radiograph with the 
immediate post-operative radiograph’s corresponding unaltered tooth.  Each patient’s 
digital radiographs were evaluated by 3-blinded evaluators.  Each point on the connecting 
bars represents the ± S.E.M. for the six different patients and each treatment group.  
Analyses for each treatment site were performed in triplicate by each evaluator.  Each 
data point was analyzed with a two-tailed paired t-test where significance was defined as 
p < .05, where a = p < .01; b = p > .05 for individual time points.  For the span of time-
periods, a two-way ANOVA was performed and significance was defined as p < .05.  For 
the time period 0 to 2 weeks PRP-treatment was significant (p < .0001); time was not 
significant (p > .05); but there was a significant interaction (p < .001) between the 
benefits of PRP-treatment and time, therefore the beneficial effects of the PRP-treatment 
and time were related for the initial 2 week post-operative healing time period.  For 
weeks 3 though 12 treatment was significant (p < .0001), but time was not (p > .05) and 
there was no significant interaction between time and treatment (p > .05).  For the time 
period 0 to 25 weeks PRP-treatment was significant (p < .0001); time was significant (p < 
.0001); but there was not a significant interaction (p > .05) between the benefits of PRP-
treatment and time, therefore the effect of the PRP-treatment was independent of time for 
the entire 25 week time period.    
 
CT Scan Results 
     Sample CT scan projections for each of the 3 patients who underwent this analysis are 
presented in Figures 40-42.  The panoramic, axial and sagital cross-sectional windows 
were viewed in one mm slices and sagital cross-sectional views were evaluated for each 
patient at their indicated time point.  Three-blinded dental personal working 
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independently analyzed each of the CT scans.  The standard error of the mean (SEM) of 
these three measurements is indicated on each of the graphs.  There is some subjective 
interpretation in outlining areas to evaluate, as there was with the digital radiographs.  
Each evaluator recorded three readings for each 1mm slice at each extraction site.  
Evaluations were done for 3 criteria: 1) percent bone fill; 2) newly formed bone density 
(NFBD); and 3) total bone formed density (TFBD).  The three readings for each scan 
slice were averaged.   
 
Figure 40.  Patient 1 CT Scan 18 Weeks 
CT scan panel for Patient 1. A. Panoramic radiographic projection (traditional x-ray);B. 
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and 
R (right) correspond to each side of the patient; D. CT scan sagittal cross-section 1mm 
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slices of left extraction site (PRP treated); E. CT scan sagital cross-section 1 mm slices of 
right extraction site (control). 
  
 
 
Figure 41.  Patient 2 CT Scan 14 Weeks 
CT scan panel for Patient 2. A. Panoramic radiographic projection (traditional x-ray);B. 
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and 
R (right) correspond to each side of the patient; D. CT scan sagital cross-section 1mm 
slices of right extraction site (PRP treated); E. CT scan sagital cross-section 1mm slices 
of left extraction site (control). 
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Figure 42. Patient 3 CT Scan 10.5 Weeks 
CT scan panel for Patient 3. A. Panoramic radiographic projection (traditional x-ray);B. 
Axial CT section superior to extraction sites; C. Panoramic CT section note: L (left) and 
R (right) correspond to each side of the patient; D. CT scan sagital cross-section 1mm 
slices of right extraction site (PRP treated); E. CT scan sagital cross-section 1 mm slices 
of left extraction site (control). 
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     Three factors were evaluated for each of the CT scans.  The first factor was percent 
bone fill that represented the degree to which the bone had developed and filled in the 
extraction socket.  This was done by measuring the radiographic evidence of bone 
formation in the socket from an inferior to superior manner and dividing this value by the 
height of the total socket (again inferior to superior measurement).  The second factor 
analyzed was newly formed bone density (NFBD) which represents the density of the 
bone that had actually formed in the socket.  This measurement was calculated by the 
computer program and was concerned only with actual new bone formation.  The third 
factor analyzed was Total Formed Bone Density (TFBD).  This factor considered the 
entire extraction socket bone density.  All three factors were analyzed for each individual 
patient’s CT scan at a specific time with three readings (averaged) from three blinded 
evaluators using the two-tailed paired t test.  The data for the three patients’ individual 
factors were combined and analyzed with a two-way ANOVA, because three different 
time points were considered.    
     For the first factor percent bone fill of the extraction sockets were examined and 
compared.  PRP treated sites were compared with non-PRP treated sites (control).    
Percent bone fill for all of the patients (Patient-1 at 18 weeks, Patient-2 at 14 weeks, and 
Patient-3 at 10.5 weeks) did not reveal a substantial difference in bone height between the 
PRP treatment sites and control sites (Figures 43 A-C).  Patient-1 (18 weeks) CT scan 
(Figure 43-Panel A) indicated that bone fill for the PRP treated side was 96% in 
comparison to the control side at 90%.  Patient-2 CT scan (14 weeks) illustrated that the 
PRP treated side bone fill was 90% in comparison to the control side at 81% (Figure 43-
Panel B).  Patient-3 (Figure 43-Panel C) had the earliest CT scan (10.5 weeks) indicated 
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that the PRP treated side had 55% bone fill while the control side was approximately 
42%.  The lesser percent bone fill for the earliest CT scan and greater bone fill for the 
subsequent later time point CT scan was expected.  When using a two-way ANOVA to 
compare all 3 patients and their respective time points together, the PRP sites did 
show significant (F=19.76, p < .05) greater percent bone fill than the control sites 
(Figure 47-Panel D); time was also significant (F=185.3, p < .01). 
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Figure 43.  Percent Bone Fill of Extraction Sockets Analyzed by 
CT Scan  
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Panels A-C represents CT scan analyses of percent bone fill for the PRP-treated and 
control extraction sites on three different patients at a specific time point.  Panel A 
represents a patient’s percent bone fill at 18-weeks.  Panel B represents a patient’s 
percent bone fill at 14-weeks.  Panel C represents a patient’s percent bone fill at 10.5-
weeks.  Panel D represents the three patients over the three time points and analyzed by 
two-way ANOVA where significance was defined as p < .05.  Where a = p < .05 revealed 
that PRP-treatment significantly enhanced the percent bone fill when compared to non-
PRP-treated sites (control).  For b = p < .01 Time elapsed since tooth removal was also 
found to be significant.   
 
               The second factor examined was bone that had developed since the extraction 
had taken place and it is referred to as newly formed bone.  PRP treated sites were 
compared with non-PRP treated sites (control).  New bone that formed was measured in 
HUs and illustrated in Figure 44 A-D.  It is referred to as newly formed bone density 
(NFBD).  As expected, the NFBD was greater at the later time points than the earlier 
10.5-week time point.  Patient -1 (18-weeks) NFBD is presented in Figure 44A.  Patient-
2 (Figure 44 B) had denser bone at the 14-week time point in comparison to Patient-3 
(Figure 44-C)at the 18-week time point, but this may be due to individual patient 
variation or measurement variables.  When comparing all patient treatments together 
(Figure 44 D) and the various time points with a two-way ANOVA, the PRP-treated and 
control sites did not differ significantly (F=0.01475.134, p > .05) in NFBD, and time was 
not a significant (F=13.19, p > .05) factor either.   
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Figure 44.  Newly Formed Bone Density (NFBD) of Extraction 
Sockets Analyzed by CT Scan  
Panels A-C represents CT scan analyses of newly formed bone density (NFBD) for the 
PRP-treated and control extraction sites on three different patients at a specific time 
point.  Panel A represents a patient’s NFBD at 18-weeks.  Panel B represents a patient’s 
NFBD at 14-weeks.  Panel C represents a patient’s NFBD at 10.5-weeks.   Panel D 
represents the three patients over the three time points and analyzed by two-way ANOVA 
where NFBD with PRP-treatment was not significant (p > .05) in comparison to the 
control sites.  Time elapsed was found not a significant (p > .05) factor for NFBD.   
       The third factor considered was the average bone density for the entire tooth 
extraction site.  PRP treated sites were compared to non-PRP treated sites (control).  
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Total Formed Bone Density (TFBD) represents the density of the complete extraction 
socket.  This measurement includes new bone that had actually formed in the socket and 
areas of the socket where bone had not yet developed.  TFBD is measured in HUs and 
illustrated in Figures 45 A-D.  Again, as expected Patient-3 (10.5-weeks) (Figure 45 C) 
with the earliest CT scan had the lowest TFBD, while Patient-2 (14-weeks) (Figure 45 B) 
did have a slightly higher value than Patient-1 (18-weeks) (Figure 45 A). When 
comparing all of the patients together (Figure 45 D) with a two-way ANOVA analysis, 
the PRP-treated sites did not have a significant increase (F = 0.2557, p > .05) in TFBD, 
but time elapsed since tooth removal was a significant (F = 96.12, p > .0001) factor.   
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Figure 45.  Total Formed Bone Density (TFBD) of Extraction 
Sockets Analyzed by CT Scan  
Panels A-C represents CT scan analyses of total formed bone density (TFBD) for the 
PRP-treated and control extraction sites on three different patients at a particular time 
point.   Panel A represents a patient’s TFBD at 18-weeks.  Panel B represents a patient’s 
TFBD at 14-weeks.  Panel C represents a patient’s TFBD at 10.5-weeks.  For each of 
these patients there was no substantial difference between PRP-treatment and control 
sites.  Panel D represents the three patients over the three time points and analyzed by 
two-way ANOVA, where TFBD with PRP-treatment was not significant (p > .05) in 
comparison to the control sites.  Time elapsed did have a significant effect (p <.0001) on 
TFBD.  
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     Next, the TBFD values obtained from the CT scan analysis were compared to the 
grayscale digital radiographic analysis.  The digital radiograph grayscale values were of 
the entire socket (as were the TBFD values) and therefore, represent similar 
measurements.  Figure 39 shows the normalized percent change in digital radiographic 
bone density from the baseline value.  Table 12 shows the ratio of the normalized 
grayscale value of the PRP treated site to the control site in each of these three patients 
who underwent CT scans.  To minimize radiation exposure for patients the CT scans 
were obtained midway between two digital radiographic time points.  This comparison 
revealed that the CT scan percent TBFD were similar, but higher than the digital 
radiograph grayscale values.  The results for the two later time point CT scans had greater 
similarity to the digital radiograph grayscale values than for the CT scan taken at the 
earlier time point.  
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Patient (A) Digital 
Radiograph prior to 
CT scan ± S.E. 
(B) CT scan ± S.E. (C) Digital Radiograph 
after CT scan ± S.E. 
1  101.0 ± 3.377 (16 
wks) 
106.0± 3.99 (18 wks) 97.25 ± 0.8253 (20 wks) 
2 102.7 ± 1.448 (12 
wks) 
107.6 ± 7.353 (14 wks) 101.2 ± 0.5452 (16 wks) 
3 101.2 ± 2.247 (9.5 
wks) 
115.7± 5.108 (10.5 wks) 105.3 ± 2.717 (11.5 wks) 
 
Table 12.  Total Bone Formed Density (TFBD) - Percent Change 
Comparisons of Digital Radiographs and CT Scans 
These TBFD values compare the percent radiographic density changes observed between digital 
radiographs and CT scans.  Column A represents the digital radiograph taken 2-4 weeks prior to 
the CT scan (column B) and column C represents the digital radiograph taken 1-2 weeks after the 
CT scan.  Comparison revealed that the CT scan percent TBFD were comparable, but 
higher than the both earlier and later digital radiograph grayscale values.  The results for 
the two later time point CT scans had greater similarity to the digital radiograph grayscale 
values than for the CT scan taken at the earlier time point.  It is commonly accepted that 
CT scan Hounsfield Unit readings are more accurate than digital radiographic grayscale 
values; therefore, the digital radiographic analysis may be artificially lower than reality.  
Patients’ Evaluation Results 
      Patients were asked to use a visual analogue scale (VAS) with a 1-10 rating for pain 
and a 1-3 rating for bleeding, numbness, facial edema and facial temperature for each 
time point.  The patient is asked to pick a numerical score on a horizontal line that has a 1 
to 10 or 1 to 3 markings to evaluate the severity of the factor being considered.  The 
higher the numbered response represents a greater the severity of the factor.  An example 
being a score of “8” signifies greater pain than a score of “2”.  Figure 46 provides 
illustrations for the patients’ post-operative observations.  Patients were blinded to which 
side received the PRP treatment.   
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Figure 46.  Patient VAS Evaluated Post-Operative Pain, Bleeding, 
Numbness, Facial Edema, and Facial Temperature  
Visual analogue scale (VAS) ratings by patients for post-operative perceptions of pain 
(Panel A, 1-10 scale), bleeding (Panel B, 1-3 scale), numbness (Panel C, 1-3 scale), facial 
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edema (Panel D, 1-3 scale), and facial tissue temperature (Panel E, 1-3 scale).  Patients 
provided ratings for the initial nine post-operative days.  Ratings were taken every 8 
hours for days 1-3 and scores are reported as a total for the entire 24-hour time period for 
a total possible score of 30 points for pain and 9 points for the other factors.  Ratings 
were reported every 12 hours for days 4 -9 and scores were again reported as a total for 
the entire 24-hour time period for a total possible score of 20 points for pain and 6 points 
for the other factors.  Two-tailed paired t tests revealed that there was no significant 
difference (p > .05) for any of these factors at any specific time point.  For the entire nine 
day time two-way ANOVA analysis demonstrated that time elapsed since the surgical 
procedure was significant (p < .0001) for pain, bleeding, numbness, facial edema, and 
facial temperature (p < .05).  PRP treatment did not have a significant impact on any of 
the factors (p > .05).  Time and PRP treatment were independent of each other.  
 
    Patients were asked to post-operatively rate their perception of pain using a 1-10 visual 
analogue scale (VAS) (Figure 46 A). There was a total possible score of 30 for the first 3 
days and then 20 for the subsequent days.  When using a two-tailed paired t test for each 
specific time point there was no statistical difference (p > .05) between the PRP treatment 
side and the control side for any of the parameters.  Patients were administered 
dexamethasone sodium phosphate IV intra-operatively; ketorolac trimethamine IV, and 
methylprednisolone suspension IM, and 4% bupivacaine with 1:200,000 epinephrine via 
an inferior alveolar block immediately following the procedure.  Patients were instructed 
to take 600 mg ibuprofen every 6 hours for the first 3 days and thereafter, as needed.  The 
adjuvant medications most probably reduced the post-operative pain, which may explain 
why the patients did not report high pain ratings.  The use of bupivacaine local anesthesia 
would explain the higher numbness rating for the initial 24 hours.  When examining the 
entire nine day time with a two-way ANOVA, treatment did not have a significant effect 
(F = .003, p > .05), time did have a significant effect (F = 9.01, p < .0001), and there was 
no interaction between treatment and time.    
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       Patients reported minimal post-operative bleeding (Figure 46 B).  Two-tailed paired t 
test analysis for each specific time point revealed no significant differences between the 
PRP treated sides and the control sides (p > 05).  Two-way ANOVA analysis for the 
entire nine day post-operative period did show that treatment was not significant (F = 
.373, p > .05), time was significant (F = 9.47, p < .0001), and there was no interaction (F 
= .117, p > .05) between treatment and time.  Therefore, PRP treatment and time were 
independent of each other.      
      Patient reports of post-operative numbness (Figure 46 C) was substantial on both 
treatment and control sides for the 1
st
 day, thereafter it was very slight.  The numbness on 
the initial post-operative day is due to the administration of the long-acting local 
anesthetic bupivacaine HCl 0.5% with epinephrine 1:200,000.  The half-life for soft 
tissue anesthesia of this local anesthetic is 7 to 8 hours (470).  Subsequent numbness over 
the remaining 8 days was minimal and most likely due to the formation of edema.  The 
two-tailed t test analysis for each time point revealed no significant differences between 
the PRP treated sides and the control sides (p > .05).  Two-way ANOVA analysis for the 
entire post-operative period showed that PRP treatment did not make a difference (F = 
0.72, p > .05), time was significant (F = 13.81, p < .0001) and there was no interaction (F 
= 0.72, p > .05) between treatment and time. 
      Facial edema was higher on both the treatment and control sides for each of the first 3 
days but the two-tailed t test revealed that there was no significant difference (p > .05) 
between sides  (Figure 46 D).  The administration of glucocorticosteroids and the 
patient’s use of ice packs may also have contributed to the lower ratings for edema.  
When examining the entire nine day time with a two-way ANOVA, treatment did not 
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have a significant effect (F = .076, p > .05), time did have a significant effect (F = 27.71, 
p < .0001), and there was no interaction between treatment and time (F = 0.246, p > .05).  
      At no time did any of the patients report marked increases in tissue temperatures 
(Figure 46 E).  The two-tailed paired t test for each specific time point revealed that skin 
temperature was not significantly different (p > .05) for any of the time points.  Two-way 
ANOVA for the entire nine day post-operative period showed that tissue temperature was 
not affected by PRP treatment (F = .083, p > .05), time was significant (F = 3.176, p < 
.05), and there was no significant interaction between treatment and time (F = 1.254, p > 
.05).   
      The patients use of NSAIDs (ketorolac and ibuprofen) may have helped keep 
temperature elevations to a minimum.  It has been well documented that the use of 
glucocorticosteroids and/or NSAIDs may interfere with new bone formation (471, 472), 
but this does not appear to be the case here.  This is likely because the medications were 
administered for only a short time period.  Also, the presence of PRP with constituent 
multiple growth factors and cytokines could have mitigated the negative effects of these 
medications. 
A comprehensive listing of patient rated post-operative parameters are presented in Table 
13. 
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Pain No >.05 .003 Yes < .0001 9.01 No >.05 .053 
Bleeding No >.05 .373 Yes <.0001 9.47 No >.05 .117 
Numbness No >.05 .72 Yes <.0001 27.71 No >.05 .72 
Facial 
Edema 
No >.05 .076 Yes <.0001 27.71 No .>.05 .246 
Temp. No >.05 .083 Yes <.05 3.176 No >.05 1.254 
 
Table 13. Summary Table of Two-way ANOVA Analysis of Patient 
Post-operative Observations 
Two-way ANOVA statistics summary of the significance, F ratio, and p-values for each 
of the patient evaluated post-operative parameters.  PRP treatment was not significant for 
any of the parameters.  Elapsed post-operative time did have a significant impact on all of 
the parameters.  Time and PRP treatment effects were independent of each other. 
Observers’ Evaluation Results 
     Blinded clinical observers evaluated the degree of tissue opening (dehiscence), 
bleeding, inflammation, facial edema, intra-oral edema, and perceived pain using a VAS 
(Figure 47 A-F).   
204 
 
  
 
1 2 3 4 6 8
0
1
2
3
4
5
6
7
8
9
PRP
Control
Week
D
e
h
is
e
n
c
e
 (
m
m
)
A. Dehiscence
 
0.5 1.0 2.0 3.0 4.0 6.0 8.0 10.0
0
1
2
3
4
5
6
7
8
9
PRP
Control
Week
V
A
S
 R
a
ti
n
g
B. Bleeding
 
0.5 1.0 2.0 3.0 4.0 6.0 8.0 12.0
0
1
2
3
PRP
Control
Week
V
A
S
 R
a
ti
n
g
C. Inflammation
 
0.5 1.0 2.0 3.0 4.0 6.0 8.0 12.0
0
1
2
3
PRP
Control
Week
V
A
S
 R
a
ti
n
g
D. Facial Edema
 
0.5 1.0 2.0 3.0 4.0 6.0 8.0 12.0
0
1
2
3
PRP
Control
Week
V
A
S
 R
a
ti
n
g
E. Intra-Oral Edema
 
0.5 1.0 2.0 3.0 4.0 6.0 8.0 12.0 16.0 20.0
0
1
2
3
4
5
6
7
8
9
10
PRP
Control
Week
V
A
S
 R
a
ti
n
g
F. Pain
 
 
Figure 47.  Observer VAS Evaluated Post-Operative Dehiscence, 
Bleeding, Inflammation, Facial Edema, Intra-Oral Edema, and 
Pain 
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Visual analogue scale (VAS) ratings as reported by blinded observers for post-operative 
perceptions of dehiscence (Panel A), bleeding (Panel B), inflammation (Panel C), facial 
edema (Panel D), intra-oral edema, (Panel E) and pain (Panel F).  Dehiscence, bleeding, 
inflammation, facial edema, and intra-oral edema evaluations were done on a 1-3 scale, 
pain was evaluated on a 1-10 scale.  Observers provided evaluations at the following 
post-operative time points: days 3 and 7, then weeks 2, 3, 4, 6, 8, 12, 16, 20, and 24.  
Two-tailed paired t tests revealed that there was no significant difference (p > .05) for any 
of the parameters at specific time points.  When analyzing the entire 24-week time with a 
two-way ANOVA analysis PRP treatment was significant for reducing facial edema (p < 
.05).  PRP treatment was not significant for any of the other parameters (p > .05).  Two-
way ANOVA analysis demonstrated that time elapsed since the surgical procedure was 
significant for dehiscence (p < .01), inflammation (p < .0001), facial edema (p < .0001), 
intra-oral edema (p < .0001), and pain (p < .0001).  Time was not significant for bleeding 
(p > .05).  Treatment and time were independent of each other (p > .05).   
 
      Observers found no dehiscence (Figure 47 A) on day 3 because primary closure was 
obtained with sutures.  Subsequent ratings did reveal tissue retraction, but this does not 
translate to exposed bone.  This was the result of the edges of the tissue rolling back, but 
the socket was covered initially by a blood clot and later by soft tissue.  No patients 
experienced exposed bone.  The two-tailed paired t test showed that there was no 
significant (p > .05) difference between the two treatment sites in regards to dehiscence 
for any of the specific time points.  The two-way ANOVA did reveal the treatment was 
not significant (F = .019, P > .05), time was significant (F = 4.198, p < .01), and there 
was no interaction between these two factors (F = .117, p > .05).  
       Observer’s perception of bleeding (Figure 47 B) was that there was minimal bleeding 
from all operative sites.  The two-tailed paired t test analysis of the specific time points 
showed no significant difference between the PRP treated sides and the control sites (p > 
.05).  Two-way ANOVA showed that treatment, time, and interaction were not 
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significant factors [treatment (F = .617, p > .05), time (F = 1.367, p > .05), and interaction 
(F = .277, p > .05)].   
     Inflammation (Figure 47 C) was not significantly different (p > .05) between PRP 
treated sides and the control sides for any of the specific time points when rated by the 
observers and analyzed by the two-tailed t test.  The two-way ANOVA analysis of the 
24-week post-operative period revealed that PRP treatment was not significant (F = 
2.577, p > .05), time was significant (F = 13.20, p < .0001), and there was no interaction 
between these two factors (F = .339, p > .05). 
      Observers’ evaluation of facial edema (Figure 47 D) and two tailed paired t test 
analysis revealed that PRP treatment provided no significant differences (p > .05) 
between treatment and control at any of the specific time points.  Two-way ANOVA of 
the entire post-operative period did show that treatment was significant (F = 4.416, p < 
.05), time was extremely significant (F = 8.986, p < .0001) and there was no interaction 
(F = .639, p > .05). 
     Intra-oral edema (Figure 47 E) was rated by the observers and two-tailed paired t test 
analysis revealed that treatment provided no significant differences (p > .05) for any of 
the specific post-operative time points.  The two-way ANOVA analysis of the entire post-
operative time revealed that treatment was not significant (F = 3.843, p > .05), time was 
significant (F = 11.4, p < .0001) and these two factors were independent of each other (F 
= 0.696,  p > .0001). 
     Observers’ ratings of the patients’ pain (Figure 47 F) analyzed with the two-tailed 
paired t test showed that there was no significant difference (p > .05) at any of the 
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specific time points.  Analysis of the entire post-operative period with two-way ANOVA 
revealed that treatment was not significant (F = 1.104, p > .05), time was significant (F = 
44.5, p < .0001), and there was not a significant interaction between these two factors (F 
= 0.185, p > .05).  There were similarities between the pain ratings provided by the 
patients (Figure 50-Panel A) and those provided by the observers at day 3 (Figure 51-
Panel F).  Observer ratings were at day 3, week 1, then weekly thereafter, while the 
patient ratings were on a daily basis for the initial nine post-operative days following 
surgery.  Patients rated their pain on day 3 as 10.83 (total - maximum of 30) for the PRP 
side and 11.00 for the control side, representing the sum of three readings for the day.  If 
the patient readings were divided by three to give an average reading for each 8 hour time 
period that the patients evaluated it would translate to 3.61 for the PRP side and 3.67 for 
the control side.  Observers provided only one rating on day 3 resulting in a score of 4.5 
for the PRP side and a score of 5 for the control side.  The other reading that overlapped 
for the observers and patients was day 7.  Patients provided an average score of 1.5 
(average 12 hour reading) for the PRP side and 1.83 for the control side.  Observers 
provided scores of 1.8 for the PRP side and 2.2 for the control side.  These overlapping 
pain ratings were similar, but the observer always rated the pain slightly more severe than 
did the patients.   
      A summary of the statistical analysis of the post-operative parameters evaluated by 
the observers are listed in table 14.  
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Dehiscence No >.05 .019 Yes <.01 4.198 No  >.05 .117 
Bleeding No >.05 .617 No >.05 1.367 No >.05 .277 
Inflammation No >.05 2.577 Yes <.0001 13.20 No >.05 .339 
Facial 
Edema 
Yes <.05 4.416 Yes <.0001 8.986 No >.05 .639 
Intra-oral 
edema 
No >.05 3.843 Yes <.0001 11.4 No >.05 .696 
Pain No >.05 1.104 Yes <.0001 44.5 No >.05 .185 
 
Table 14. Summary Table of Two-way ANOVA Analysis of 
Observers Post-operative Observations 
Two-way ANOVA statistical summary table of the significance, F-ratio and p-values for 
each of the observer evaluated parameters.  PRP treatment over the 24-week time was 
significant (p < .05) for facial edema.  PRP treatment was not significant for any of the 
other parameters.  Elapsed post-operative time did have a significant impact on all of the 
parameters.  Time and PRP treatment effects were independent of each other.   
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D. Discussion 
     This prospective blinded third molar pilot study offers insight to what is occurring 
clinically when BC-PRP is applied to fresh extraction sites.  Third molar extractions are 
often used as a measurement tool for comparing treatments because they are usually 
performed electively on a younger population that do not present with multiple 
confounding factors such as systemic pathologies or multiple medications.  Therefore, 
data analysis and interpretation from this study applies to healthy 18 to 40 year old 
patients. 
 Intra-oral digital radiographs taken of the individual surgical sites revealed that 
the effects of PRP were significantly beneficial (p < .05) for bone density determined by 
grayscale analysis.  One can make the argument that this significant difference in bone 
density suggests a greater volume of new bone formation with PRP treatment.  This 
increase in bone density (presumed as increased volume of new bone formation) was 
found to occur at earlier time points than the non-PRP treated control sites.  Figure 48 is 
the same as Figure 39, except grid lines that allow for closer interpretation of the data 
points.    
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Figure 48.  Percent Radiographic Density Change of Surgical 
±PRP Treatment compared to Control Radiograph Taken 
Immediately Following Tooth Removal 
 
This graph is the same as Figure 43 with the exception that grid lines have been added.  .  
Grid lines allow for time comparison between PRP treated and control sides.  Each data 
specific time point was analyzed with a two-tailed paired t-test where significance was 
defined as p < .05, where a = p < .01; b= p > .05 for individual time points.  The marked 
difference in bone density during the initial 2 weeks post-operatively denotes the 
accelerated bone formation PRP treatment seems to provide.  This immediate increase in 
bone density at the PRP treated sites indicates early bone formation in comparison to the 
control sites that have a decrease in bone density indicating further bone loss.  Note that it 
takes 6 weeks to reach the same degree of bone density that the PRP treated sites had 
achieved at week 1.     
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     Of note was the immediate increase in grayscale readings which represents bone 
density and therefore early bone formation.  This finding corresponds with the results 
from the molecular study that demonstrated PRP treatment of hMSCs induced an early 
proliferation of these cell types and possibly differentiation into osteoblasts.  This 
accelerated bone formation is in contrast to the control site that showed a drop in bone 
density (representing bone loss) before bone formation began to take place.  It took 
approximately 6 weeks for the control side to reach the same degree of bone density that 
the PRP treated site had reached at week 1 (Figure 48).  The PRP induced accelerated 
bone formation may be due to the presence of BMPs 2 and 6 in PRP that stimulated the 
hMSCs to begin the osteoblast differentiation development and subsequent calcification 
(473, 474).  The control sites would be dependent upon osteoclast activity to initially 
breakdown existing bone so the bone matrix could release these two BMPs and then 
stimulate the hMSCs to begin bone development.  These findings correspond well with 
the known and accepted bone-repair time-line (475).  This immediate start of bone 
formation is of clinical relevance because, it is the initial two weeks following bone-
manipulation oral surgery that is important in preventing infection, loss of the blood clot 
and/or AO (dry socket) formation.  Moreover, there was a slight drop in grayscale density 
at the 1.5 to 2 week period suggesting that the initial direct impact of BC-PRP treatment 
might end, or at the minimum decrease, by the 1.5 – 2 week time point.  
 Further examination of the digital radiographic density changes shows that 
subsequent changes in bone density with the PRP treated sites and control sites are 
parallel, with no significant differences, except for the 12 and 20-week time points.  The 
finding of the parallel lines most likely represents that normal healing is now taking place 
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at both sites, but the change in bone density was greater for the PRP treated site because 
it had the immediate bone formation, whereas the control site did not.  The significant 
differences seen at the 12 and 20-week time points may be due to bone remodeling or 
inherent variations in the radiographic evaluation technique.  
      It should also be noted that it takes the control side 16 weeks to reach the same degree 
of increased radiographic grayscale for the total extraction socket as the PRP treatment 
achieves in 8 weeks.  This is of clinical significance because it suggests decreased 
healing time.  Therefore, patients bone recovers more rapidly to full function or is ready 
for the next step in dental reconstruction at an earlier date.  Examples of this benefit 
include patients who undergo complete arch extractions and are in need of prosthesis for 
esthetics and function.  The patient may be given an initial temporary denture that is 
normally utilized for 6 months prior to constructing the definitive final denture that has 
superior esthetics and function.  This final denture could be constructed at the 2 to 3 
month time point and therefore return the patient to full function in a shorter time-period.  
The decrease in bone healing time would also apply to the placement of dental implants 
that normally occurs after 4 to 6 months, unless expensive bone-grafting techniques are 
utilized which still require a 4-month bone healing time.  With PRP treatment at the time 
of tooth removal, dental implants can be placed at a 2 to 4 month time, thereby 
decreasing the time to implant placement by 50%.  
     The instrumentation in this portion of the study utilized non-invasive radiographic 
techniques.  Admittedly, bone histology studies could provide additional information 
with greater validity, but that analysis technique would be invasive, requiring surgical 
reentry.  Individual site digital radiographs were taken and normalized to baseline 
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radiographs.  The initial radiographs were normalized between the two surgical sites of 
the patient.  Digital panoramic radiographs may have been a better measurement tool 
because the two surgical sites would be represented on one film, thereby eliminating the 
need for radiographic normalization between the initial surgical sites.  Nonetheless, 
normalization between the series of radiographs and baseline radiographs would still 
have been necessary.  The disadvantage of the digital panoramic radiograph is that these 
films have a 20 to 25% distortion factor incorporated into the image because it is an 
extra-oral film as opposed to the intra-oral individual (periapical) digital radiographs.  
The periapical radiograph was chosen over the panoramic radiograph because the 
periapical radiograph has less distortion incorporated into the images than with 
panoramic films.  There is less distortion because the periapical film is in close proximity 
to the oral site being evaluated as opposed to being removed from the immediate site of 
interest as is the extra-oral panoramic radiograph is.    
     The CT scans may have shown greater differences between the PRP treated sites and 
the control sites, had they been obtained at earlier time points.  Based on these findings 
and now knowing the effects of PRP-treatment are greatest during the initial 2 weeks it 
would be beneficial to acquire the CT scans at earlier time points.  Therefore, future 
studies will have the CT scans taken at earlier time points to confirm the early effects of 
PRP treatment.   
     Patients in this study were exposed to medications (dexamethasone sodium phosphate, 
methylprednisolone suspension, ketorolac trimethamine, and ibuprofen) that interfere 
with inflammation and therefore may have an impact on bone healing.  During the early 
phase of bone formation there is increased gene expression of pro-inflammatory 
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cytokines, mitogenic growth factors, and cell-differentiating factors.  Inflammation, 
which occurs at the onset of early phase injury- or surgically-induced bone formation, is 
hypothesized to provide the initial signaling molecules for continuation of the healing 
cascade (476, 477).  Cyclooxygenase-2 (COX-2) is important to the course of normal 
inflammation (476, 478-480).  The rate-limiting step in the synthesis of prostaglandins 
from arachidonic acid is catalyzed by COX-2.  Prostaglandins are bioactive lipids and are 
of significance because they possess pro-inflammatory effects plus other varied 
physiological effects (476, 481).  COX-2 is responsible for PGE2 and PGF2 formation 
and is thought to have a functional role in healing (482).    
     Glucocorticosteroids (dexamethasone, methylprednisolone) and NSAIDs (ibuprofen, 
ketorolac) were used during this clinical study because of their analgesic and anti-
inflammatory efficacy.  The inhibition of cyclooxygenases is the mechanism by which 
glucocorticosteroids and NSAIDs achieve their intended effects.  Following the 
hypothesis that inflammation is necessary for normal bone healing and formation, post-
operative NSAID therapy may potentially delay bone healing.  However, PRP may be a 
suitable agent to offset this inhibition when NSAIDs are prescribed for a short post-
operative course.  Figure 49 offers a possible mechanism for the beneficial effects of PRP 
that can offset the negative bone healing effects of NSAIDs.  PRP contains platelets and 
monocytes.  Both platelets and monocytes contain the cytokine interleukin-1α (IL-1α) 
(483, 484).  IL-1α is involved in the local regulation of bone homoeostasis (485).  It is 
also known that IL-1α stimulates PGE2 formation (485-489).  This IL-1α-induced 
stimulation of PGE2 formation would counter the PGE2 inhibition induced by systemic 
post-operative NSAID and glucocorticoid steroid administration.  Transient IL-1α has 
215 
 
been shown to have a potent stimulatory effect on bone formation (490, 491).  PRP 
administration is transient in nature.  The platelets in PRP also contain several growth 
factors (PDGF-AA, PDGF-BB, ILGF, TGFβ1, VEGF, and OPG) which work in concert 
in bone development and repair.  Therefore, PRP use most likely would sufficiently 
counter any PGE2 inhibition induced by short-term use of NSAID/glucocorticoid.   
 
Figure 49: Effect of NSAIDs on Bone Formation  
The use of NSAIDs blocks the formation of PGE2 initiated by the release of arachidonic 
acid.  The lack of PGE2 formation associated with the inflammatory response interferes 
with bone formation.  The use of PRP, which contains WBCs that release IL-1α and 
platelets, which release IL-1α, TGF-β1, PDGF-BB, VEGF, and OPG, may potentially 
medicate the adverse effects that NSAID use has on bone development.  
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  An alternative to using glucocorticosteroids and NSAIDs would be to use 
acetaminophen and/or narcotics for post-operative pain control.  Acetaminophen does not 
have an anti-inflammatory effect and therefore the patients would experience greater 
inflammatory effects, such as edema and pain.  Narcotic administration often times are 
fraught with unwanted side effects such as decreased mental acuity, lethargy, and GI 
disturbance.  Therefore, these two analgesics have little advantage over NSAIDs.  
       When examining the data from this study it appears that PRP does accelerate bone 
formation and decreases the time necessary to return to full function.  Other factors are 
present that would affect the patients’ pain perception, bleeding, and numbness so it is 
difficult to confirm the effect PRP has on these factors.  Blinded observers did report 
significantly less inflammation and facial edema (p < .05) on the sides receiving PRP.  
However, a larger study with fewer confounding factors would be necessary to confirm 
the effectiveness of PRP on inflammation and subsequent edema. 
 E.  Conclusion 
    The results of this study validate the use of this simple cost-effective buffy coat (BC) 
PRP method with oral surgical procedures.  The use of this BC system would be 
beneficial for the patient and clinician because it significantly increases the rate of bone 
formation early one (initial 2 weeks) and decrease healing time as evidenced by digital 
radiographic technology.  However, it may not have an effect on pain perception, 
bleeding, and numbness.  It is possible that PRP decreases inflammation and, therefore, 
the discomfort of edema.  Having evidence-based support from this and future studies for 
the use of this procedure may result in expanded use of PRP with other surgical 
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procedures with improved clinical outcomes.  Other surgical procedures requiring 
enhanced and predictable bone formation that would benefit from this technology include 
orthopedic joint implants, spinal surgeries, and trauma cases involving bone fractures.  
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General Discussion  
      This project contributes directly to evidence based dentistry with a possible 
application to orthopedics.  There has been a great deal of interest in both of these 
disciplines regarding PRP application for enhancing outcomes by decreasing healing time 
in surgeries that involve osseous manipulation.  A historical review of the literature 
reveals that PRP and its various techniques have been used with limited scientific 
evidence.  Some authors have stated that only complex and expensive techniques for 
preparing PRP had clinical validity (10).  This project used both in vitro and in vivo 
investigations to offer strong support for the use of a simple cost-effective technique for 
preparing PRP.  Because this technique is inexpensive and simple, its use can be applied 
to all osseous surgical procedures, thereby improving the quality of life for more patients.   
     The Preparation and Characterization of PRP (Study I) confirmed that platelet 
recovery and enrichment of PRP using the Cliniseal™ Centrifuge was consistently 
optimal with a 10-minute centrifugation time (Figure 16).  Moreover, platelet recovery 
and enrichment did not change significantly after centrifugation for up to six hours of 
bench set time at room temperature (Figure 18).  Growth factors of interest were present 
at all bench set times and therefore, not affected for up to 6 hours of setting at room 
temperature.  Platelets did aggregate and possibly undergo activation while undergoing 
the bench set, but the GFs that may have been released were not lost as they were most 
likely retained in a flexible fibrin junction (Figure 11).  The aggregation and activation 
process is done slowly so it would most likely mimic the flexible fibrin structure of the 
platelet rich fibrin processing technique (page 48)   Therefore, the Buffy Coat (BC) 
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method of PRP preparation provides platelet concentrations and recoveries that are 
adequate for clinical use. 
     A finding not reported previously in the literature is how platelet morphology changed 
with bench set time over a period of six hours at room temperature (Figure 19).  At two 
hours of bench set time, platelets in the PRP began to appear less normal and formed 
small-aggregates that suggest platelet activation and growth factor release.  The loss of 
GFs with bench set time is a concern for clinicians, because the whole blood is usually 
collected at the start of a clinical procedure and the blood centrifuged before coagulation 
begins, despite the presence of trisodium citrate anticoagulant in the collection vessel.  
Since it is well established that TGF-β1 stimulates osteogenesis, [7, 416, 417] a 
significant loss of this factor or the bioactivity of this factor by the various PRP 
preparation methods may account for the conflicting reports by clinicians concerning the 
osseous generating efficacy of PRP use.  ELISA results (Table 5) suggest that PRP bench 
set times using our BC method of PRP preparation should not be of consequence up to a 
maximum of 6 hours (Table 5).  Photomicrographs (Figure 19) did reveal that with the 
BC PRP technique platelets do begin to aggregate and possibly becoming activated after 
2 hours of bench set time.  The ELISA analysis in this study revealed no significant 
change (p > .05) in any of the key growth factors examined, including TGF-β1.  
Researchers have reported that TGF-β1 activity decreases when prepared using bovine 
thrombin.  We feel that the decreased TGF-β1 activity experienced by others may be due 
to: 1) natural hydrolysis, 2) degradation by proteases or 3) specific irreversible binding by 
molecules that may be present in various preparations of PRP.  We hypothesize that 
bovine thrombin activates latent TGF-β1 and therefore may become subject to all of the 
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above.  The technique examined here does not use bovine thrombin as an activator for 
that reason.     
     Growth factor levels obtained in our study were generally higher than those reported 
by other researchers (238).  These findings may result from our analytical method for 
treating the platelet lysates with diluted 0.5% Triton X-100 (TX-100) prior to adding the 
samples to the ELISA plates. We believe that diluting the TX-100 lysates allowed for 
lower binding interference by the detergent and allowed a maximal TGF-β1 signal from 
the samples during ELISA analysis.  In addition, the ELISA kit for TGF-β1 analysis 
utilized a monoclonal capturing antibody, whereas other researchers used kits employing 
Type II TGF-β1 receptor or polyclonal anti-TGF-β1 capturing antibodies to detect the 
growth factor.  We believe these differences, in addition to not adding bovine thrombin, 
may account for the higher TGF-β1 yields in our study.  
     The second investigation of this dissertation was a retrospective analysis of 904 
mandibular extraction sites.  The study revealed the beneficial effects of PRP in reducing 
the incidence of alveolar osteitis (AO).  AO is believed to be due to either premature 
contraction of the blood clot within the socket or a localized infection.  Multivariate 
analysis (Figure 22) revealed the odds of AO formation was 2.37 times higher for 
extraction sites without PRP treatment (95% CI, 1.3 to 4.4) than those with PRP 
treatment were.  Bivariate analysis (Figure 21) demonstrated that extraction sockets 
treated with the immediate placement of a gelled BC PRP resulted in a significant 
decrease (p < .00043) in AO.  The beneficial effects of PRP treatment that resulted in a 
reduced incidence of AO may be related to the variety of growth factors found in PRP 
that stimulate cell mitosis and differentiation [452], increased collagen production, 
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recruitment of leukocytes and other cells to the surgical site, and initiation of vascular in-
growth (15).  The presence of these growth factors in PRP promotes both soft and hard 
tissue healing and angiogenesis, all critical to the prevention of AO.  In addition, the 
platelets found in PRP promote clot formation and the white blood cells found in PRP 
can inhibit bacterial growth.  Therefore, PRP application may reduce the currently 
accepted causes of AO by facilitating clot and soft tissue formation and inhibiting 
bacterial colonization.  
      Multivariate analysis (Figure 22) also revealed that in addition to the absence of PRP 
administration, there were three other significant risk factors for AO: bruxism, oral 
contraceptive use, and complete impaction.  Oral contraceptive use and complete 
impaction had been reported in the literature previously as being risk factors for AO (392, 
492).  Bruxism had not been reported previously as a causative factor for AO.  PRP 
treatment reduced the incidence AO formation associated with each of these other factors 
by approximately 50% (Figure 22).  The reduction was again most likely due to the 
variety of growth and other factors found in PRP that promote hard and soft tissue 
healing and decreased healing time.  As mentioned previously in this dissertation there 
are PRP variants that may affect the growth factor content (234, 235, 238).  Some of 
these variants do not contain WBCs and therefore they may not be as effective in 
preventing AO.  In addition, if GF concentrations were to decrease below a critical 
concentration with some PRP variants, then that particular PRP variant may not 
significantly reduce AO formation.  Our gelled BC PRP variant contains both WBCs and 
GFs; therefore, it is difficult to predict how other PRP variants would affect AO 
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formation.  We conclude that not using gelled BC PRP following tooth extraction is the 
most important risk factor for AO formation.   
      The molecular study highlighted two important aspects of PRP- first, increased 
proliferation of hMSCs and second, PRP does not stop hMSC differentiation into the 
terminal osteoblast.   
      Cell count studies (Figure 25) confirmed the early proliferative effects of a 24-hour 
PRP exposure on hMSCs.  PRP treated cells had a 3.2 fold increase in cell number over 
cells cultured in growth medium alone The BC-PRP technique compared favorably with 
(and actually surpassed in some aspects) the results of the MTT proliferation studies of 
Lucarrelli et al. (106) and Graziani et al. (328).  The Lucarrelli and Graziani studies used 
bovine thrombin and calcium gluconate to activate platelets in their PRP.  The results of 
our study brings into question whether it is in fact necessary, or beneficial, to activate the 
platelets through these methods.  As discussed in the introduction, there are several 
reasons not to use bovine thrombin including: development of antibodies against 
thrombin, prothrombin, factor V, cross reactivity with analogous human coagulation 
proteins, and decreased PRP TGF-β1 concentrations.  It is highly likely that in vivo, 
platelets from the BC technique are activated by collagen, thrombin, fibronectin, ADP, 
and thromboxane A2 present at the surgical site.  Therefore, based on the results of this 
study and the drawbacks of bovine thrombin, the addition of bovine thrombin to PRP is a 
questionable clinical practice.   
      The significant (p < .001) increase in cellular total RNA production seen with PRP 
treated groups and not with non-PRP treated groups at day 5 (Figure 27 A) strongly 
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suggests that the presence of WBCs in PRP may be a confounding factor and therefore 
distorting the true increase in total RNA due to increased cellular metabolism.  WBCs 
have RNA and vital WBCs would be making mRNA that may be inflating what is 
thought to be the cellular total RNA concentration.  WBCs may have accounted for over 
50% of the total RNA increase observed.  Further study separating the platelets and 
WBCs will help discern the true effect of the platelets on total RNA production. This 
could be accomplished by using a Ficoll™ separating gradient to separate the WBCs and 
platelets.  The project would be greatly improved by using alternate methods to determine 
cell proliferation, such as the use of the CellTiter-Glo
®
 Luminescent Cell Viability Assay 
that is a homogeneous method of determining the number of viable cells in culture based 
on quantification of ATP present (444, 445).    
      Cell differentiation was measured by two methods: 1) alkaline phosphatase assay 
(ALP), an early differentiation marker and 2) examination of the expression of specific 
mRNAs signifying osteoblast formation.  The ALP assay (Figure 28) suggested that PRP 
does not stop differentiation when differentiation signals are present in vitro.  When 
normalizing for cell number by considering percent confluence of cells (Figure 29), it 
appears that PRP does not induce differentiation for hMScs in growth medium.  ALP 
activity did not increase at either Day 5 or 15 for cells cultured in growth + PRP medium 
when compared to growth medium.  However, at Day 5 differenentiation + PRP medium 
did show ALP activity but it was lower than that seen with differentiation medium.  At 
Day 15, the ALP activity for differentiation + PRP medium was similar to that seen with 
differentiation medium.  Therefore, it can be suggested that PRP does not induce 
differentiation, but neither does it stop differentiation when the proper differentiation 
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signals are present.  This study cannot clearly state if differentiation is decreased or if the 
level of ALP activity with PRP-treatment of hMSCs meets that of differentiation medium 
at any specific time point.  Day 5 ALP activity was diminished when compared to 
differentiation medium, yet Day 15 ALP activity was similar, it may be suggested that 
future studies should include several time points to determine if PRP treated cells express 
the same peak ALP activity seen with differentiation medium at a similar or different 
time point.  It may be suggested that PRP induces proliferation during the initial 5 days 
and therefore delays differentiation when differentiation signals are present.  Since 
proliferation and differentiation of cells cannot occur simultaneously, a question to be 
addressed is does the proliferation signals of PRP override the differentiation signals of 
differentiation medium, and if so for how long.  The clinical use of PRP may be 
improved by following PRP treatment with an agent that further enhances differentiation 
and shifts it to a shorter time than normally occurs physiologically.  The ALP studies may 
not reflect consistent findings, because ALP activity was not normalized for cell number 
or total protein.  The cell number issue that must be corrected in future studies.  Another 
question to be examined is what effect continuous or intermittent PRP exposure would 
have on differentiation.     
      PRP treatment increased relative mRNA expression at day 21 for two osteoblast 
differentiation gene markers, osteocalcin and bone sialoprotein (Table 11).  Bone 
sialoprotein mRNA relative expression was greater than that of osteocalcin.  Bone 
sialoprotein is expressed earlier than osteocalcin.  Therefore, we may be witnessing the 
peak of the bone sialoprotein mRNA expression and the osteocalcin mRNA peak is yet to 
appear.  Differentiation medium exceeded the relative expression of these two gene 
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mRNAs when compared to growth + PRP medium.  However, differentiation medium 
did not attain the levels of relative expression that the differentiation + PRP treatments 
did.  Therefore, this data suggests that at Day 21 (Table 11), PRP may induce 
differentiation when added to growth medium and it may enhance differentiation when 
added to differentiation medium.  The expression of these mRNA markers signifies that 
differentiation down the osteogenic pathway has occurred, but it does not assure that 
functional osteoblasts have been created.  We can only assume that the bone sialoprotein 
and osteocalcin proteins would be synthesized by these terminally differentiated cells, but 
we cannot be certain without doing an assay of these proteins.   
     The 5- and 10-day time points for evaluating differentiation gene markers (Table 11) 
with PRP treatment could not be determined due to the GAPDH levels being elevated, 
which are likely due to the WBCs providing additional housekeeper gene (GAPDH) 
expression.  This finding was surprising and, therefore, future studies may be beneficial 
utilizing a gene whose expression is not affected by PRP treatment.  The use of a more 
appropriate housekeeper gene would provide useable mRNA data.  An alternative would 
be to use a leucodepleted PRP technique, but then we would lose the ability to confirm 
the effect of WBCs and its released factors on hMSC differentiation.   
      The molecular study confirmed that a 24-hour PRP treatment significantly increased 
proliferation and suggests that it does not stop differentiation.  Additionally, it provided 
evidence that proliferation occurs at a significantly earlier time point than what is 
normally found for cells using growth medium (Figure 25).   
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      The clinical prospective study utilized both digital radiographs and CT scans to 
determine the effect of PRP treatment on bone density.  The digital radiograph analysis 
demonstrated that PRP treatment in mandibular third molar extraction sites did have a 
significant effect (p < .001) on changes in bone density in comparison to baseline values 
for the first 2 weeks following application at the time of surgery Figure 39).  Two-way 
ANOVA showed that time and PRP treatment for the entire 25-week study were both 
significant and that time and treatment were independent of each other (Figures 39 and 
48).  Of interest is that bone density in the PRP-treated side was observed to increase 
during the initial 3- day post-operative digital radiographic observation, whereas the 
control side experienced an initial decrease in bone density before returning to baseline at 
the 2-week time point.  The control sites did not reach the same change in bone density as 
the PRP treated sites at week 1 until approximately weeks 4 to 5.  Additionally, in the 
long term, it took the control side 16 weeks to reach the same percent change in bone 
density that the PRP treated site had achieved by 8 weeks.  Based on this result, the 
clinician may not have to allow for 6 months healing time prior to initiating implant 
placement surgeries, but rather may be able to perform implant placement after 2 to 3 
months.      
     CT scan analyses were performed on three patients at each of the following times: 
10.5, 14, and 18 weeks.  Three parameters were examined, including total percent bone 
fill (Figure 43), newly formed bone density (NFBD) (Figure 44), and total formed bone 
density (TFBD) (Figure 45).  When comparing averages for the three CT scans the 
percent bone fill for PRP-treated sites had significantly greater percent bone fill than the 
control sites (p < .05).  When examining individual CT scans the total socket bone filled 
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bone density and newly formed bone density were not significantly different between 
PRP treated and control sites (p > .05).  This is not surprising because CT scans were 
taken at later time points 10.5-, 14-, and 18-weeks and normal bone modeling takes 
approximately 16 weeks.  The 10.5-week CT scan had markedly less total formed bone 
density and newly formed bone density than later CT scans, but when combining the 
three-time point scans together, there was no significant difference between sites.  The 
results may have been different had the CT scans been obtained at earlier time points.   
       Therefore, the results of the digital radiographs and the CT scan analysis suggest that 
the BC PRP technique does enhance bone formation at an earlier time point than sites not 
treated with BC PRP.  It can also be recommended that when deciding on time points for 
evaluating the effectiveness of PRP treatments that bone formation endpoints should be at 
earlier time points (0 to 12 weeks) and not at later time points (14 to 24 weeks).   
      Patients’ perception of pain, bleeding, numbness, facial swelling and external skin 
temperature was not significantly different between PRP treated and control sites.  
Moreover, the observers’ perception of patient pain, tissue opening, bleeding, 
inflammation, facial edema and intra-oral edema was similar to the patients’ perception. 
There was no significant difference between the two treatment sites in dehiscence, 
bleeding, intra-oral edema, and perceived pain and there was great similarity between 
patients and observers pain perception values, although the observers gave slightly higher 
scores. The PRP treated sides did demonstrate significantly less inflammation and facial 
edema in comparison to the matched control side (p < .05).  The findings that both of 
these items were significant are not surprising since edema is a clinical sign of 
inflammation. 
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   The in vitro portions of this study offer a validation of the BC PRP technique and 
possible mechanistic explanation as to why the method significantly decreases AO 
formation (Figure 21) and significantly enhances radiographic bone density (Figure 39) 
and bone fill (Figure 43).  Confirmation that platelets and WBCs are concentrated with 
the use of the clinical centrifuge (Figures 16 and 17), knowing  that platelet morphology 
is not disturbed during collection and centrifugation (Figure 24) validates the use of this 
centrifuge for BC PRP preparation. The confirmation of the presence of growth factors 
(PDGF-BB, TGF-β1, EGF, and VEGF) in the BC PRP preparation (Figure 20 and Table 
5) is of importance because each of these GFs are known to play an important role in 
healing (102, 104-106, 109-111, 116, 117, 125, 135).  The prospective clinical study of 
the effects of PRP is consistent with the results from the cell culture study and the 
retrospective clinical analysis.  The prospective clinical study results of increased 
radiographic bone density with PRP treatment at early time points (Figure 39) correlates 
well with the in vitro findings of early cell proliferation (Figure 25) followed by possible 
differentiation.  There was also a correlation between the retrospective clinical AO study 
and the prospective clinical study.  The increase in bone density during the first 2 weeks 
in the prospective study is most likely due to the presence of multiple GFs found in PRP 
that stimulate hMSCs to proliferate with eventual differentiation into osteoblasts.  
Additionally, GFs contained in PRP facilitate by the formation of soft tissue (493) that 
would help preserve thrombus (clot) formation thereby lessening the likelihood of AO.   
    The application of PRP has great clinical utility because it appears to decrease the risk 
of complications by closing the window of vulnerability early during post-operative 
healing.  There are clinicians who anecdotally claim that PRP does not work and there are 
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those who say that it does.  They may both be correct.  Clinical success with PRP may be 
due partially to PRP processing technique and/or the temporal end-point used as a 
measurement tool for improved bone formation.  If the temporal endpoint for measuring 
bone formation is beyond 12 to 14 weeks, there may not be an observable difference 
between PRP treatment and control.   
      The in vivo conditions cannot be duplicated in the in vitro environment.  Therefore 
these studies focused on the effects of PRP on hMSCs and their differentiation into 
osteoblasts.  Clinically, PRP may have an effect on osteoclasts in addition to osteoblasts.  
In the Preparation and Characterization (Study I) section of this dissertation 
osteoprotegerin (OPG) was found(Table 5), but it could not be quantified as it was below 
the detectable limits of the standard curve.  OPG has been reported in murine platelets 
(494),but not human platelets.  If OPG were present in human platelets and at effective 
concentrations, then PRP would effect osteoclasts as well.  OPG is known to inhibit the 
maturation of osteoclasts (495).  Therefore, an additional explanation for the early 
increase in bone density seen in the prospective study with PRP-treatment may be that 
OPG (if present) would interfere with the normal bone healing process of initial bone 
breakdown by osteoclasts.  Osteoclasts free necessary osteoblast stimulating factors from 
the bone matrix, therefore beginning the bone healing process (496).  This explains the 
initial drop in bone density observed at the non-PRP-treated sites in the prospective 
study.  OPG would block this initial bone breakdown. Therefore, with future studies it 
may be determined that hMSC proliferation and possible differentiation is a partial 
mechanistic answer and that PRP possibly has an effect on osteoclasts as well.    
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Conclusion   
     This study confirms that a simple and cost-effective technique for concentrating 
platelets when performed properly will not alter platelet morphology or growth factor 
contents.  Additionally, the BC-PRP methodology significantly decreased the formation 
of AO when applied immediately to tooth extraction sockets and facilitated the process of 
soft and hard tissue healing.  This facilitation was most likely due to the enhanced 
proliferation and enhanced differentiation of stem cells mediated by growth factors 
released by PRP at the surgical site.  Since PRP application facilitates healing there is less 
opportunity for the occurrence of complications such as AO or delayed bone formation.  
Based on our prospective study results the effects of PRP are optimal during the first two 
weeks following application.  This correlates well with the proliferation of hMSC during 
the initial 5 days and enhanced differentiation seen at Day 21following exposure to PRP 
treatment.  Patients and clinicians would benefit from the use of PRP in oral surgical 
procedures.  This BC PRP technique may have applications in other types of surgery 
requiring bone healing. 
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 Appendix 1 
 
Institutional Review Board Forms 
 
A.  IRB Cover letter 
 
December 1, 2004 
Institutional Review Board 
403 Administration Building 
Duquesne University 
600 Forbes Avenue 
Pittsburgh, PA  15282  
 
Dear IRB Members: 
This Investigational Review Board application is being submitted to permit us to validate 
a dental surgical procedure that is currently being done by some dental practitioners.  
This clinical research project would provide a scientific examination of the effectiveness 
of this procedure.   In the procedure, a small quantity of blood is drawn from each subject 
and centrifuged to concentrate the patient’s own platelets.  This would be done prior to 
the surgical removal of bilateral mandibular (lower jaw) third molars.  Platelets contain 
multiple growth factors that may be beneficial in the healing process.  This blood 
drawing procedure would be exactly the same as that performed by many hospital 
laboratories, medical offices and a few dental practitioners today.  Most dentists simply 
remove the tooth and do not necessarily place anything into the tooth extraction site, 
while some practitioners will place the concentrated platelets and the growth factors 
contained within them, into the extraction site to accelerate healing.  It may be that post-
operative complications are prevented by the addition of these concentrated platelets into 
the surgical site.  Each patient would be his/her own control.  One side would receive the 
concentrated platelet treatment while the contra-lateral side would not.  There would not 
be any new or novel treatments involved in this project.  The FDA currently approves the 
use of PRP in dental surgical procedures.  This project would help provide scientific 
validity for providing the additional platelet treatment.   
Thank you for your time and consideration with this application.  If we can provide any 
additional information, please do not hesitate to contact us.  
Respectfully, 
James L. Rutkowski, D.M.D.                            David A. Johnson, Ph.D. (Co-Investigator) 
E-Mail: james.rutkowski@verizon.net              E-Mail: johnsond@duq.edu 
Home:  814-226-8691                                        Office: 412-396-5952 
Office:  814-226-8690 
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B.  IRB Submission Form 
Research Question: 
The research question to be answered is:  Does the placement of autogenous platelet rich 
plasma (PRP) in the surgical site enhance the soft tissue healing and radiographic density 
following the removal of bilateral, mandibular third molars?  The radiographic density 
would be a measure of bone density and maturity.  The purpose of the study is to verify 
the validity of obtaining and placing autogenous PRP in recent extraction sites to 
decrease post-operative complications and hasten bone formation for future dental 
implant placement.  If a significant difference is found between a control extraction site 
(no treatment) on one side versus a treated PRP contra-lateral side, then it would give a 
scientific basis for the continual and possibly expanded use of this technique in other oral 
surgical procedures.  Currently, extraction sites are often left untreated which may result 
in multiple complications such as: 
1. delayed healing of the soft tissue 
2. soft tissue invasion of the extraction site 
3. delayed and/or decreased bone formation 
4. and infection. 
 
Many times, dental implantologists treat extraction sites with allografts (bone from 
cadavers), xenografts (bone from another species, such as bovine), or synthetic grafts.  
Barriers such as teflon sheets, collagen, or cadaver bone sheets are placed over these 
grafts to prevent the invasion of soft tissue into the extraction site.  These procedures are 
costly, difficult to perform, unpredictable in the presence of an existing infection, and 
time consuming.  Autogenous PRP is often mixed with these grafting materials.  The 
literature is divided on the benefits of using PRP with this procedure.  Some practioners 
have anecdotally place autogenous PRP only in extraction sites and report improved soft 
and hard tissue healing.  If the PRP treated sites do demonstrate improved healing, then 
this would offer a predictable treatment protocol for all extraction sites.   
Research Design and Procedures:    
This research will be based on the use of a bilateral 3
rd
 molar extraction human model.  
The primary investigator, in a private dental office, will perform the clinical procedures.  
The following criteria (protocol) will be followed on all patients: 
1. Procedures will be done with intravenous (IV) sedation. 
 
2. After sedation, but prior to administration of other medications or 
commencement of surgery, the researcher will perform a venous puncture in the 
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arm opposite the IV administration site, so that two 4.5 mL tubes of whole 
blood can be drawn.  These tubes will be drawn via the use of a disposable 
Vacutainer
TM
 with a 21 gauge 1 ½ inch beveled needle.  One tube will be used 
for a whole blood platelet count (PC) for baseline values. The other tube will be 
centrifuged for 10 minutes in the Clinaseal Centrifuge
TM
.  The PRP will be 
removed, from the centrifuged tube, and placed in only one of the extractions 
sites after completion of the tooth removal.  The contra-lateral extraction site 
will be treated by a traditional procedure that does not include the use of PRP. 
 
3. Patients will be administered either AncefTM 2.0 gram or Clindamycin 600 mg. 
immediately pre-operative via IV. 
 
4. Adequate local anesthesia will be obtained by the use of mandibular blocks and 
local infiltration.  This is normally achieved with the use of three to four 1.8 
mL. carpules of the lidocaine 2% with epinephrine 1:100,000 for each surgical 
site.   
 
5. To help prevent excessive post-operative inflammation, patients will be 
administered dexamethasone 4-8 mg. IV pre-operatively and methyprednisolone 
acetate suspension 40 mg. IM immediately post-op. 
 
6. Patients will be given ToradolTM 30 mg. IV immediately post-op. 
 
7. Immediate post-operative bilateral Gow-Gates mandibular block injection using 
1.8 ml. of  bupivacaine 0.5% with 1:200,000 epinephrine will be administered 
to prevent immediate post-op pain. 
 
8. Bilateral 3rd molars of a similar eruptive state and angulation will be removed 
(both sides must be either impacted or erupted). 
 
9. After removal of the teeth, a periapical (small) digital radiograph (Dentsply 
Gendex
TM
) will be taken of each side, using an XCP mount with documented 
KVP and time settings to determine a baseline gray scale at each extraction site.  
Digital radiographs will be used for two reasons: 1. the technique will allow for 
consistent radiograph opacity and evaluation and 2. it exposes patients to only 
25% of the radiation used with conventional radiography.  A correlation of bone 
density will be confirmed during the study with computerized axial tomography 
scanning technology (CAT scan) and computer reformatting for bone density 
determination via Hounsfield units (HU) on 3 patients.  Because of the need to 
evaluate the post-operative bone healing, participants in this study will be 
exposed to 22 digital peri-apical radiographs, and some participants will also be 
required to get a limited CAT scan analysis of the extraction sites.  Patients not 
involved in this study would not normally receive these radiographs.  The 
radiation exposure of these 22 digital radiographs is equivalent to that received 
with 6 traditional peri-apical dental radiographs.   
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10. The control side will be treated immediately post-extaction as follows: 
a. Digital radiograph  
b. Place GelfoamTM only  
c. Primary closure with 3-O chromic gut suture material. 
 
11. The contra-lateral side will be treated immediately post-extraction as follows:  
a. Digital radiograph  
b. Injection of 200 L of PRP into the extraction site.   
c. Placement of GelfoamTM moistened with 100 L PRP. 
d. Primary closure with 3-O chromic gut suture material. 
 
12.  Dismiss patient with a grade card for notations every 8-hours for 3 days, then 
                notations every 12 hours for the following 4 days. Each side will be graded for: 
a. Visual analogue scale (VAS) for pain  
b. Number of and type of analgesic tablets taken  
c. Temperature (external feeling of warmth) 
d. Facial swelling  
e. Bleeding  
f. Numbness or altered sensation of tongue, face, lip or chin. 
 
13. Patient will return in 3 days for a post-op grading scale evaluation for each side 
                  by a licensed dental hygienist that is blinded to the study.  The PI (who would 
               not be blinded) will also examine the patient, but will not be involved in the 
               grading process.  The following will be graded: 
a. Dehiscence (degree of opening) 
b. Inflammation  
c. Bleeding  
d. Pain  
e. Swelling intra-oral and extra-oral  
 
14.  Patient will return 7 days post-op for the above evaluations plus  
                digital radiographs (same protocol as immediate post-op)  
15.  The above will be repeated at weeks 2, 3, 4, 6, 8, 12, 16, 20, and 24. 
 
16.  Starting at 6 weeks post-op periodontal probe readings will be recorded for the      
       bilateral mandibular 2
nd
 molars. 
17. Three of the patients will have mandibular CAT scans performed at a local 
hospital at post-op week 12.  This would allow for verification of the gray scale 
from digital radiography with the bone density HU of the CAT scan.  
 
Sample Selection and Size: 
All patients will be between ages 18-40 and with a negative medical history and non-
smokers.  Six patients will be included in the study.  
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Recruitment of subjects: 
Subjects will be recruited from the PI’s private practice.  Patients who meet sample 
selection criteria and in need of the removal of mandibular third molars, will be asked if 
they would like to enroll in the study.  After the completion of their radiographic 
examinations, subjects will receive a $250.00 remuneration.  Risks/benefits will be 
explained in detail to all patients.  Patients will be given the opportunity to have questions 
answered prior to surgery.  Attached is a recruitment hand-out that will be given to 
potential candidates.  
Informed Consent Procedures: 
Standard intravenous sedation consent and surgical third molar removal consent forms 
will be used (see attached forms).  HIPAA acknowledgement consent forms will be used 
(see attached form).  Subjects will also be informed of the need to have two 4.5 mL tubes 
of whole blood drawn prior to surgery.  They will also be informed for the need to: 
1. complete post-operative questioners  
2. permit post-operative digital radiographs and a possible limited CAT scan of 
the mandible  
3. report for follow up evaluations.  
 
Please see the attached post-operative evaluation forms for the study participants.   A 
certified dental assistant will explain the sedation and surgical procedures to be 
performed.  This same dental assistant will go thru the consent forms line by line, as is 
normally done with non-study patients.  The researcher (Dr. Rutkowski) will be present 
and available to clarify any terms and answer questions that subjects may have.   
Collection of Data and Method of Data Analysis: 
Data will be collected for the following items: 
1. Patient self-evaluation for: 
a. Visual analogue scale (VAS) for pain  
b. Number of and type of analgesic tablets taken  
c. Temperature (external feeling of warmth) 
d. Facial swelling  
e. Bleeding  
f. Numbness or altered sensation of tongue, face, lip or chin. 
 
2.  Investigator evaluation of:  
a. Dehiscence (degree of opening) 
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b. Inflammation  
c. Bleeding  
d. Pain 
e. Swelling intra- and extra-orally.  
f. Post-operative digital radiographs at 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. 
g. CAT scans on 3 of the subjects at week 12. 
  
     Data will be analyzed by a paired T-test or Mann-Witney U test.  Data will be kept in 
a      locked cabinet for 5 years, and then destroyed.     
Issues relating to interactions with subjects and subjects’ rights: 
Subjects will have the opportunity to ask questions prior to surgery and then decide to 
participate or not.  Subjects’ needs for pain control, post-operative examinations, further 
treatment, and referrals will be the same as those extended to all non-research patients.  If 
subjects do not wish to partake in the study, they will be given the opportunity to be 
treated as routine (non-research) patients.  All records or data with names associated will 
be stored in a locked cabinet, which only the researcher has access. No name identity will 
be made in the data analysis.    
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C. Wisdom Tooth Study Announcement 
       
LOWER WISDOM TOOTH SUDY 
 
If you are between the ages of 18 and 40 and need your lower wisdom teeth removed, 
you may be eligible to participate in a study that involves the removal of lower wisdom 
teeth.  The study compares two techniques currently used by dentists when removing 
these teeth.  Both techniques remove the teeth by the same surgical principles, but upon 
closure of the extraction sites one technique utilizes a self-dissolving surgical plug and 
sutures, while the other technique utilizes concentrated blood products (platelets and 
growth factors) taken from the patient via a standard blood drawing technique.  The 
method that utilizes the blood drawing technique is believed to enhance the healing 
process and decrease post-operative complications.  Retrospective studies appear to 
support this believe.  This project would compare the two techniques in the patient.  One 
side from the removal of the wisdom teeth would receive the traditionally used technique 
of a self-dissolving surgical plug and sutures.  The other side would receive the blood 
products that had been concentrated, the self-dissolving surgical plug and sutures.  We 
must emphasize that the blood products are taken from the subject’s own blood.  Two 
small tubes of blood would be drawn from the patient’s arm just prior to starting the 
extractions.  The blood would be centrifuged and a layer of concentrated platelets would 
be removed and placed in the surgical site.  To be eligible for this study you must be: 
1. in need of the removal of two lower wisdom teeth 
2. willing to participate in the study under your own free will  
3. between the ages of 18 and 40 
4. in good health  
5. not taking any medications prior to the removal of the teeth  
6. willing to have 2 small tubes of blood drawn from your arm 
7. willing to be sedated for the tooth removal  
8. willing to have a series of 10 digital radiographs taken over a 6 month period of 
time after the surgery 
9. the possibility of having a CAT scan at a local hospital 3 months after the 
surgery  
10. complete a post-surgical evaluation form for pain, swelling, and other 
complications for 4 days after the removal of the teeth 
11. present for routine post-surgical in-office evaluations by our staff over a 6 month 
time period. 
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You would be free to leave the study at any time if you should so desire.  If you complete 
the study you would receive a $250.00 remuneration at the conclusion of the final 6 
month radiograph and post-op evaluation.   
 
If you are interested in learning more about the possibility of your involvement in this research 
project, please contact: James L. Rutkowski D.M.D. 
                        35 South Second Ave.  
                        Clarion, Pa. 16214 
                        Phone: 814-226-8690 
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D.  Third Molar Consent Form 
 
THIRD MOLAR/PRP RESEARCH PROJECT  
CONSENT FORM 
 
 
This consent form consists of four (4) parts: 
 
1. Third molar removal consent form that includes possible surgical and  
post-operative complications. 
2. Intravenous conscious sedation consent form that includes possible  
sedation risks. 
3. Intravenous conscious sedation patient information sheet. 
 
4. Health Insurance Portability and Accountability Act (HIPAA)  
acknowledgment form. 
 
All forms are to be completed and signed by a patient or legal guardian, prior to  
participation in the study. 
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Appendix 2  
Patients’ Post-Surgical Evaluation Form 
 
PARTICIPANTS POST-SURGICAL EVALUATION FORM 
 
Post-surgical grade card for participants of the research project titled: “Effects of Growth 
Factors on Cell Proliferation and Differentiation with Radiographic Analysis of Tooth 
Extraction Socket Fill Utilizing Autogenous Growth Factors” 
(To be completed by the participant.  A new form should be completed every 8 
hours for the 1
st
 3 days, then every 12 hours for the next 4 days.)  
 
Patient ID: _______________ (Do not use your name only use the ID # assigned to you) 
 
Date:____________________ 
 
Time:____________________ 
 
A.  Visual analogue scale for pain  
 (Please place circle the number that represents your perception of the pain you are 
currently experiencing.  0 = no pain; 10 = severe pain) 
 
 
0…….1…….2…….3…….4…….5…….6…….7…….8…….9…….10  
 
B. Please check analgesic tablets and number taken since surgery (if this is your first 
     report) or since your last report 
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Check if any of 
the following 
were taken  Analagesic 
Strength (dose) 
Quantity  
 Advil  
 
200 mg  
 Alleve  
 
200 mg  
 Darvocet-N 100 
 
100 mg  
 Ibuprofen  
 
200 mg  
 Nuprin  200 mg  
 Percocet  
 
  
 Percodan  
 
  
 Tylenol regular 
strength  
325 mg  
 Tylenol extra 
strength  
500 mg  
 Tylenol with 
Codeine ½ grain  
325/30  
 Viocodin  
 
500/5  
 Vicodin ES 
 
750/7.5  
 Vicodin HP  
 
660/10  
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Check if any of 
the following 
were taken  Analagesic 
Strength (dose) 
Quantity  
Other  please 
specify  
   
 
        
C. Left: Temperature   _________
o
F                            Right: Temperature   _________
o
F                  
 
D. Swelling (Please circle the best description) 
     
   Left:  Slight……..Moderate………Severe                Right: 
Slight……..Moderate………Severe 
 
E. Bleeding (Please circle the best description) 
 
    Left:  Slight……..Moderate………Severe              Right: 
Slight……..Moderate………Severe 
 
F. Numbness or altered sensation of tongue, face, lip or chin. (Please give location 
and circle the best description(s)  
          
      Location________________   Slight……..Moderate………Severe 
 
      Location________________   Slight……..Moderate………Severe 
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Appendix 3 
Observers’ Post-Surgical Evaluation Form 
 
OBSERVERS POST-OP EVALUATION FORM 
Post-surgical evaluation sheet for participants of the research project titled; “Effects of 
Growth Factors on Cell Proliferation and Differentiation with Radiographic Analysis of 
Tooth Extraction Socket Fill Utilizing Autogenous Growth Factors” 
(To be completed by the blinded Dental Hygienist on post-op days 3 & 7, plus weeks 
2,3,4,6,8,12,16,20 & 24.) 
 
Patient ID:_____________________________(Do not use patient’s name) 
 
Date:_________________________________ 
 
Time:_________________________________ 
 
Dental Hygienist ID:_____________________ 
 
A. Dehiscence (degree of opening): Site #17___mm opening; Site #32____mm  
 
B. Inflammation: (degree of)    Circle the best description. 
 
Left side: Slight….Moderate....Severe;    Right side: Slight….Moderate....Severe 
 
C.  Bleeding: (degree of)      Circle the best description. 
 
Left side: Slight….Moderate....Severe;    Right side: Slight….Moderate....Severe 
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C. Pain (Observers perception of pain at the time of visit) 
Circle the number that best describes the observed pain (0 = no pain; 10= severe 
pain) 
 
            Left side: 0….. 1.….2…….3…….4…….5…….6……..7…….8…….9…….10 
 
           Right side: 0…..1.….2…….3…….4…….5…….6……..7…….8…….9…….10 
 
      D.  Swelling (extra-oral)      Circle the best description. 
 
Left side: Slight….Moderate....Severe;    Right side: Slight….Moderate....Severe 
      
      E. Swelling (intra-oral)      Circle the best description. 
            
            Left side: Slight….Moderate....Severe;    Right side: Slight….Moderate....Severe 
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Appendix 4 
Percent Radiographic Density Changes of Surgical ±PRP 
Treatment Compared to Control Radiograph Taken Immediately 
Following Tooth Removal in Six Trial Patients 
In all graphs, percent bone density change on the Y-axis represents the change in bone 
density that has occurred at the extraction site in comparison to the extraction site 
immediately after tooth removal and placement of the Gelfoam
®
 sponge ± PRP and 
suturing.  Digital radiographs were normalized to the immediate post-operative film by 
comparing the unaltered adjacent tooth on the time point radiograph with the immediate 
post-operative radiograph’s corresponding unaltered tooth.  Each digital radiograph was 
evaluated by 3-blinded evaluators.  Patients are coded as Patients 1,2, 5,6, 9, and A. 
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Appendix 5  
 
Representative Real Time RT-PCR Results for Day 21 Bone 
Sialoprotein Gene (IBSP) Expression in Growth, Growth + PRP, 
Differentiation, and Differentiation + PRP media 
The reaction protocol was completed in a Bio-Rad Chromo4 Real Time Detection 
System
®
 using the iScript One-Step RT-PCR Kit
®
 (Bio-Rad, Hercules, CA).  Each 
reaction mixture contained 100 nM RNA.  The 50 μL reaction mixture was placed in the 
thermal cycler and incubated at 55°C for 10 minutes, 5 minutes at 95°C for cDNA 
synthesis and reverse transcriptase inactivation.  The PCR cycling was completed after 45 
cycles; 10 seconds at 95°C, 30 seconds at 57°C.  A melt curve analysis was completed; 1 
minute at 95°C, 1 minute at 55°C, and 10 seconds at 55°C for 80 cycles, increasing 0.5°C 
each cycle.  Data were analyzed using MC Opticon
®
 software.  Panel A represents the 
melt curve for  bone sialoprotein gene (IBSP) in growth medium, growth + PRP medium, 
differentiation medium, and differentiation + PRP medium.  The peaks are all relatively 
close over a specific high temperature range indicating amplification of one specific 
product in the PCR reaction.  The specific, thermodynamically stable product is 
represented by the single peak followed by the sharp decrease in fluorescence at the 
higher temperature range.  Panel B represents cycle expression (CT) for the same gene in 
the same media. The CT cycle was defined automatically by the iCycler software.    
